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	Abstract		Cardiovascular	 diseases	 (CVD)	 are	 the	major	 cause	 of	 death	 globally	with	myocardial	infarction	 (MI)	 being	 one	 of	 the	 main	 causes	 of	 mortality.	 The	 limited	 regenerative	capacity	 of	 adult	 human	 tissues	 is	 particularly	 pertinent	 to	 the	 heart,	 which	 cannot	repair	itself	fully	after	injury;	instead,	the	damaged	myocardium	is	replaced	by	fibrotic	scar	 tissue	 and	 the	 heart	 progressively	 decrement	 in	 function.	 To	 date,	 efforts	 to	develop	 interventions	 for	 alleviation	 of	 this	 inevitable	 destructive	 progression	 have	proven	 largely	 ineffective.	 Although	 over	 the	 past	 decades,	 treatment	 for	 myocardial	ischemia	 has	 made	 significant	 progress,	 myocardial	 infarction	 remains	 an	 unsolved	therapeutic	target.	In	attempting	 to	address	 this	problem,	 insulin	growth	 factor	 splicing	variant	4	(IGF-1Ea)	has	been	extensively	tested	for	its	therapeutic	properties	in	the	resolution	of	tissue	 injury.	 In	 the	 heart,	 constitutive	 overexpression	 of	 IGF-1Ea	 (αMHC.IGF-1Ea)	restored	 heart	 functionality	 post-infarct,	 reducing	 scar	 formation	 and	 increased	 anti-apoptotic	signalling.			This	 thesis	 provides	 deeper	 understanding	 on	 the	 role	 of	 IGF-1Ea	 in	 early	modulation	 of	 the	 inflammatory	 process	 after	myocardial	 infarction	 in	 αMHC.IGF-1Ea	transgenic	 mice.	 In	 fact,	 the	 enhanced	 repair	 in	 αMHC.IGF-1Ea	 after	 myocardial	infarction	 is	 due	 to	 IGF-1Ea	modulating	 several	 aspects	 of	 the	 cellular	 repair	 process	after	MI,	 including	 immune	cell	recruitment,	cytokine	expression,	and	reduction	of	 the	extracellular	 matrix	 turnover.	 However,	 the	 heart-specific	 transgene	 is	 constitutively	expressed	 from	 birth	 and	 does	 not	 simulate	 delivery	 to	 humans	 in	 the	 clinic.	With	 a	better	understanding	of	IGF-1Ea	in	cardiac	repair,	this	thesis	also	focused	on	the	design	of	both	cell-	and	gene-based	approaches	to	deliver	the	IGF-1Ea	therapeutic	payload	into	the	 heart	 by	 (i)	 adoptive	 immunotherapy	 approach	 using	 bone-marrow	 derived-macrophages	mediated	 cell	 delivery	 of	 IGF-1Ea	 and	 (ii)	 IGF-1Ea	 gene	 transfer	 to	 the	heart	 using	 a	 cardiotropic	 adeno-associated	 viral	 vector	 (AAV9)	 after	ischemia/reperfusion.	Of	the	two	approaches,	only	the	gene-based	approach	was	able	to	deliver	IGF-1Ea	into	the	heart	achieving	therapeutically	relevant	levels.	AAV9-mediated	IGF1Ea	gene	transfer	proved	to	be	a	potential	therapeutic	clinical	approach	to	prevent	the	adverse	ventricular	remodeling	after	myocardial	infarct.	The	knowledge	acquired	in	this	thesis	will	be	relevant	to	 inform	and	design	future	therapeutic	approaches	for	the	treatment	of	patients	suffering	from	myocardial	infarction.			
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Chapter	1	–	Introduction	
1.1	The	heart	The	 main	 function	 of	 the	 heart	 is	 to	 pump	 oxygenated	 blood	 to	 the	 body	 and	deoxygenated	 blood	 to	 the	 lungs	 for	 oxygenation,	 maintaining	 body	 homeostasis.	 To	achieve	 this	 goal,	 two	 circulatory	 systems	 are	 required.	 The	 systemic	 circulation	facilitates	 the	 distribution	 of	 nutrients,	 oxygen	 (O2)	 and	 water	 and	 the	 pulmonary	circulation	 allows	 the	 collection	 of	 metabolic	 waste	 products	 such	 as	 carbon	 dioxide	(CO2)	and	the	exchange	of	gases	in	the	lungs.	Inside	the	lungs,	the	architecture	of	alveoli	and	alveolar	capillaries	facilitates	the	exchange	of	oxygen.	Deoxygenated	(venous)	blood	flows	 through	 the	 capillaries	 in	 close	 contact	 with	 ventilated	 alveoli	 and	 becomes	oxygenated	 (arterial	 blood).	 Blood	 also	 serves	 as	 a	 vehicle	 for	 cells	 and	 molecules	(Sedmera	et	al.	2008	and	Aird	et	al.	2011).		Because	 of	 its	 fundamental	 role,	 the	 heart	 is	 the	 first	 organ	 formed	 in	 the	 developing	embryo.	The	developing	heart	receives	cellular	contributions	from	three	main	sources:	the	 cardiogenic	 mesoderm,	 the	 cardiac	 neural	 crest	 and	 the	 epicardium-derived	 cells	(EPDC)	 (Laugwitz	 et	 al.	 2008).	 The	 primitive	 heart,	 originated	 from	 the	 cardiogenic	mesoderm,	 is	 no	 more	 than	 a	 linear	 tube	 composed	 of	 myocardial	 and	 endocardial	layers.	 In	human	heart	development,	 contraction	of	 the	heart	 tube	begins	at	 around	3	weeks	of	development,	propelling	blood	in	a	peristaltic	fashion.	Soon	after	initiation	of	the	heartbeat,	 the	myocardium	increases	 in	size	and	the	 linear	heart	tube	undergoes	a	series	of	transitions,	which	involves	a	process	of	looping,	the	atria	and	ventricles	begin	to	form.		At	this	stage,	a	new	vascular	system	is	required	to	support	the	oxygen	demand	(Tomanek	et	al.	2005).	Studies	performed	in	chicken	eggs,	suggests	that	cardiac	neural	crest	 cells,	 from	 the	 dorsal	 neural	 tube,	 migrate	 to	 contribute	 into	 vascular	 smooth	muscle	 cells	 (VSMCs)	 to	 the	 great	 arteries	 and,	 at	 the	 same	 time,	 proepicardial	precursors	contact	the	surface,	to	form	the	epicardium	(Manner	et	al.	1993	and	Mikawa	et	 al.	 1996).	 The	 epicardium,	 in	 turn,	 gives	 rise	 to	 EPDCs,	 multipotent	 cardiac	progenitors	(Wessels	et	al.	2004)	with	the	potential	to	differentiate	into	VSMC	(Mikawa	et	al.	1996),	endothelial	cells	(ECs)	(Perez-Pomares	et	al.	2002),	cardiomyocytes	(Perez-Pomares	 et	 al.	 2002),	 cardiac	 fibroblasts	 (CF)	 (Gittenberger	 et	 al.	 1998).	 In	 the	 chick	embryo,	 EPDCs	 may	 also	 contribute	 to	 AV	 cushion	 mesenchyme	 giving	 rise	 to	 the	cardiac	valves	(Gittenberger	et	al.	1998	and	Manner	et	al.	1999).	Through	various	processes	involving	septation,	valve	formation,	cell	differentiation,	cell	proliferation	and	epicardium	formation,	the	primitive	heart	evolves	into	the	adult	four-chambered	heart	(Sedmera	et	al.	2008).	
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In	the	four-chambered	heart,	deoxygenated	blood	enters	the	heart	from	the	inferior	and	superior	vena	cava	to	the	right	atrium.	Through	the	tricuspid	valve,	blood	enters	into	the	right	ventricle.	 Immediately	after,	 the	valve	closes	 to	prevent	blood	 from	flowing	back	into	 the	 right	 atrium.	 The	 right	 ventricle	 contracts,	 sending	 blood	 through	 the	pulmonary	 valve	 to	 the	 lungs.	 Again,	 immediately	 after,	 the	 pulmonary	 valve	 close	 to	prevent	 backflow.	 Blood	 enters	 the	 lung	 capillaries	where	 carbon	 dioxide	 is	 removed	and	oxygen	is	picked	up	(Figure	1.1).	Oxygenated	blood	exits	the	lungs	and	is	sent	back	to	the	heart	through	the	pulmonary	veins	into	the	left	atrium.	The	mitral	valve	closes	to	prevent	backflow	of	 the	blood	 into	 the	 left	 atrium.	After	 this,	 the	 left	 atrium	contracts	and	 blood	 enters	 the	 left	 ventricle.	 The	 left	 ventricle	 is	 the	 thickest	 of	 the	 chamber	muscles	since	it	has	to	produce	enough	pressure	to	pump	oxygenated	blood	to	the	entire	body.	Following	left	ventricular	contraction,	blood	passes	through	the	aortic	valve	to	the	aorta	 (Aird	 et	 al.	 2011).	 The	 aorta,	 the	 largest	 and	main	 systemic	 artery	 of	 the	 body,	branches	off	distributing	oxygenated	blood	to	all	parts	of	the	body	(Figure	1.1).	At	the	root	of	the	aorta,	just	after	the	aortic	valve,	two	coronary	arteries	branch	off	to	nurture	the	heart	with	oxygenated	blood.		Over	time	the	coronary	arteries	that	supply	your	heart	muscle	with	 oxygen-rich	blood	may	become	narrowed	or	 occluded,	 leading	 to	 a	 heart	attack	or	myocardial	infarction	(MI)	(Section	1.3).			
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.1.	Internal	view	of	the	4-chambered	healthy	heart.	The	picture	depicts	right	and	left	atrium,	ventricles,	the	cardiac	valves	and	both	systemic	(red)	and	pulmonary	circulation	(blue).		The	left	ventricle	wall	thickness	allows	the	heart	to	gather	enough	pumping	force	to	propel	the	blood	to	the	whole	organism.	Schematics	adapted	from	http://cliparts.co.		
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1.2	Regeneration	of	the	mammalian	heart	Through	 evolution,	 higher	 mammals	 such	 as	 vertebrates	 have	 lost	 the	 ability	 to	regenerate	damaged	tissue	and	appendages,	limiting	this	capacity	to	organs	such	as	lung	or	 liver.	 Consequently,	 scientists	 have	 been	 attempting	 to	 answer	 some	 fundamental	questions	for	centuries:	Why	does	regeneration	occur	only	in	certain	organs	and	not	in	others?	 Why	 was	 this	 remarkable	 ability	 not	 preserved	 or	 maintained	 through	mammalian	 natural	 selection?	 Is	 there	 a	 regenerative	 genetic	 program,	 hidden	 deep	within	 the	 genome?	 The	 prevailing	 view	 is	 the	 heart	 does	 not	 regenerate.	 Instead,	damaged	 myocardium	 is	 replaced	 by	 fibrotic	 scar	 tissue,	 leading	 to	 a	 worsening	 of	cardiac	 function	 and	 motion.	 	 In	 the	 cardiovascular	 field,	 three	 missing	 hallmarks	 of	regeneration	 prevent	 full	 heart	 repair:	 cell	 replacement,	 de	 novo	 vascularisation,	 and	inflammatory	resolution.			In	other	species,	however,	the	heart	still	preserves	this	capacity	to	some	degree.	Recent	research	shows	that	zebrafish	are	capable	of	fully	regenerating	hearts	within	2	months	after	 20%	 ventricular	 resection.	 In	 this	 model,	 regeneration	 occurs	 through	 robust	activation	and	proliferation	of	cardiomyocytes	localised	at	the	leading	epicardial	edge	of	the	 new	 myocardium	 (Poss	 et	 al.	 2002,	 Poss	 et	 al.	 2012	 and	 Kikuchi	 et	 al.	 2010).	Interestingly,	 genetic	 ablation	 studies	 in	 zebrafish	 showed	 reversal	 of	 cardiac	 failure	after	 60%	 ablation	 of	 total	 cardiomyocytes.	 In	 this	model,	 up-to	 four-fold	 increase	 in	cardiomyocyte	 proliferation	 was	 observed	 compared	 to	 resection.	 Although	 the	mechanism	 underlying	 the	 enhanced	 regeneration	 capacity	 remains	 unclear,	 all	 three	missing	hallmarks	of	regeneration	to	achieve	full	cardiac	repair	were	achieved:	Specific	ablation	 of	 cardiomyocytes,	 sparing	 non-cardiomyocyte	 tissue,	 optimally	 engaged	regeneration	 by	 promoting	 cardiomyocyte	 regeneration,	 epicardial	 and	 endocardial	production	 of	 retinoic	 acid,	 epicardial	 proliferation,	 de	 novo	 vascularisation	 and	macrophage	recruitment	in	absence	of	a	large	clot		(Wang	et	al.	2011).	Interestingly,	the	endocardium	and	epicardium	has	been	proposed	to	support	neovascularisation	during	zebrafish	 regeneration.	 As	 early	 as	 3-hours	 after	 apical	 heart	 resection,	 in	 zebrafish,	robust	 epicardial	 and	 endocardial	 production	 of	 Raldh2	 promoted	 cardiomyocyte	proliferation	and	neovascularisation	(Kikuchi	et	al.	2011)		In	summary,	 injury-induced	cardiomyocyte	proliferation	can	overcome	scar	 formation,	allowing	cardiac	muscle	to	regenerate	(Poss	et	al.	2002,		Poss	et	al.	2012	and	Wang	et	al.	2011).	 Nonetheless,	 it	 is	 worth	 mentioning	 that	 another	 teleost	 animal	 model,	 the	medaka	 fish,	 responded	 rather	 differently	 to	 cardiac	 injury.	 The	 medaka	 hearts	
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displayed	an	excessive	collagen	deposition	by	activated	myofibroblasts	where	existing	cardiomyocytes	 remained	 steady	 and	 no	 substantial	 proliferation	 was	 observed.	Interestingly,	Raldh2	gene	expression	was	not	 found	 suggesting	 that	 the	endocardium	remained	in	an	inactive	state	(Ito	et	al.	2014).			In	 mammals,	 the	 failure	 of	 the	 adult	 heart	 to	 recover	 from	 injury	 has	 been	 largely	attributed	to	 the	 ineffective	replacement	of	damaged	cardiomyocytes,	which	withdraw	from	 the	 cell	 cycle	 soon	 after	 birth.	 Cardiac	 function	 is	 maintained	 through	 cardiac	growth	dependent	on	cellular	hypertrophy	and	proliferation	of	other	cell	types	acting	as	a	 compensatory	 mechanism.	 Interestingly,	 recent	 studies	 identified	 a	 brief	 window	during	 the	 first	 7	 days	 of	 post-natal	 development,	when	 neonatal	mice	 hearts	 retains	significant	 regenerative	 capabilities	 in	 response	 to	 either	 resection	 of	 the	 apex	 or	myocardial	 ischemia	 by	 permanent	 ligation	 of	 the	 left	 anterior	 descending	 artery	(Porrello	et	al.	2011	and	Porrello	et	al.	2012).			Neonatal	 post-MI	 mice	 hearts	 were	 characterized	 by	 a	 robust	 cardiomyocyte	proliferation	from	pre-existing	cardiomyocytes	and	de	novo	formation	of	large	coronary	vessels	 in	 the	 infarcted	 area.	 Interestingly,	 not	 all	 newly	 formed	 cardiomyocytes	 are	derived	 from	 pre-existing	 cardiomyocytes.	 In	 fact,	 neonatal	 post-MI	 mouse	 hearts	induced	the	localized	expression	of	the	c-kit	and	Nkx2.5	expressing	cells	that	contribute	to	 the	myogenic	and	vascular	 fates	(Jesty	et	al.	2012).	Strikingly,	 fibrotic	scar	 tissue	 in	neonatal	mouse	hearts	 is	almost	completely	resolved	within	21	days	post-MI	(Porrello	et	 al.	 2011).	 MI	 studies	 on	 monocyte/macrophage	 depleted	 hearts	 within	 this	 brief	window	during	post-natal	development	indicated	that	macrophages	are	essential	for	de	
novo	 vascularisation	 rather	 than	 for	 stimulating	 fibrosis	 and	 scar	 tissue	 formation.	Interestingly,	 cardiomyocyte	 proliferation	 was	 not	 dependent	 on	monocytes/macrophage	 depletion	 (Aurora	 et	 al.	 2014).	 All	 these	 studies	 indicate	 that	full	cardiac	repair	is	achieved	when	the	three	missing	hallmarks	are	met,	however,	the	lost	of	regenerative	potential	beyond	7	days	after	birth	is	yet	not	fully	understood.		
1.3	Cardiovascular	heart	diseases	Cardiovascular	 heart	 diseases	 (CHD),	which	 are	mainly	 disorders	 of	 the	 blood	 vessels	and	the	heart,	are	the	number	one	cause	of	death	globally	(Go,	Alan	et	al.	2014).	In	the	UK,	 CHD	 represent	 29%	 of	 all	 deaths	 and	 it	 is	 estimated	 that	 7	 million	 people	 are	currently	 suffering	 from	 CHD.	 Among	 the	 most	 common	 types	 of	 cardiovascular	diseases,	ischemic	injury	leading	to	left	ventricular	dysfunction	also	known	as	MI,	is	the	
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CHD	with	 the	highest	death	 rate	 (Douglas	 et	 al.	 2012	and	Clyde	 et	 al.	 2013).	 From	an	economic	 standpoint,	 the	 direct	 and	 indirect	 CVD	 costs	 are	 estimated	 to	 £19	 billion	 a	year	to	the	UK’s	economy	(Cardiovascular	disease	statistics,	BHF,	2014)	
	
1.3.1	Clinical	features	of	myocardial	infarction	In	 pathology,	 myocardial	 infarction	 (MI)	 is	 defined	 as	 myocardial	 cell	 death	 due	 to	prolonged	 ischemia	 (Jaffe	 et	 al.	 2013).	 As	 discussed	 in	 Section	 1.1,	 because	 of	 the	inability	of	the	heart	to	regenerate,	the	damaged	myocardium	becomes	necrotic	within	2-4	hours	 after	 injury.	The	 extent	of	damage	 to	 the	myocardium	depends	both	on	 the	collateral	 circulation	 of	 the	 ischemic	 zone,	 which	 supply	 the	 heart	 with	 oxygen-rich	blood,	 and	 the	 length	of	 time	 the	occlusion	 is	present.	The	entire	process	 leading	 to	 a	healed	 myocardium	 usually	 takes	 at	 least	 5-6	 weeks,	 which	 by	 then,	 if	 untreated,	jeopardises	the	functionality	of	the	heart	(Jaffe	et	al.	2013	and	Clyde	et	al.	2013).	Due	to	the	 inability	of	 the	heart	 to	 regenerated,	 the	healing	of	 the	 infarcted	myocardium,	 is	a	process	 by	 which	 the	 left	 ventricle	 undergoes	 remodeling	 through	 a	 a	 succession	 of	molecular,	 cellular,	 and	 extracellular	 changes	 that	 culminate	 in	wall	 thinning,	 dilation,	and	 fibrosis	 (Smart	 et	 al.	 2014).	This	process	 is	 necessary	 to	prevent	 cardiac	 rupture,	maladaptive	remodeling.		In	the	clinical	environment,	the	symptoms	associated	with	the	onset	of	MI,	which	results	from	an	imbalance	between	oxygen	supply	and	demand,	are	the	initial	step	to	recognise	and	 determine	 if	 a	 patient	 is	 suffering	 from	 a	 MI	 event	 or	 heart	 attack.	 Symptoms	typically	 include	 chest	 pain,	 upper	 extremity	 pain,	 sweating,	 anxiety	 and	 light-headedness.	Dyspnoea	and	fatigue	are	also	observable	symptoms	of	the	deficit	in	oxygen	supply	 as	well	 as	 the	 deterioration	 in	 heart	 function	(Jaffe	 et	 al.	 2013).	 An	 additional	indicator	of	MI,	signalling	to	clinicians	that	myocardial	injury	is	present,	is	the	release	of	cardiac	biomarkers	into	the	circulation	as	a	consequence	of	cardiac	injury.	The	necrosis	process	 discharges	 specific	 biomarkers,	 which	 are	 chiefly	 proteins	 and	 peptides	 from	neurohormonal	systems,	myocardial	enzymes	and	structural	proteins.	Elevated	levels	of	these	biomarkers	can	be	easily	detected	by	performing	simple	tests	to	determine	their	concentration	 in	 plasma.	 Peptides	 such	 as	 BNP	 (brain	 natriuretic	 peptide)	 and	 NT-proBNP	 (pro-brain	 natriuretic	 peptide)	 are	 associated	 with	 ventricular	 dysfunction.	Levels	of	biomarkers	may	remain	elevated	 for	2	weeks	or	more	 following	the	onset	of	myocyte	necrosis	 (Thygesen	et	al.	2009	and	McMurray	et	al.	2013).	These	biomarkers	have	been	used	in	this	thesis	to	evaluate	the	level	of	cardiac	damage	after	MI.		
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1.3.2	Immune	system	response	after	myocardial	infarction			After	MI,	the	injured	myocardium	releases	inflammatory	signals	that	trigger	a	battery	of	cellular	processes	 in	order	to	clean,	restore	and	repair	 the	damaged	tissue.	The	 innate	immune	system	is	the	host’s	first	line	of	defence	against	injury	and	infection.	As	part	of	this	defence	mechanism,	myeloid	cells	such	as	neutrophils	and	monocytes	are	recruited	to	 initiate	 the	 inflammatory	 response,	 which	 will	 lead	 to	 a	 healed	 myocardium	(Nahrendorf	et	al.	2013).	At	the	site	of	injury,	these	two	populations	release	proteolytic	enzymes	 and	 reactive	 oxygen	 species	 (ROS),	 which	 eliminate	 dead	 or	 dying	 tissue	facilitating	 the	 repair	 of	 the	 wound	 (Frangogiannis	 et	 al.	 2002).	 	 Monocytes	 are	primarily	 produced	 in	 the	 bone	 marrow	 from	 progenitor	 cells.	 Upon	 maturation,	monocytes	enter	the	circulation,	where	they	patrol	vessels	 for	several	days	(Auffray	et	al.	 2009	 and	 Skalak	 et	 al.	 2007).	 When	 an	 injury	 such	 as	 MI	 occurs,	 monocytes	 and	neutrophils	 orchestrate	 heart’s	 healing	 process,	 which	 in	 humans,	 may	 require	 up	 to	two	weeks	(Nahrendorf	et	al.	2010).			
1.3.2.1	Activation	of	the	inflammatory	process	Myocardial	 cell	 necrosis	 leads	 to	 the	 release	 of	 subcellular	 components	 such	 as	mitochondrial	 membranes,	 which	 are	 capable	 of	 triggering	 the	 C1,	 C2,	 C3	 and	 C4	components	of	the	complement	cascade	(Pinckard	et	al.	1975).	Complement	activation	is	 considered	 one	 of	 the	 early	 events	 triggered	 by	 the	 damaged	myocardium	with	 an	important	 and	 direct	 role	 in	 mediating	 neutrophil	 and	 monocyte	 recruitment	 in	 the	injured	 myocardium,	 thus	 initiating	 the	 inflammatory	 process	 and	 wound	 healing	(Vakeva	et	al.	1998).	In	1998,	Vakeva	and	collaborators	demonstrated	that	blockade	of	the	 complement	 cascade,	 by	 anti-C5	 monoclonal	 antibody,	 significantly	 inhibited	neutrophil	and	monocyte	infiltration	as	well	as	apoptosis	and	necrosis	after	MI.	Another	complement	 component	 such	 as	 C3b	 is	 important	 for	 phagocytosis	 and	 iC3b	 is	 an	important	ligand	for	CD11b-mediated	neutrophil	adherence	(Vakeva	et	al.	1998).		Another	 key	 component	 involved	 in	 triggering	 the	 inflammatory	 response	 are	 the	reactive	oxygen	 species	 (ROS)	 generated	by	neutrophils	 in	 the	 ischaemic	myocardium	especially	 after	 reperfusion,	which	 can	 directly	 injure	 the	 cell	membrane	 of	myocytes	and	vascular	cells	 (Hori	et	al.	2009	and	Duilio	et	al.	2001).	This	process	has	also	been	reported	 to	 be	 involved	 in	 the	 activation	 of	 inflammatory	 cascades	 and	 cytokine	production,	 which	 can	 also	 trigger	 the	 recruitment	 of	 neutrophils	 and	 monocytes	(Dhalla	et	al.	2000).	
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1.3.2.2	Neutrophil-	and	macrophage-mediated	inflammatory	responses	Akin	to	an	orchestra,	inflammation	is	modulated	through	control	of	the	timing	and	pace	at	which	cells	are	recruited	to	the	injured	site.	If	the	rhythm	of	inflammation	is	lost	due	to	 underlying	 disease,	 it	may	 lead	 to	 chronic	 inflammation,	 considered	 as	 unresolved	inflammation.	 Through	 interactions	 with	 chemokine	 and	 its	 receptors	 expressed	 by	leukocyte	 subpopulations,	 the	 chemokine	 expression	 profile	 in	 the	 infarcted	myocardium	 determines	 the	 composition	 of	 the	 leukocytic	 infiltrate.	 Leukocyte	infiltration	 from	 blood	 into	 the	 infarcted	 myocardium	 requires	 adhesive	 interactions	with	 activated	 vascular	 endothelial	 cells	 involving	 a	 family	 of	 cell	 adhesion	 receptors,	the	 selectins.	 Neutrophils,	 first	 immune	 cells	 recruited	 to	 the	 damaged	 myocardium,	represent	 the	 primary	mechanism	 for	 local	 amplification	 of	 the	 inflammatory	 process	(Jordan	et	al.	1999	and	Frangogiannis	et	al.	2002).	The	main	function	of	neutrophils	 is	the	clearenace	at	the	injure	site	through	the	phagocytosis	of	dying	cells,	cellular	debris	and	 the	 reabsorption	 of	 the	 necrotic	 tissue.	 These	 functions	 are	 facilitated	 through	 at	least	3	major	mechanisms:	 (i)	ROS	release,	 (ii)	 release	of	arachidonic	acid	metabolites	and	 platelet	 activating	 factors,	 (iii)	 elastase	 and	 protease	 degranulation	 (Jordan	 et	 al.	1999	and	Duilio	et	al.	2001).		Following	 the	 initial	 burst	 of	 neutrophils,	 other	 immune	 cells	 such	 as	 monocytes,	macrophages,	 dendritic	 cells,	 lymphocytes	 and	mast	 cells	 are	 also	 recruited	 from	 the	bloodstream	 to	 the	 damaged	myocardium.	 In	 the	 infarction	 orchestra,	monocytes	 and	macrophages	are	the	major	cell	types	dominating	the	inflammatory	process	(Arnold	et	al.	 2007).	 In	 this	 context,	 macrophages	 undertake	 removal	 of	 cellular	 debris	 and	apoptotic	 neutrophils	 via	 phagocytosis;	 regulate	 inflammation	 and	 protective	 scar	formation.	 Moreover,	 macrophages	 support	 cell	 proliferation	 and	 re-pattern	 vascular	architecture	 (Swirski	 et	 al.	 2013	 and	 Frangogiannis	 et	 al.	 2014).	 The	 participation	 of	macrophages	in	the	body’s	response	to	injury	is	endorsed	by	their	capacity	to	detect	and	migrate	 to	 sites	 of	 tissue	 damage.	 To	 achieve	 this,	 macrophages	 express	 many	chemokine	receptors	and	pattern	recognition	receptors	that	enable	chemotaxis.			In	 acute	 injury,	 the	 temporal	 dynamics	 of	 monocytes	 is	 controlled	 by	 cytokines	 and	chemokines	produced	during	this	process	(Figure	1.2).	In	mice,	from	days	1	to	3	after	MI,	 inflammatory	 Ly-6Chigh	 monocytes	 are	 recruited	 via	 the	 MCP-1/CCR2	 chemokine	(Uguccioni	et	al.	1995).	From	3	to	5	days,	another	type	of	monocyte,	Ly-6Clow	monocytes,	are	recruited	via	fractalkine/CX3CR1	(Swirski	et	al.	2013	and	Florian	et	al.	2012).	These	monocytes	may	give	rise	 to	 the	 inflammatory	and	reparative	macrophage	populations,	
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being	 temporally	 regulated	 by	 inflammatory	 macrophages	 preceding	 reparative	macrophage	populations.	During	the	inflammatory	phase	(Figure	1.2	and	 Figure	1.3),	this	 first	wave	 of	 inflammatory	monocytes	 is	 polarized	 to	 inflammatory	macrophages	and	resembles	a	“demolition	crew”,	removing	debris	and	necrotic	cardiomyocytes	at	the	infarct	 site.	 Inflammatory	macrophages	 amplify	 signals	 such	 as	 IL-1β,	 IL-12	 and	nitric	oxide	 (NO),	 phagocytosing	 cellular	 debris	 and	 releasing	 chemokines	 to	 recruit	 more	inflammatory	cells.	After	the	clean-up	phase,	during	the	reparative	phase	(Figure	1.2),	reparative	 macrophages	 support	 and	 promote	 the	 deposition	 of	 new	 extracellular	matrix	 as	 a	 central	 part	 of	 the	 granulation	 tissue	 formed	 in	 the	 wound.	 In	 addition,	reparative	 macrophages	 display	 an	 anti-inflammatory	 profile	 which	 promote	 cell	growth	 and	 regeneration,	 as	 well	 as	 serve	 as	 mediators	 on	 the	 resolution	 of	 the	inflammatory	 process	 due	 to	 high	 production	 of	 IL-10,	 TGFβ	 and	 IGF-1	 itself	(Danielpour	et	al.	2006,	Frangogiannis	et	al.	2014	and	Bujak	et	al.	2007).	The	reparative	population	 further	 dampens	 the	 activity	 of	 inflammatory	 macrophages,	 assisting	progression	 from	 the	 inflammatory	 to	 the	 regenerative	 phase	 of	 repair.	 Inflammatory	macrophages	 must	 be	 tightly	 regulated	 since	 the	 inflammatory	 cytokines	 and	 ROS	species	released	can	directly	cause	myofibre	lysis,	exacerbating	injury.		
	
Figure	 1.2.	 Biphasic	 monocyte/macrophage	 inflammatory	 response	 and	 remodelling	
process	 after	 myocardial	 infarction	 in	 the	 mice.	 CF,	 cardiac	 fibroblast;	 CMF,	 cardiac	myofibroblast;	 ECM,	 extracellular	 matrix;	 GF,	 growth	 factor;	 MMP,	 matrix	 metalloproteinase.	Adapted	from		Nieuwenhoven	et	al.	2013.		
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It	 is	 important	 to	 discuss	 that	 the	 current	 view	 on	 monocyte/macrophage-mediated	inflammatory	 response	 is	 still	 controversial.	 There	 is	 considerable	 evideance	 that	monocyte	 subsets	 and	 macrophage	 correspond	 to	 each	 other.	 However,	 there	 is	 still	insufficient	 knowledge	 regarding	 the	 lineage	 relationships	 of	 monocyte	 and	macrophages	 after	 MI	 (Tacke	 et	 al.	 2007).	 Matthias	 Nahrendorf	 and	 colleagues	 have	provided	 some	 insights	 into	 how	 this	 relationship	 might	 be	(Nahrendorf	 et	 al.	 2010,	Nahrendorf	 et	 al.	 2013	and	Hilgendorf	 et	 al.	 2014).	During	myocardial	 injury,	 Ly6Chigh	monocytes	 acquire	 inflammatory-like	 macrophage	 properties.	 These	 inflammatory	macrophages	continue	 to	express	Ly-6C,	 and	contribute	 to	 inflammation	 (Figure	 1.3).	Over	 time,	 the	 inflammatory	 environment	 changes	 towards	 a	 more	 reparative	environment	 with	 a	 second	 Ly6Cint/low	monocytes	 being	 recruited.	 It	 is	 still	 unknown	whether	macrophages	 at	 the	 reparative	phase	 arise	 via	 the	differentiation	of	 Ly-6Chigh	monocytes	 (Figure	 1.3)	 and	 less	 via	 differentiation	 of	 Ly6Clow	 monocytes	 or	 via	polarization	of	 inflammatory	macrophages	 to	reparative	macrophages	as	suggested	by	Tonkin	et	al.	2015.																
Figure	 1.3.	 Potential	 lineage	 relationships	 of	 monocytes	 and	 macrophages	 after	
myocardial	 infarction.	The	only	lineage	relationship	which	is	widely	accepted	to	be	happening	is	 the	 Ly-6Chigh	 monocytes	 contribution	 to	 inflammatory	 Ly6Chigh	 macrophages	 in	 tissue.	 The	other	lineage	relationships	presented	in	this	figure	remain	to	be	experimentally	explored	in	the	setting	of	acute	myocardial	infarction.	Extracted	from	Nahrendorf	et	al.	2013.		
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Furthermore,	the	resident	cardiac	tissue	macrophages	(cTM),	which	do	not	rely	on	the	bone	 marrow	 for	 replenishment	 but	 rather	 selfrenewal,	 from	 local	 progenitors	 or	through	proliferation	cell	contribution	to	wound	healing	resolution	 it	 is	still	unknown.	Pinto	and	collaborators	have	provided	with	new	insights	on	the	role	of	cTM	in	normal	homestatic	 functions.	 cTM	 expression	 analysis	 with	 other	 adult	 tissue	 macrophages	exhibit	an	anti-inflammatory	phenotype	and	the	capacity	to	secrete	salutary	factors	such	as	IGF-1	(Pinto	et	al.	2012).		
1.3.2.3	Wound	healing	and	heart	remodeling	As	previously	described	in	Section	1.2,	the	heart	cannot	regenerate	and	therefore	other	mechanisms	are	established	to	preserve,	as	much	as	possible,	the	integrity	and	stability	of	 the	 heart.	 When	 the	 inflammatory	 activity	 resolves,	 non-leukocytic	 cells	 carry	 the	remodeling	process	forward	in	order	to	replace	the	missing	myocardium	with	a	newly	synthesised	extracellular	collagen	matrix	(ECCM),	the	fibrotic	scar.		The	maturation	phase	 (Figure	 1.2),	 following	 the	 inflammatory	and	 reparative	phase,	involves	 the	 recruitment	 and	 activation	 of	 endothelial	 cells	 (Zeisberg	 et	 al.	 2007)	 and	bone	 marrow	 cells	 (Mollmann	 et	 al.	 2006).	 Additionally,	 interstitial	 and	 vascular	fibroblasts	trans-differentiate	into	cardiac	fibroblasts.	Recent	studies	indicated	that	the	conversion	 from	 fibroblast	 to	 myofibroblast	 requires	 the	 activation	 of	 TGF-β	(Frangogiannis	 et	 al.	 2014,	 Nieuwenhoven	 et	 al.	 2013	 and	 Bujak	 et	 al.	 2007)	 and	 the	removal	of	pro-inflammatory	mediators	such	as	IL-1β.	These	cardiac	fibroblasts	deposit	large	amounts	of	collagen,	which	preserves	the	structural	and	functional	integrity	of	the	ventricle,	strengthening	the	emerging	scar	(Jugdutt	et	al.	2003).		At	histological	level,	in	mice	and	humans	these	changes	may	take	months.	After	MI,	the	main	feature	is	a	thinning	in	the	left	ventricular	wall	accompanied	with	expansion	of	the	infarct	zone.	Consequently,	 the	mechanisms	previously	described	 induce	alterations	 in	the	 left	 ventricule	 (LV)	 function,	 filling	 pressure,	 wall	 stress,	 shape	 and	 volume	 and	generates	 a	 process	 called	 adverse	 remodeling.	 These	 adaptive	 changes	may	preserve	structural	 integrity	 but	 may	 also	 lead	 over	 time	 to	 infarct	 expansion,	 left	 ventricular	dilation,	 and	 left	 ventricular	 wall	 thinning	 and	 in	 some	 cause	 to	 infarct	 rupture	 and	death	 also	 know	 as	 myocardial	 infarction-derived	 heart	 failure	 (Van	 der	 Laan	 et	 al.	2012).	 	 Conversely,	 therapies	 are	 designed	 to	 provide	 sufficient	 healing	 in	 order	 to	preserve	left	ventricular	geometry	and	to	prevent	heart	failure	(Nahrendorf	et	al.	2010).		
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1.3.3	Current	treatments	after	myocardial	infarction-derived	heart	failure	Over	 the	past	decades,	 treatment	 for	MI	has	made	 significant	progress;	 unfortunately,	MI	 remains	 an	 unsolved	 therapeutic	 target.	 Current	 treatments	 for	 MI	 embrace	 all	aspects	 of	 the	 disease	 process,	 from	 changes	 in	 lifestyle	 to	 surgical	 intervention.	Although	heart	transplant	is	still	considered	today,	the	number	of	patients	that	undergo	cardiac	 replacement	 is	 limited	 mainly	 due	 to	 the	 low	 availability	 of	 organ	 donors	(McMurray	et	al.	2013).			When	coronary	arteries	become	occluded	or	narrowed	due	to	coronary	heart	diseases,	invasive	 interventional	 strategies	 are	 applied	 in	 order	 to	 improve	 or	 restore	 blood	supply.	Following	the	removal	of	the	obstruction,	several	pharmacological	strategies	for	the	treatment	of	ischemic	disease	are	facilitated	to	reduce	or	block	cardiac	remodeling	and	prevent	heart	failure	(Minicucci	et	al.	2011).	To	boost	the	reparative	capacity	of	the	heart,	 pharmacological	 strategies	 could	 potentially	 be	 combined	 with	 cell-based	therapies	(Ptaszek	et	al.	2012)	and	gene	transfer	therapies	(Fang	et	al.	2013,	Kaspar	et	al.	2005	and	Muller	et	al.	2006).			In	 order	 to	 design	 successful	 therapies	 to	 ameliorate	 the	 adverse	 effects	 of	 heart	remodeling,	 further	 understanding	 of	 the	 current	 available	 treatments	 is	 required.	 A	more	detailed	overview	of	the	main	strategies	for	the	treatment	of	the	post-MI	condition	is	presented	in	the	following	sections.			
1.3.3.1	Interventional	cardiology	after	myocardial	infarction	Current	 interventions	 for	 ischemic	 injury	 are	 targeted	 at	 physical	 removal	 of	 the	obstructions	 of	 the	 heart	 vessels	 to	 restore	 blood	 flow	 to	 ischemic	 tissue.	 These	interventions	fall	into	two	main	categories:	coronary	artery	bypass	graft	(CABG)	surgery	and	percutaneous	coronary	intervention	(PCI)	also	called	coronary	angioplasty	(Deb	et	al.	 2013).	 However,	 these	 interventions	 will	 only	 transiently	 eliminate	 the	 symptoms	especially	 if	 the	obstruction	 is	caused	by	 the	rupture	of	an	atherosclerotic	plaque.	The	reperfusion	 that	 comes	 after	 removing	 the	 obstruction	 has	 the	 potential	 to	 rescue	myocardium	at-risk,	however,	 for	 the	myocardium	that	 is	unable	to	survive	the	 injury,	reperfusion	 is	 of	 little	 help.	 In	 fact,	 reperfusion	 of	 the	 tissue	 leads	 to	 increased	 ROS	production,	 which	 potentially	 causes	 adverse	 effects	 on	 the	 surviving	 myocardium	(Zweier	 et	 al.	 1988).	 Research	 is	 now	 focused	 on	 promoting	 the	 regeneration	 of	 the	myocardium	 that	 is	 unable	 to	 survive	 through	 cell-	 or	 gene-based	 approaches	 which	
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aims	 to	 promote	 the	 reparative/regenerative	 abilities	 of	 the	 heart.	 These	 approaches	are	further	discussed	in	Section	1.4.	
	
1.3.3.2	Pharmacological	treatment	after	myocardial	infarction	Several	drugs	have	shown	to	be	the	best	approach	to	ameliorate	the	adverse	effects	of	MI-derived	heart	failure.	The	drugs	are	designed	to	target	the	neurohormonal	pathways,	in	 particular	 the	 pharmacological	 inhibition	 of	 the	 renin-angiotensin-aldosterone	 and	sympathetic	 nervous	 systems.	 The	 main	 drugs	 are	 angiotensin-converting-enzyme	(ACE)	 inhibitors	 and	 β-blockers	 which	 have	 been	 demonstrated	 to	 prevent	 left	ventricular	remodeling	and	reduce	mortality	after	MI.		
ACE	inhibitors:	ACE	inhibitors	are	considered	a	first-line	therapy	for	all	patients	after	MI.	ACE	drugs	 inhibit	 the	 angiotensin-converting	 enzyme,	 an	 important	 component	of	 the	renin-angiotensin	aldosterone	system.		These	drugs	cause	relaxation	of	blood	vessels,	as	well	 as	decrease	blood	 leading	 to	 a	decrease	 in	blood	pressure	 and	decreased	oxygen	demand	from	the	heart.	ACE	inhibitors	such	as	trandolapril	(Torp-pedersen	et	al.	1994),	zofenopril	(Ambrosioni	et	al.	1995)	and	ramipril	(Cleland	et	al.	1993,	Pfeffer	et	al.	1992)	have	been	demonstrated	to	improve	the	outcome	of	patients	after	MI.	The	Survival	And	Ventricular	Enlargement	(SAVE)	trial	was	the	first	to	report	the	beneficial	effect	of	the	ACE	 inhibitor	 captopril	 on	 patients	 after	MI	 (Pfeffer	 et	 al.	 1992).	 Results	 showed	 that	administration	of	captopril	for	two	years	resulted	in	a	27%	reduction	in	mortality	and	a	25%	reduction	in	re-infarction	rate	in	patients	with	left	ventricular	dysfunction.		
β-blockers:	β-blockers	block	the	action	of	endogenous	catecholamines	(adrenaline)	and	noradrenaline	on	the	adrenergic	beta-receptors,	of	the	sympathetic	nervous	system.	The	effect	of	beta-blockers	in	the	heart	is	to	reduce	the	heart	rate	besides	a	decrease	in	renin	secretion	by	 the	kidney,	which	 in	 turn	 reduced	 the	heart	oxygen	demand	by	 lowering	extracellular	 volume	 and	 increasing	 the	 oxygen-carrying	 capacity	 of	 the	 blood.	 The	Carvedilol	Post-Infarct	Survival	Control	in	LV	dysfunction	(CAPRICORN)	trial	tested	the	effects	of	beta-blocker	agents	 in	patients	with	 left	ventricular	dysfunction	after	MI	and	<40%	ejection	fraction.	In	this	trial,	the	administration	of	carvedilol	was	associated	with	a	23%	decrease	 in	mortality	 and	a	40%	reduction	 in	 re-infarction	 rate	 after	1.3	years	(Harris	et	al.	1992).			Other	 pharmacological	 treatments	 using	 angiotensin-II	 receptor	 blockers	 (ARB)	 and	aldosterone	 have	 shown	 similar	 results.	 Additionally,	 no	 differences	 in	 mortality	 or	
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morbidity	were	found	with	these	treatments	when	compared	with	ACE	inhibitors.	Thus,	both	drugs	can	be	used	as	alternatives	to	ACE	inhibitors.			All	 the	 drugs	 described	 here	 improve	 the	 course	 of	 heart	 failure	 after	 MI,	 exerting	 a	positive	 effect	 on	 the	 outcome	 of	 the	 patient	 as	 well	 as	mortality	 and	 hospitalisation	times.	Besides	the	administration	of	these	drugs,	diuretics	are	also	given,	to	relieve	the	symptoms	and	signs	of	congestion	(Minicucci	et	al.	2011).		
	
1.3.3.3	Other	post-MI	treatments:	implantable	medical	devices	After	 MI,	 electrical	 coupling	 in	 the	 heart	 becomes	 compromised	 at	 the	 fibrotic	 area,	which	may	lead	to	lethal	arrhythmias	and	potentially	sudden	death.	Implantable	medical	devices	are	designed	to	prevent	sudden	cardiac	death.	Implantable	medical	devices	are	classified	 according	 to	 their	 function	 as	 (i)	 rhythm	 control	 and	 (ii)	 to	 support	 the	circulation	(American	Heart	association	website).			For	 rhythm	 control,	 the	 implantable	 cardioverter-defibrillator	 or	 ICD	 device	 is	commonly	 used	 and	 recommended	 to	 patients	 who	 develop	 sustained	 ventricular	tachycardia	 (VT)	or	ventricular	 fibrillation	 (VF)	48h	after	MI.	The	device	 continuously	monitors	 the	 rhythms	 of	 the	 heart	 and	 delivers	 electrical	 countershocks	 to	 restore	normal	rhythm	(American	Heart	association	website).	Another	rhythm	control	device	is	the	 well-known	 pacemaker.	 Similar	 to	 the	 cardioverter-defibrillator,	 the	 pacemaker	controls	 heart	 rhythm.	 The	 pacemaker,	 however,	 is	 recommended	 when	 the	 heart’s	‘natural	pacemaker’	 is	defective,	 causing	 the	heart	 to	beat	 either	 too	 slow,	 too	 fast,	 or	irregularly	 (American	 Heart	 association	 website).	 	 The	 other	 most	 common	 ICDs	 are	those	 that	 support	 circulation,	 the	 so-called	 left	 ventricular	 assist	 devices	 or	 LVAD.	 In	stages	of	advanced	heart	failure,	this	device	maintains	the	pumping	ability	of	the	heart	when	the	left	ventricle	is	no	longer	able	to	perform	such	work.	LVADs	are	also	known	as	‘bridge	 to	 transplant’	 devices,	 mainly	 because	 this	 mechanical	 pump	 is	 implanted	 in	patients	waiting	for	a	heart	transplant	(Frazier	et	al.	1994	and	Birks	et	al.	2005).		Unfortunately,	interventional	and	pharmacological	strategies	only	boost	and	reduce	the	worsening	 of	 heart’s	 condition,	 however,	 these	 strategies	 do	 not	 boost	 the	 intrinsic	capacity	 of	 the	 heart	 to	 regenerate	 and	 repair	 itself.	 Therefore,	 new	 therapeutic	strategies	 are	 being	 researched	 to	 potentially	 work	 in	 synergy	 with	 pharmacological	strategies	to	promote	heart’s	own	capacity	to	regenerate	and	repair	itself.			
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1.4	Therapeutic	approaches	for	myocardial	infarction	injury		Over	the	past	decade,	the	use	of	cellular	therapy	has	emerged	as	a	promising	option	to	treat	patients	after	MI.	In	order	to	improve	cardiac	function	in	the	injured	myocardium,	two	 main	 strategies	 can	 be	 followed:	 delivering	 cells	 from	 either	 heterologous	 or	autologous	 sources	 to	 promote	 repair/regeneration	 or	 stimulating	 the	 endogenous	regenerative	capacity	of	the	heart.		
1.4.1	Cell-based	therapeutic	approaches	One	 of	 the	 first	 cell-based	 attempts	 that	 aimed	 to	 achieve	 improvement	 of	 cardiac	function	through	cardiac	regeneration	involved	the	use	of	skeletal	myoblasts	(Menasche	et	 al.	 2008).	 Although	 these	 cells	 do	 not	 have	 a	 cardiac	 origin,	 the	 transplantation	 of	these	donor	 cells	was	 reported	 to	 improve	 cardiac	 functionality	 after	MI.	While	 initial	results	were	promising,	 further	 tests	carried	out	shortly	after	 in	animal	models	and	 in	human	 trials	 raised	 concerns	 and	 doubts	 about	 cell	 engraftment.	 The	 Myoblast	Autologous	Grafting	in	Ischemic	Cardiomyopathy	(MAGIC)	trial	showed	that	these	cells	failed	 to	 improve	 cardiac	 functionality	 and	 ventricular	 contractile	 function.	Interestingly,	 skeletal	myoblasts	 did	 indeed	 engraft,	 but	 instead	 of	 differentiating	 into	cardiomyocytes,	 they	 became	 skeletal	 myocytes.	 Furthermore,	 the	 engrafted	 skeletal	myocytes	were	not	electrically	 coupled	with	 the	healthy	myocardium	(Menasche	et	al.	2008).		In	 2011,	 bone	 marrow-derived	 cells	 (BMCs)	 began	 to	 be	 considered	 the	 cell	 type	 of	choice	 for	 cell-based	 therapies	 (Chavakis	 et	 al.	 2010).	 BMCs	 have	 the	 potential	 to	differentiate	into	diverse	phenotypes.	Secondly,	BMCs	can	be	easily	procured	and	third,	these	 cells	 do	 not	 require	 extensive	 culture	 techniques	 (Birks	 et	 al.	 2005).	 The	work	from	Piero	Anversa	and	colleagues	suggested	that	stem	cells	found	in	the	bone	marrow	could	be	differentiated	into	functional	cardiomyocytes	(Orlic	et	al.	2001	and	Quaini	et	al.	2002).	However,	in	2004,	the	reproducibility	of	Anversa’s	experiments	was	questioned	when	Charles	Murry	and	collaborators	found	that,	in	fact,	haemotopoietic	stem	cells	do	not	transdifferentiate	into	cardiac	myocytes	after	MI	(Sil	et	al.	2004).	Later	on,	Van	Berlo	and	 collaborators	 found	 that	 the	 endogenous	 cardiac	 stem	 cells	 (eCSCs)	 c-kitpos	 were	indeed	 capable	 of	 differentiating	 into	 new	 cardiomyocytes	 at	 a	 rate	 of	 approximately	0.03%.	These	authors	concluded	that	this	percentage	could	not	substantially	contribute	to	improve	cardiac	function	to	a	significant	level	(Van	Berlo	et	al.	2014).		
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Many	 preclinical	 and	 clinical	 trials	 carried	 out	 after	 these	 discoveries	 also	 produced	controversial	and	conflicting	results.	Preclinical	tests	in	dogs	(Mathieu	et	al.	2009)	and	rats	(Kim	et	al.	1999)	reported	that	BMC	transplantation	improved	myocardial	function	and	angiogenesis,	and	led	to	a	reduction	in	plasma	levels	of	Nppb	(N-terminal	probrain	natriuretic	peptide).	 In	contrast	to	these	finding,	studies	 in	sheep	(Bel	et	al.	2003)	and	pigs	 (Waksman	et	 al.	 2004),	 reported	 that	BMC	 therapy	produced	no	 improvement	 in	left	 ventricular	 function.	 The	 reason	 for	 these	 differences	 are	 not	 obvious,	 but	 the	hypothesis	 put	 forward	 was	 that	 perhaps	 the	 technique	 employed	 to	 cause	 the	infarction,	the	specie	selected	for	the	study	and	the	site	of	cell	delivery	could	have	been	contributing	factors	for	such	disappointing	results	(Bel	et	al.	2003).			At	the	clinical	 level,	the	use	of	BMC	to	treat	chronic	MI	has	provided	modest	benefit	 in	most	 but	 not	 all	 studies.	 Unfortunately,	 the	 disparity	 between	 results	 has	 sent	researchers	back	to	the	bench	to	gain	a	clearer	understanding	on	the	exact	mechanism	of	 action	 of	 BMCs.	 Other	 aspects	 that	 are	 being	 considered	 include	 the	 type	 of	 donor	stem	cell,	the	enhancement	of	homing	capacities,	dose	and	route	of	administration	and	improvement	 of	 long-term	 engraftment	 (Bolli	 et	 al.	 2001	 and	 Ptaszek	 et	 al.	 2012).	Hypothetically,	 if	 the	 damaged	myocardium	 is	 replenished,	 there	 is	 no	 guarantee	 that	electrical	 coupling	 will	 be	 achieved,	 thus	 further	 studies	 should	 tackle	 that	 aspect	 as	well.		The	clinical	 trials	with	 the	most	promising	results	 to	date	using	cell-based	 therapy	 for	the	 treatment	of	MI	 are	 the	REPAIR-AMI	 and	BALANCE	 studies.	 In	2006,	 the	REPAIR-AMI	 study,	 the	 first	 of	 this	 kind,	 quantified	 global	 improvement	 in	 left	 ventricular	ejection	 fraction.	 Two	 hundred	 and	 four	 patients	 were	 randomized	 to	 receive	 an	intracoronary	injection	of	2.36x107	bone	marrow-derived	stem	cells	3	to	7	days	after	MI.	After	1	year,	cell-transplanted	patients	showed	a	reduction	 in	death	and	recurrence	of	MI	(Gersh	et	al.	2007).	The	BALANCE	study	in	2009,	following	a	similar	approach	as	the	REPAIR-AMI	 study,	 investigated	 the	 quantitative	 improvement	 in	 ventricular	 function	and	contractility	of	patients	treated	with	autologous	bone	marrow	cells	after	MI.	From	124	patients,	62	underwent	 intracoronary	bone	marrow	cell	 infusion	5	to	9	days	after	MI.	In	this	case,	6.1±3.9	x	107	bone	marrow-derived	cells	were	infused	directly	into	the	infarct	 area	 via	 an	 angioplasty	 balloon	 catheter.	 Three	 months	 after	 BMC	 therapy,	patients	displayed	an	improvement	in	cardiac	function	and	in	the	stroke	volume	index.	The	study	also	showed	a	reduction	in	mortality	only	in	the	BMC-treated	group	(Yousef	et	al.	2009).	
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In	conclusion,	the	heart	is	a	remarkable	organ,	made	of	various	cell	types	with	different	functionality.	 Because	 of	 this	 complexity,	 a	 single	 approach	 to	 promote	 cardiac	regeneration	 has	 proved	 to	 be	 challenging;	 therefore,	 the	 ideal	 cardiac	 regenerative	therapy	would	comprise	a	combination	of	key	cells	working	 in	synergy	with	paracrine	factors	 to	 create	 a	 permissive	 environment	 for	 the	 heart	 to	 heal	 or	 even	 regenerate.	Many	other	cell	types,	including	mesenchymal	stem	cells,	CD34+/CD133+	cells,	adipose-derived	 cells,	 iPS	 cell-derived	 cardiomyocytes	 and	 cardiac-derived	 cells,	 are	 also	currently	being	used	in	both	preclinical	and	clinical	studies	with	great	potential	(Ptaszek	et	 al.	 2012).	 Future	 regenerative	 therapies	 will	 need	 to	 combine	 aspects	 of	 stem	 cell	biology,	 tissue	 engineering,	 modulation	 of	 the	 inflammatory	 response,	 organ/tissue	transplantation,	 personalised	 medicine,	 pharmacological	 treatments	 and	 medical	devices.		
1.4.1.1	Immunological	therapies	The	use	of	macrophages	as	cell-based	therapy	to	deliver	genes	to	diseased	tissues	have	been	studied	for	many	years	(Fidler	et	al.	1994	and	Wang	et	al.	2008).	The	aim	of	these	studies	was	to	assess	the	ability	of	macrophages	to	“home”	to	injured	sites	after	local	or	systemic	infusion	into	humans	(Ben-Efrain	et	al.	1994	and	Wiltrout	et	al.	1983)	and	mice	(Burke	et	al.	2002).	This	new	interest	resides	in	the	fact	that	only	a	few	current	forms	of	systemic	gene	delivery,	either	viral	or	non-viral,	have	been	shown	to	penetrate	far	from	the	vasculature	into	damaged	tissues,	particularly	as	the	vasculature	is	often	disrupted	in	 such	 tissues.	 Thus,	 exploiting	 the	 natural	 tendency	 of	macrophages	 to	migrate	 into	such	sites	in	response	to	the	release	of	cytokines/chemokines	may	be	key	for	a	new	cell-mediated	 gene	 delivery	 system,	 in	 other	 words,	 monocyte/macrophage	 adoptive	immunotherapy.			It	would	seem	 logical	 to	assume	 that	 since	monocytes,	not	macrophages,	are	 taken	up	across	 the	 endothelium	 into	 normal	 and	 pathological	 tissues,	monocytes	would	 prove	more	 effective	 in	 “homing”	 to	 such	 tissues	 (Burke	 at	 al.2002).	 	 For	 instance,	 work	 in	murine	models	has	indicated	that	mature	ex	vivo-manipulated	monocytes	are	capable	of	migrating	 into	 tissues,	 where	 they	 undergo	 further	 maturation	 and	 cell	 division	(Kennedy	et	al.	1998).	Although	studies	in	murine	models	indicated	that	monocytes	are	suitable	vectors	for	cell-therapy,	the	technical	difficulties	regarding	monocyte	yield,	cell	number,	isolation	procedures,	cell	culture	and	monocyte	activation,	makes	macrophages	a	 much	 better	 adoptive	 immunotherapeutic	 alternative.	 For	 these	 reasons,	 greater	success	 has	 been	 achieved	 using	 local	 administration	 of	 macrophages.	 For	 example,	
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Chokri	 and	 co-workers	 reported	 that	 greater	 than	 70%	 of	 locally-injected	 LPS/TNFα	macrophages	 homed	 to	 the	 tumour	 site	 in	 mice	 carrying	 a	 subcutaneous	 melanoma	(Chokri	 et	 al.	 1990).	 In	 another	 study,	 infusing	 macrophages,	 adeno-transfected	 to	express	 IL-4,	 to	 inflamed	 glomeruli	 resulted	 in	 a	 remarkable	 75%	 reduction	 in	albuminuria,	a	sensitive	indicator	of	glomerular	damage	(Kluth	et	al.	2000	and	Kluth	et	al.	 2001).	 	 Other	 approaches	 have	 considered	 the	 use	 of	 macrophages	 as	 delivery	vehicles	for	therapeutic	genes.			Macrophages	manipulated	ex	vivo	 have	 also	been	 shown	 to	be	 capable	of	homing	 to	 a	dystrophic	muscle	after	intravenous	(i.v.)	administration.	The	retention	of	macrophages	in	 these	 tissues	 produced	 a	 long-term	 engraftment	 of	 up	 to	 2	 months	 (Parrish	 et	 al.	1996).	 	 As	 described	 above,	 one	 of	 the	 main	 potential	 advantages	 of	 macrophage	adoptive	transfer	is	the	ability	to	circulate	the	body	after	i.v	injection	and	target	multiple	diseased	sites,	 for	example,	 tumour	metastases.	Unfortunately,	 these	 studies	have	also	shown	that	the	majority	of	the	systemically-administered	macrophages	become	trapped	in	organs	such	as	the	lungs,	liver	and	spleen	(Burke	et	al.	2002,	Kennedy	et	al.	1998	and	Chokri	et	al.	1992).	 Interestingly,	better	 success	has	been	achieved	when	studying	 the	homing	 competencies	 of	 activated	 macrophages	 to	 atherosclerotic	 plaques	 in	apolipoprotein	E-deficient	mice	(Patel	et	al.	1998).	Activated	macrophages	loaded	with	fluorescent	 microspheres	 were	 used	 to	 test	 new	 monoclonal	 antibodies	 to	 block	macrophage	cell	adhesion	to	the	atherosclerotic	plaque.		Novel	 approaches	 are	 providing	 new	 insights	 suggesting	 that	 it	 might	 be	 possible	 to	target	macrophages	to	certain	organs	or	injured	sites	by	specific	pre-treatments	or	even	by	engineering	them	to	express	particular	cell	surface-expressed	proteins.	Among	these	approaches,	researchers	have	engineered	ex	vivo-manipulated	macrophages	to	express	certain	 cytokines	 or	 to	 carry	 DNA	 constructs	 as	 well	 as	 studying	 trafficking	 upon	injection	into	a	host	organism	(Fidler	et	al.	1974	and	Andreesen	et	al.	1998).	In	another	very	 interesting	 study,	 oncolytic	 viruses	 were	 delivered	 by	 infiltrating	 macrophages,	which	 abolished	 tumor	 regrowth	 and	 extended	 the	 survival	 of	 tumour-bearing	 mice	(Muthana	et.	al	2011	and	Muthana	et.	al	2013).	This	was	achieved	by	cotranducing	the	oncolytic	 virus	 genome	 with	 an	 hypoxia-regulated	 construct.	 Following	 systemic	injection,	 contransduced	macrophages	 reached	 the	area	of	 extreme	hypoxia	 inside	 the	tumour,	triggering	activation	of	the	hypoxia-regulated	element	(HRE)	and	activating	the	replication	of	the	adenovirus.			
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To	conclude,	the	data	on	macrophage	adoptive	transfer	therapy	also	suggested	that	may	be	 a	 relatively	 risk-free	 procedure	 (Fidler	 et	 al.	 1974	 and	 Andreseen	 et	 al.	 1998).	Therefore,	 understanding	 how	 these	 cells	 home	 is	 essential	 for	 future	monocytes/macrophages	gene	therapies	to	treat	specific	inflammatory-driven	diseases.	In	this	thesis,	Chapter	4	is	centred	on	a	series	of	experiments	to	determine	whether	the	injury-homing	 capacity	 of	 macrophages	 can	 be	 used	 to	 deliver	 immunomodulatory	payloads	 to	 the	 site	 of	 injury,	 with	 the	 potential	 to	 augment	 tissue	 repair	 and	regeneration.		
1.4.2	Gene-based	therapeutic	approaches	Gene	therapy	 is	an	experimental	 technique	based	on	the	transfer	of	exogenous	nucleic	acids	 to	 treat	 or	 prevent	 diseases.	 Such	 nucleic	 acids	 include	 DNA,	 mRNA,	 small	interfering	RNA	(siRNA),	microRNA	(miRNA)	and	antisense	oligonucleotides	(Wolfram	et	 al.	 2013).	 Successful	 gene	 therapy	does	not	 imply	 complete	 gene	 transfer	 to	 all	 the	target	cells,	rather	the	transduction	of	sufficient	cells	to	trigger	the	desired	effect.	So	far,	several	gene	delivery	methods	have	been	developed	and	tested	using	non-viral	and	viral	approaches	for	the	treatment	of	myocardial	infarction.			In	 the	 cardiac	 field,	 Lin	and	 colleagues	were	one	of	 the	 first	 to	 achieve	non-viral	 gene	transfer	 in	 adult	 rat	 cardiac	 myocytes.	 Their	 approach	 was	 to	 directly	 inject	 purified	plasmid	 DNA	 encoding	 the	 β-galactasidose	 gene	 into	 the	 left	 ventricular	 wall.	 In	 the	study,	gene	 transfer	was	proven	to	be	successful	since	cardiac	cells	started	expressing	the	β-galactasidose	gene	after	3	days;	however,	the	effect	was	very	much	localised	to	the	area	of	delivery	(Lin	et	al.	1990).	A	similar	study	performed	in	rats,	also	achieved	certain	level	 of	 gene	 transfer	 by	 directly	 injecting	 a	 luciferase	 plasmid	 into	 the	 damaged	myocardium	after	 ischemia/reperfusion	 injury	 (Prentice	 et	 al.	 1996).	Notably,	 fibrosis	and	 inflammation	were	 observed	 at	 the	 area	 along	 the	 track	 of	 the	 needle	 (Lin	 et	 al.	1990	 and	 Prentice	 et	 al.	 1996).	 The	 conclusion	 from	 these	 studies	 was	 that	 intra-myocardial	naked	DNA	injections	were	very	inefficient	with	poor	delivery	and	retention,	mainly	 because	 only	 a	 small	 fraction	 of	 target	 cells	 expressed	 the	 reporter	 gene	 after	injection.	Recent	advances	in	the	bioengineering	and	nanotechnology	field	have	yielded	a	whole	 new	world	 of	 biomaterials,	 including	 new	 polymers	 (Pack	 et	 al.	 2005),	 lipid-based	vectors	(Semple	et	al.	2010	and	Love	et	al.	2010)	and	nanoparticles	(Davis	et	al.	2009),		which,	in	theory,	would	bring	therapeutic	nucleic	acids	to	their	sites	of	action.			Viral	approaches,	on	the	other	hand,	have	evolved	very	rapidly,	and	have	been	shown	to	deliver	genes	much	more	efficiently	 into	mammalian	cells	 than	via	naked	DNA.	 In	 fact,	
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70%	 of	 all	 gene	 therapy	 clinical	 trials	 are	 viral-based,	 using	modified	 viruses	 such	 as	retroviruses,	lentiviruses,	adenoviruses	(Ads)	and	adeno-associated	viruses	(AAVs)(Yin	et	al.	2014).	Over	the	years,	there	has	been	a	shifting	trend	towards	Ads	and	AAV	gene	therapy,	 primarily	 due	 to	 the	 advantages	 regarding	 efficiency	 and	 efficacy	 of	 gene	transduction.		
	
1.4.2.1	Viral	vectors	for	cardiac	transfer	Retroviruses	 poorly	 transduce	 somatic	 cells,	 as	 they	 require	 active	 cell	 division	 for	integration.	Lentivirus,	on	the	other	hand,	does	not	require	active	cell	division	to	infect	cells,	 however,	 this	 type	 of	 virus	 has	 very	 low	 transduction	 efficiency	 and	 moderate	success	has	been	achieved	predominantly	through	intramyocardial	injection	(Nalinda	et	al.	 2012).	 	 Ads	 and	AAVs	have	drawn	much	more	 attention	over	 the	 years	 since	 their	main	 advantage	 is	 the	 ability	 to	 infect	 non-diving	 cells	 with	 reasonable	 efficiency.	Although	all	viral	vectors	trigger	an	immune	response	to	some	degree,	thereby	limiting	efficiency	 to	 a	 period	 of	 a	 few	days	 to	weeks,	 AAVs	 are	much	 less	 immunogenic.	 This	feature	 together	 with	 the	 fact	 that	 AAV	 gene	 expression	 last	 much	 longer	 than	equivalent	 Ad	 infection,	 has	 positioned	 AAVs	 as	 the	 vector	 of	 choice	 for	 cardiac	 gene	transfer	(Kaspar	et	al.	2005,	Muller	et	al.	2006	and	Walker	et	al.	2009).		The	 CUPID	 trial	 (Calcium	 Upregulation	 by	 Percutaneous	 Administration	 of	 Gene	Therapy	in	Cardiac	Disease)	was	the	first	clinical	application	of	AAV	vectors	for	cardiac	transfer.	In	this	study,	Roger	Hajjar	and	colleagues	demonstrated	the	safety	and	efficacy	of	 AAV1-SERCA2	 delivery	 in	 a	 randomized	 double	 blind,	 placebo	 controlled,	 phase	 2	study	in	patients	with	advanced	heart	failure	(Giacca	et	al.	2011	and	Jessup	et	al.	2011).	Thirty-nine	CUPID	trial	patients	were	randomized	 into	 four	groups	and	treated	with	3	doses	of	AAV1-SERCA2a,	 low-	(6x1011),	mid-	(3x1012),	high-dose	(1x1013)	and	placebo.	For	 these	 study,	 seven	 efficacy	 parameters	 were	 assessed	 in	 5	 domains:	 symptoms,	functional	 status,	 biomarkers,	 left	 ventricular	 function	 and	 remodeling,	 and	 clinical	outcomes.	 Six	 months	 after	 gene	 transfer,	 both	 LV	 end-systolic	 volume	 and	 LV	 end-diastolic	 volume	 were	 improved	 when	 compared	 with	 the	 placebo	 group,	 however,	improvement	in	the	ejection	fraction	was	not	therapeutically	relevant	(Giacca	et	al.	2011	and	Jessup	et	al.	2011).	Interestingly,	in	the	CUPID	study,	patients	were	pre-screened	for	neutralizing	 antibodies	 against	 the	 AAV1	 in	 order	 to	 find	 a	 viable	 population	 for	 the	study.			
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Gene	 and	 cell	 therapy	 has	 produced	 promising	 results	 in	 both	 preclinical	 and	 clinical	settings	for	the	treatment	of	cardiovascular	diseases.	Nevertheless,	safety	and	possible	off-target	 effects	 of	 each	 of	 these	 approaches	must	 be	 carefully	 established	 such	 that	patient	welfare	and	health	is	prioritized.		
	
1.4.2.2	Adeno-associated	virus	biology	Adeno-associated	 virus	 belongs	 to	 the	Parvoviridae	 family.	 This	 family	 has	 evolved	 in	such	a	manner	that	in	nature,	AAV	infection	is	dependent	on	a	helper	virus	(Berns	et	al.	1996).	 The	most	 common	 helper	 viruses	 are	 the	 well-known	 Ad	 and	 herpes	 simplex	virus	 (HSV).	 Wild-type	 AAV	 genomes	 are	 very	 similar	 to	 Ad;	 in	 fact,	 AAVs	 may	 have	evolved	from	Ad.	The	genome	of	AAV	has	very	limited	coding	capacity,	and	therefore	it	relies	entirely	on	the	helper	virus	to	replicate	and	spread.	AAV	viruses	have	not	yet	been	associated	with	any	human	disease.	In	humans,	in	the	absence	of	the	helper	virus,	AAV	remains	latent	inside	the	host	cell.	If	the	helper	virus	is	present,	wild-type	AAV	tends	to	integrate	 into	 a	 specific	 locus	 on	 chromosome	 19	 (Kotin	 et	 al.	 1992).	 The	 main	difference	 between	 Ads	 and	 AAVs	 is	 related	 to	 the	 genome	 size	 and	 gene	 types.	 Ad	genomes	are	linear,	double-stranded	DNA	of	approximately	36	Kb.	The	AAV	genome	is	a	single-stranded	DNA	of	 approximately	 4.7	Kb.	 The	 key	 feature	 of	AAV	 genomes	 is	 the	presence	 of	 inverted	 terminal	 repeats	 (ITR).	 The	 ITRs	 form	 T-shaped,	 base-paired	hairpin	structures,	which	promotes	replication	and	facilitates	packing	(Figure	1.4A	and	Figure	1.4C).		
	
Figure	 1.4.	 Basic	 structure	 of	 a	wild-type	 adeno-associated	 viral	 genome.	 (A)	Three	viral	promoter,	p5,	p19,	p40,	controls	the	transctiption	of	the	two	genes	REP	and	CAP.		(B)	Schematic	diagram	of	 the	7	basic	protein	expression	cassette.	 	 (C)	DNA	sequence	of	 the	 inverted	terminal	repeats	 flanking	 the	 AAV	 genome.	 (D)	 AAV	 capsid	 structure	 from	http://www.rcsb.org/pdb/home/home.do	
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The	AAV	genome	 is	 comprised	of	 two	genes,	 rep	and	 cap,	which	encode	 for	 four	non-structural	proteins	required	for	replication	(Rep78,	Rep68,	Rep52	and	Rep40)	and	three	structural	proteins	that	constitute	the	capsid	(VP1,	VP2,	VP3).	Three	viral	promoters,	p5,	p19	and	p40,	regulate	expression	of	these	two	genes	(Walker	et	al.	2009)(Figure	1.4B).		Any	viral	gene-based	 therapy	 is	 founded	on	 the	deletion	of	 the	rep	and	cap	genes	and	the	 incorporation	 of	 therapeutic	 genes.	 Because	 the	 rep	 and	 cap	 genes	 are	 removed,	integration	 into	 the	 host	 genome	 does	 not	 occur	 and	 the	 AAV	 genome	 remains	 in	 an	“episomal”	manner;	 however,	 random	 integration	may	 occur	 (Qiu	 et	 al.	 2008).	 	Wild-type	AAV	genomes	are	encapsulated	inside	an	icosahedral	particle	of	roughly	20	nm	in	diameter	made	of	the	three	capsid	protein	VP1,	VP2,	VP3	in	a	1:1:10	ratio.	Similar	to	all	viruses,	docking	of	 the	virion	at	 the	surface	receptor	 is	necessary	 for	proper	 infection.	VP1,	 VP2	 and	 VP3	 are	 responsible	 of	 such	 binding	 (Walker	 et	 al.	 2009).	 AAV	internalization	is	a	process	dependent	on	binding	to	a	primary	receptor	and	interactions	with	 co-receptors,	 which	 will	 induce	 AAV	 internalization	 via	 clathrin-dependent	endocytosis.	At	the	gene	level,	the	capsid	genes	have	hyper-variable	regions,	which	are	susceptible	 to	 mutations	 and	 recombination,	 thus	 conditioning	 AAV	 tropism	 to	 the	ability	of	AAV	capsids	to	bind	different	cell	surface	glycans	of	the	target	cell	(Walker	et	al.	 2009	 and	 Gao	 et	 al.	 2003)(Table	 1.1).	 Diverse	 tissue	 tropism	 determined	 by	 the	capsid	serotype,	 the	 lack	of	pathogenicity	and	 the	persistence	of	viral	expression	have	increased	 the	 potential	 of	 AAV	 as	 a	 delivery	 vehicle	 for	 gene	 therapy	 applications.	Indeed,	 more	 than	 12	 human	 serotypes	 and	 100	 nonhuman	 primate	 serotypes	 have	been	discovered	to	date.	A	summary	of	the	main	AAV	applications	can	be	found	in	Table	
1.1.	In	this	thesis,	Chapter	5	is	focused	on	a	set	of	experiments	to	determine	whether	the	use	of	a	particular	serotype	of	adeno-associated	virus	can	efficiently	deliver	and	transfer	a	therapeutic	gene	into	the	heart	after	MI.		
1.4.2.2.1	AAV	neutralizing	antibodies	In	 preclinical	 studies,	 AAVs	 have	 proven	 to	 be	 a	 very	 promising	 tool	 for	 delivering	therapeutic	genes	for	a	myriad	of	diseases.	However,	a	major	concern	regarding	the	use	of	 AAVs	 for	 human	 treatment	 of	 diseases	 is	 the	 presence	 of	 neutralizing	 antibodies	(Nab)	for	most	of	the	AAV	serotypes.	Several	studies	have	revealed	that	approximately	80%	of	the	population	is	seropositive	for	anti-AAV	antibodies	(Calcedo	et	al.	2009).		Nab	can	be	found	against	serotypes	1,	2,	3	and	5,	in	60%	of	the	population	at	age	10,	which	will	 generally	 persist	 into	 adulthood	 (Walker	 et	 al.	 2009).	 In	 some	 cases,	 a	 serum	dilution	 of	 neutralizing	 antibodies	 1/60	 can	 causes	 100%	 transduction	 inhibition	
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(Halber	et	al.	2015).	Clinical	studies	are	currently	prescreening	patients	for	neutralizing	AAV	antibodies	in	order	to	achieve	more	efficient	AAV	approaches.		
1.4.2.2.2	Production	of	recombinant	AAVs	For	 preclinical	 studies,	 AAVs	 are	 produced	 by	 a	 classic	 triple	 transfection	 of	 human	embryonic	 kidney	 cells	 (HEK293)	 by	 three	 plasmids:	 	 AAV	 cis-plasmid	 encoding	 the	gene	of	interest;	AAV	trans-plasmid	containing	AAV	rep	and	cap	genes;	and	adenovirus	helper	 plasmid,	 pDF6.	 The	 isolation	 protocol	 for	 the	 AAV	 particles	 differs	 between	laboratories;	however,	in	general,	the	culture	medium	containing	the	vector	particles	is	collected,	 concentrated	 using	 tangential	 flow	 filtration,	 purified	 by	 iodixanol	 gradient	ultracentrifugation,	followed	by	further	concentration	and	buffer	exchange	(Penn	Vector	Core.	University	of	Pennsylvania	website).																																							
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Table	1.1.	Glycan	receptors,	 co-receptors,	 tissue	specificity,	AAV	 tropism,	preclinical	and	
clinical	 studies	of	AAVs.	HSPG,	Heparan	Sulfate	Proteoglycan;	α2-4	N	linked	SA,	α2-4	N-linked	sialic	 acid;	 PDGFR,	 Platelet-derived	 growth	 factor	 receptor;	 FGFR1,	 fibroblast	 growth	 factor	receptor	 1;	 HGFR,	 hepatocyte	 growth	 factor	 receptor;	 37/67	 KDa	 LamR,	 37/67	 KDa	 Laminin	receptor.	 A1ATD	 a-1	 antitrypsin	 defi	 ciency,	 DMD	 Duchenne	 muscular	 dystrophy,	 LCA	 Leber	
Serotype	 Receptor	 Tissue	Organ	
Preclinical	
studies	in	small	
animal	models	
Preclinical	
studies	in	large	
animal	models	
Clinical	studies	AAV	1		(non	human	primates)5,	11	 α2-3/	α2-4	N	linked	SA	 Heart	Liver	Lung	Brain	Muscle		
Mouse21	,	Rat22	Mouse25	Mouse23	Mouse13	Mouse24,50		
Pig44,	Sheep43		Ferret,	Pig45,	NHP46	Cat41	NHP	42	Rabbit47,	Cat48,	NHP49,	dog50	
Heart	failure	(CUPID	trial)55,56				A1ATD26,	LGMD2D27,	LPLD28	AAV2	(humans)5,	11	 HSPG,	FGFR1,	HGFR,	integrins,	37/67	KDa	LamR	 Brain	Eye	Heart	Joint	Liver	Lung	Muscle	
Mouse13,	Rat1,		Mouse29,	Rat30	Hamster34,	Rat33,Mouse2	Mouse30,	Rat31	Mouse35,86,	Rat36	Mouse37	Mouse38,	Rat39	
Cat41,	NHP16,77	Dog69,	NHP78,79	Pig70	Rabbit71,	horse72	Dog73,	NHP80	Rabbit74,	NHP75	Dog81,	NHP82	
Alzheimer51,	Batten52,	Canavan53,		Parkinson54	Inflammatory	arthritis55	CF55,	A1ATD56,	Hemophilia	B57	AAV35	 HSPG,	37/67KDa	LamR	 Human	liver	cancer	cells	 	 	 	AAV4	(nonhuman	primates)5	 α2-3	O	linked	SA	 Eye	 Rat40	 Dog40,	NHP40	 Blindness	(Rpe65	mutations)	AAV5	(humans)5,11	 α2-3	N	linked	SA,	PDGFR	 Brain	Eye	Joint	Heart	Liver	Lung	
Mouse62	,	Rat	Mouse,	Rat63	Mouse64	and	Rat65	Mouse12	Mouse66	Mouse67	and	Rat68	
NHP83	NHP78,79			NHP85	NHP84	
AIP	(Phase	I	completed)	
AAV6	(humans)5,	11	 HSPG,	α2-3/	α2-4	N	linked	SA	 Heart		Liver	Muscle	 Rats7,10	Mouse	12	Mouse86	Mouse20	 Dog87	Dog86	Dog84	 	AAV7	(nonhuman	primates)5	 Not	determined	 Liver	 Mouse89	 NHP16	 	AAV8	(nonhuman	primates)5,	11	 37/67	KDa	LamR	 Brain	Heart	Liver	Muscle	Pancreas		
Mouse91,	Rat92	Mouse19,	Hamster19	Mouse86	Mouse19,	Hamster19	Mouse95	,	Hamster96	
		Dog86,	NHP16	Dog97,	NHP98	
Hemophilia	B90	
AAV9	(humans)5	 Galactose,	37/67	KDa	LamR	 Brain	Heart	Liver	Lung	Muscle	
Mouse9,18,	93,	Rat94	Mouse3,6,8	,12,15	Rat10	Mouse86	Mouse14	Mouse99	
Cat100	Pig4	Dog101	Dog86		Dog17	
Spinal	Muscular	Atrophy	type	1	(recruiting-Phase	1)	Pompe	disease	(in	process	but	not	recruiting	–	Phase	1)	AAVrh10	(nonhuman	primates)		
	 Brain	Lung	 Mouse60	and	Rat60	Mouse61	 	 Late	Infantile	Neuronal	Ceroid	Lipofuscinosis	(recruiting	–	Phase	1)	AAV115	 	 	 	 	 	AAV12	(nonhuman	primates)	 	 Muscle	Salivary	lands	 Mouse59	Mouse59	 	 “nasal	vaccine”	
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congenital	amaurosis,	LGMD2D	limb-girdle	muscular	dystrophy	type	2D,	CF	cystic	fibrosis,	LPLD	lipoprotein	 lipase	defi	 ciency,	NHP	nonhuman	primate;	AIP,	Acute	 Intermittent	Pophyria.	NHP,	nonhuman	 primates.	 Modified	 from	Walker	 et	 al.2009.	 Information	 about	 AAV	 use	 on	 clinical	trials	can	be	found	at:	https://clinicaltrials.gov	
	
1.5	The	Insulin-like	growth	factor	family	The	 insulin	 growth	 factor	 family	 consists	 of	 Insulin-like	 Growth	 Factor-1	 (IGF-1),	Insulin-like	 Growth	 Factor-2	 (IGF-2),	 cell	 surface	 receptors	 for	 both	 peptides	 (IGF-1R	and	IGF-2R)	and	Insulin	Growth	Factor-Binding	Proteins	(IGFBPs).			Insulin-like	Growth	Factor-1	(IGF-1)	is	a	potent	peptide	factor	involved	in	a	broad	range	of	tissue	processes	including	cell	growth	and	survival,	proliferation,	differentiation	and	metabolism,	but	 the	molecular	basis	of	 these	diverse	 functions	 is	not	well	understood.	Insulin-like	Growth	Factor-2	(IGF-2),	plays	a	key	role	in	mammalian	growth,	influencing	foetal	 cell	division	and	differentiation	and	possibly	metabolic	 regulation	 in	contrast	 to	Insulin-like	growth	factor	1,	which	is	a	major	growth	factor	in	adults	(Rotwin	et	al.	1986	and	Laron	et	al.	2001).			
1.5.1	Insulin-like	growth	factor	1	structure	and	post-translational	modifications		The	 IGF-1	gene	 spans	over	70	Kb	of	 genomic	DNA	distributed	over	 six	 exons	and	 five	introns	(Rotwin	et	al.	1986)	as	shown	in	Figure	1.5.	IGF-1	is	a	multi-functional	protein	due	 to	 the	 fact	 that	 alternative	 splicing	 generates	multiple	precursor	proteins	with	N-	and	 C-terminal	 variability.	 The	 diversity	 of	 IGF-1	 actions	 mainly	 derives	 from	 the	existence	 of	 multiple	 transcription	 start	 sites	 located	 at	 exons	 1	 and	 2.	 Transcripts	initiated	 at	 exon	 1	 are	 spliced	 to	 produce	 an	mRNA	 including	 exon	 1	 but	 not	 exon	 2	(Class	I	IGF-1),	whereas	transcription	initiated	at	exon	2	produce	transcripts	with	exon	2,	 lacking	 exon	 1	 (Class	 II	 IGF-1)	 (Rotwin	 et	 al.	 1986).	 Interestingly,	 class	 II	 IGF-1	knockout	 mice	 have	 shown	 that	 exon	 2	 deletion	 is	 not	 crucial	 in	 normal	 growth	processes,	due	to	compensatory	up-regulation	of	class	I	transcripts	(Temmerman	et	al.	2010).	More	complexity	is	added	as	the	transcription	of	IGF-1	can	also	be	initiated	from	alternative	 promoters,	 which	 enable	 them	 to	 initiate	 the	 IGF-1	 transcription	 in	 a	mutually	 exclusive	manner	 (Adamo	et	 al.	 1991	and	Simmons	et	 al.	 1993).	 In	 addition,	alternative	splicing	at	the	3’	end	adds	a	higher	level	of	complexity	in	the	structure	and	processing	of	 the	 IGF-1	gene	 itself,	generating	carboxy-terminal	extension-peptides,	or	E-peptides.	Two	main	E-peptides	 can	be	generated	 in	 this	process:	 (i)	when	exon	4	 is	spliced	 to	exon	6	 (exon	5	skipped),	 the	 translation	process	will	add	19	amino	acids	 to	
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the	common	16	amino	acids	thus	generating	a	35	amino	acid-long	E-peptide,	also	called	Ea	and,	(ii)	when	exons	1	to	6	are	included	in	the	mRNA	transcript	a	second	E-peptide	is	generated	called	Eb	or	mechano	growth	factor	(MGF)(Bell	et	al.	1986	and	Jansen	et	al.	1983)(Figure	1.5).													
Figure	1.5.	Structure	of	the	rodent	IGF-1	gene.	(A)	Multiple	transcription	sites	in	exon	1	and	2	(horitzontal	arrows).	Translation	ignition	codons	(Met)	are	located	in	positions,	-48	(exon	1),	-32	(exon	 2)	 and	 -22	 (exon	 3).	 Poly(A)	 addition	 signals	 are	 indicated	 by	 vertical	 arrows.	 (B)	differential	 splicing	 precursors	 RNA	 on	 the	 5’-	 and	 3’-	 end	 of	 the	 IGF-1	 gene.	 Adapted	 from	Shavlakadze	et	al.	2005.		The	primary	structure	of	IGF-1	is	highly	conserved	in	mammals.	At	the	mRNA	level,	the	sequence	 of	 mouse	 and	 human	 IGF-1Ea	 are	 highly	 conserved	 with	 94%	 identity,	differing	by	4	amino	acids	only	(Bell	et	al.	1986	and	Shavlakadze	et	al.	2005).	In	extra-hepatic	tissues,	where	most	of	the	IGF-1	isoforms	can	be	found,	the	mRNA	encoding	for	the	Ea-peptide	is	the	major	transcript	representing	95%	of	the	total	IGF-1	mRNA	(Lowe	et	al.	1988),	whereas	Eb	containing	transcripts	are	more	abundant	 in	 liver.	Because	of	this,	and	due	to	the	fact	that	the	majority	of	the	research	on	IGF-1	has	been	performed	on	the	IGF-1	mature	7-kDa	protein,	and	also	given	that	sooner	or	later	all	the	isoforms	are	processed	to	form	the	IGF-1	mature	form,	very	few	studies	are	available	in	mammals	addressing	the	question	of	 the	differential	role	of	all	 the	 IGF-1	 isoforms	(Stewart	et	al.	1996).			At	 the	 protein	 level,	 all	 the	 mRNA	 generated	 by	 the	 combination	 of	 the	 different	transcriptional	regulatory	elements	give	rise	to	a	myriad	of	IGF-1	proteins,	also	known	
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as	 pre-pro-peptides.	 The	 pre-pro-peptides	 undergo	 post-translational	 modifications	such	as	cleavage	of	the	signal	peptides,	and	glycosylation	of	both	the	mature	and	the	E-peptides	(Shavlakadze	et	al.	2005)	(Figure	1.6).		In	 circulation,	 IGF-1/2	 is	 a	 secreted	 protein	 with	 a	 half-life	 of	 less	 than	 10	 minutes.		Therefore,	 IGF-1	 and	 IGF-2	 bind	 to	 IGFBPs	 with	 high	 affinity	 serving	 as	 carrier	molecules,	 modulating	 their	 half-life	 and	 availability	 in	 the	 circulation	 and	 in	 tissue	(Denley	et	al.	2005	and	Forbes	et	al.	2012).			
	
	
	
		
	
	
	
	
Figure	1.6.	Different	 IGF-1	pre-propeptides	cleavage.	IGF-1	mature	form	(red),	pro-peptides	or	 signal	 peptides	 (N-terminal),	 and	 E-peptides	 (C-terminal).	 	 IGF-1Ea	 (21	 Kda),	 IGF-1Eb	 (17	Kda)	and	IGF-1	mature	form	(7.6	Kda).	Adapted	from	Shavlakadze	et	al.	2005.	
	
1.5.2	Insulin-like	growth	factor	1	receptor	and	signalling	pathways		The	biological	activity	of	IGF-1	is	mediated	by	the	type	1	IGF-receptor	(IGF-1R).	The	IGF-1	 receptor	 and	 the	 insulin	 receptor	 are	 α2β2	 heterotetrameric	 transmembrane	glycoproteins	 belonging	 to	 the	 receptor	 tyrosine	 kinase	 family.	 The	 α	 subunits	 of	 the	receptor	 are	 completely	 extracellular	 and	 responsible	 for	 ligand	binding	 (Ullrich	 et	 al.	1986).	The	β-subunits	of	the	receptor	consist	of	a	short	extracellular	domain	and	a	large	intracellular	domain	with	sites	for	tyrosine	and	serine	phosphorylation	responsible	for	the	 signal	 transduction	 (Frattali	 et	 al.	 1993).	 Differential	 phosphorylation	 of	 IGF-1R	leads	 to	 the	 recruitment	 of	 other	 substrates	 that	 in	 turn	 activates	 different	 signal	pathways	(Butler	et	al.	1998).	 	Activation	of	 the	 IGF-1R,	can	trigger	 the	recruitment	of	other	protein	which	can	be	another	plausible	explanation	for	why	IGF-1	can	exert	such	diverse	functions	through	the	same	receptor	(White	et	al.	1998)	(Figure	1.7).		
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1.5.2.1	MAP-kinase	signalling	The	MAP	kinase	pathway	 is	 considered	 to	be	 the	main	 canonical	 pathway	 involved	 in	the	 IGF-1-mediated	 stimulation	 of	 cell	 proliferation.	 This	 pathway	 involves	 the	phosphorylation	 of	 ERK	 (MAPKK	 family)	 by	 RAS,	 leading	 to	 its	 nuclear	 translocation,	which	 in	 turn	 induces	 the	 expression	 of	 molecular	 markers	 of	 cell	 cycle	 progression	such	as	c-Jun,	c-Fos,	Cyclin	D1,	and	cdk4	(Coolican	et	al.	1997)	(Figure	1.7).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.7.	IGF-1/IGF-1R	signalling	pathway.	IGF-1R	activation	by	IGF-1	may	potentially	trigger	several	pathways	such	as	PI3k,	MAP-Kinase,	CamK	and	calcineurin	pathways.	
	
1.5.2.2	PI3/AKT-signalling	Upon	 IGF-1R	 activation,	 active	 PI3-kinase	 phosphorylates	 inositol	 phospholipids.	 This	phosphorylation	is	required	to	induce	several	downstream	targets	such	as	Akt.	Akt	has	a	diverse	set	of	functions	and	is	the	key	molecule	for	protein	synthesis.	Activation	of	Akt	induces	differentiation	 in	 several	 cell	 types	 and	 it	 is	 considered	 the	main	pro-survival	molecule.	 Downstream	 of	 Akt,	 two	main	 pathways	 are	 required;	 the	 phosphorylation	(and	 thus	 inhibition)	 of	 glycogen	 synthase-serine	 kinase	 3α	 (GSK-3	 α),	 and	 the	phosphorylation	and	activation	of	mammalian	 target	of	 rapamycin	 (mTOR)	(Bodine	et	al.	 2001,	 Fujio	 et	 al.	 2000	 and	Rommel	 et	 al.	 2001).	 Other	 proteins	 such	 as	 the	 FOXO	transcription	factor	family	(Bodine	et	al.	2001)	and	members	of	the	Bcl-2	(Brunet	et	al.	1999	 and	 Datta	 et	 al.	 1997)	 family	 also	 meditate	 these	 pro-survival	 actions.	 After	
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activation	of	these	transcription	factors,	they	exit	the	nucleus	and	thus	cannot	perform	their	pro-apoptotic	transcriptional	functions	(Figure	1.7).	
	
1.5.2.3	Calcineurin	signalling	Several	studies	in	skeletal	muscle	cells	have	reported	a	cytoplasmatic	serine-threonine	phosphatase	activation	of	 calcineurin	by	 increased	Ca2+	 levels	 in	myoblasts	 stimulated	with	 IGF-1	 (Kato	 et	 al.	 2000	 and	Musaro	 et	 al.	 1999).	 Increased	 intracellular	 levels	 of	Ca2+	 lead	 to	 the	 activation	 of	 calcineurin,	 which	 in	 turn	 has	 an	 effect	 on	 muscle	 cell	differentiation	 and	 hypertrophy	 (Figure	 1.7).	 In	 in	 vivo	 models,	 the	 induction	 of	calcineurin	via	 cardiomyocyte-specific	overexpression	of	a	calcineurin	splicing	variant,	CnAβ1,	 promoted	 infarct	 vascularization	 and	 prevented	 infarct	 expansion	 after	 MI	(Lopez-Olaneta	et	al.	2014).	
	
1.5.3	IGF-1	isoforms	in	skeletal	muscle	regeneration	The	main	IGF-1	splicing	variant	expressed	in	the	skeletal	muscle	in	resting	muscle	is	the	IGF-1	mRNA	for	which	transcription	initiates	at	exon	1	(Class	I	IGF-1),	encoding	the	Ea-peptide	(Musaro	et	al.	2001).			After	skeletal	muscle	injury,	caused	by	contusions	or	exercise-related	injury,	the	splicing	variant	 comprising	exons	4	 to	6	 is	up	 regulated.	This	 splicing	variant	 includes	 the	Eb-peptide	in	rodents	and	IGF-1Ec	in	humans.	In	vitro	studies	using	C2C12	myogenic	cells	also	 suggest	 different	 roles	 for	 IGF-1Ea	 and	 IGF-1Eb	 isoforms.	 While	 both	 isoforms	increase	 myoblast	 proliferation,	 IGF-1Eb	 stimulates	 proliferation	 within	 the	 first	 48	hours	(Yang	et	al.	2002).	This	role	of	IGF-1Eb	in	myoblast	and	satellite	cell	proliferation,	thus	blocking	differentiation,	is	also	supported	by	in	vivo	studies	on	humans	(Hameed	et	al.	 2003)	 and	 rats	 (Hill	 et	 al.	 2003).	 Satellite	 cell	 proliferate	 after	 trauma	 and	 after	several	cell	division,	satellite	cells	fuse	to	damaged	myofibers	to	form	new	ones.		In	mice,	muscle-specific	 overexpression	of	 IGF-1Ea	 increases	 the	number	of	myogenic	progenitors	by	promoting	the	fusion	of	nascent	myocytes	enabling	increased	production	of	muscle	 proteins	 and/or	 the	 repair	 of	 damaged	 regions	 of	muscle	 fibers	 (Hill	 et	 al.	2003	and	Lee	et	al.	2004),	fibre	size,	promotes	protein	synthesis	and	healing	after	injury,	increase	 muscle	 size-hypertrophy,	 reduces	 cachexia,	 ageing	 (Musaro	 et	 al.	 2001).	Furthermore,	 it	has	been	demonstrated	 that	 IGF-1	accelerates	muscle	 regeneration	by	modulating	inflammatory	cytokines	and	chemokines	(Pelosi	et	al.	2007).	However,	little	
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is	 know	 about	 the	 role	 of	 IGF-1Ea	 regulating	 the	 inflammatory	 milieu	 and	 cell	recruitment.			
1.5.4	IGF-1	in	cardiac	repair	There	 are	 many	 studies	 that	 have	 assessed	 the	 role	 of	 both	 IGF-1Ea	 and	 IGF-1Eb	isoforms	after	cardiac	damage.	The	main	pleiotropic	effect	exerted	by	IGF-1	is	triggered	by	 the	 activation	 of	 its	 receptor	 as	 described	 in	 Section	 1.5.2.	 These	 effects	 mainly	involve	anti-apoptotic	 signals,	 control	of	 cardiac	growth,	autophagy	 inhibition,	glucose	metabolism	facilitation	and	preventing	the	ageing	of	the	heart.	Although,	the	signalling	pathways	that	are	activated	by	IGF-1	are	well	studied,	the	underlying	mechanisms	that	trigger	the	activation	of	either	one,	 two	or	even	all	 the	signalling	pathways	in	order	to	defeat	 cardiac	 death	 and	 promote	 efficient	 cardiac	 repair	 are	 still	 not	 sufficiently	understood.		In	 the	 rat	 heart,	 the	 expression	 of	 IGF-1Ea	 and	 IGF-1Eb	 isoforms	 is	 significantly	increased	 after	 MI.	 The	 research	 corroborates	 that	 coronary	 artery	 ligation–induced	myocardial	 infarction	 was	 followed	 by	 an	 endogenous	 increase	 of	 IGF-1Ea	 and	 MGF	expression,	both	at	mRNA	and	protein	levels	(Stavropoulou	et	al.	2009	and	Carpenter	et	al.	 2008).	 Anastasia	 et	 al.	 have	 shown	 that	 after	MI,	 the	 levels	 of	 IGF-1Eb	were	much	higher	than	the	IGF-1Ea	at	both	the	transcriptional	and	translational	level	(Stavropoulou	et	al.	2009).	Other	studies	performed	in	sheep	have	revealed	that	IGF-1Eb	has	the	ability	to	reduce	the	loss	of	cardiac	function	and	post	infarct	apoptosis	in	the	peri-infarct	zone	of	sheep	myocardium	measured	by	echocardiography	(Carpenter	et	al.	2008).	However,	the	 research	 also	 implies	 that	 the	 E-peptides	 (Ea	 and	 Eb)	 play	 a	 role	 in	 the	pathophysiology	 of	 rat	 myocardium,	 which	 possesses	 possibly	 autonomous	 biologic	actions.		In	recent	years,	our	laboratory	has	demonstrated	that	the	locally-acting	IGF1-Ea	induces	vessel	 formation	 after	 injury	 and	 mediates	 bone	 marrow	 mobilization	 through	 the	expression	 of	 specific	 cytokines	 (Santini	 et	 al.	 2011).	 Furthermore,	 expressed	 as	 a	cardiomyocyte-specific	 transgene	 or	 through	 local	 cell-mediated	 delivery,	 IGF1-Ea	accelerates	 cardiac	 growth,	promotes	 effective	myocardial	 repair	 as	well	 as	 functional	restoration	 after	 MI	 (Santini	 et	 al.	 2007,	 Santini	 et	 al.	 2011	 and	 Poggioli	 et	 al.	 (in	preparation)	(Figure	1.8).		Santini	et	al.	2007,	also	observed	decreased	apoptosis	at	the	injured	site,	which	is	at	least	in	part	attributable	to	IGF-1Ea	triggering	the	up-regulation	of	UCP-1,	metallothionein	2	and	the	cardioprotective	cytokine	adiponectin.	Despite	the	
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known	properties	of	Akt	as	a	cardioprotective	mediator	besides	the	function	of	IGF-1	as	regulator	of	AKT	via	PI3K,	an	alternative	signalling	cascade	seems	to	contribute	to	IGF-1Ea	mediated	cardioprotection	(Santini	et	al.	2007,	Yasushi	et	al.	2000	and	Takashi	et	al.	1999).														
Figure	 1.8.	 Enhanced	 cardiac	 repair	 in	 αMHC-IGF1Ea	 transgenic	 mice	 after	 myocardial	
infarction.	Whole	mount	 and	 histological	 analysis	 of	 sham-operated	 control	 (WT)	 heart	 (left)	and	LCA	WT	and	TG	hearts	(right)	2	months	after	operation.	Arrows	indicate	fibrotic	tissue.	LA	indicates	left	atrium;	LV,	left	ventricle;	RA,	right	atrium;	RV,	right	ventricle.	Histological	analysis	by	trichrome	staining	is	shown	for	each	treatment.	Extracted	from	Santini	et	al.	2007.			Interestingly,	 research	 on	 IGF-1Ea	 in	muscle-restricted	 (Pelosi	 et	 al.	 2007)	 and	 heart-restricted	 (Santini	 et	 al.	 2007)	 prompted	 a	 new	 hypothesis	 where	 IGF-1Ea	 local	expression	 accelerates	 the	 regenerative/reparative	 properties	 by	 modulating	inflammatory	 cytokines	 and	 chemokines	 and	 limiting	 fibrosis.	 After	 skeletal	 muscle	injury,	IGF-1Ea	supplemental	expression	significantly	down-regulated	proinflammatory	cytokines,	such	as	tumor	necrosis	factor	(TNF)-alpha	and	interleukin	(IL)-1beta	(Pelosi	et	 al.	 2007).	 After	 heart	 injury,	 IGF-1Ea	 expression	 resulted	 in	 repression	 of	 the	 pro-inflammatory	 cytokines	 IL-1β	 and	 IL-6,	 while	 the	 anti-inflammatory	 IL-4	 and	 IL-10	showed	 higher	 expression	 levels	 when	 compared	 to	 wild-type	 (WT)	 animals	 after	cardiotoxin	injury	(Santini	et	al.	2007).	These	results	suggests	a	new	role	of	IGF-1Ea	in	modulating	the	environment	during	muscle	repair	and	the	recruitment	of	myeloid	cells	however,	the	molecular	and	cellular	mechanism	behind	enhanced	reparative	capacities	are	still	unknown.	Chapter	3,	of	this	thesis	is	designed	to	unveil	the	role	of	IGF-1Ea	in	the	recruitment	of	monocytes/macrophages.			
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Furthermore,	 our	 group	 has	 recently	 published	 that	 the	 E-peptides	 bind	 to	 the	extracellular	 matrix	 (ECM)	 with	 varying	 affinities,	 thereby	 controlling	 IGF-1	bioavailability	 and	 preventing	 IGF-1	 release	 into	 the	 systemic	 circulation.	 	 Thus,	 the	combinatorial	effect	of	 IGF-1	and	the	E-peptides	are	a	potentially	powerful	 therapy	by	which	 IGF-1	 can	 be	 anchored	 into	 the	 ECM	 nearby	 the	 site	 of	 synthesis	 and/or	administration	(Hede	et	al.	2012).		In	summary,	both	in	vivo	and	in	vitro	studies	have	provided	a	remarkable	insight	on	the	actions	of	IGF-1,	although	the	role	of	each	isoform	is	still	under	investigation,	IGF-1	has	gained	 a	 place	 on	 the	 podium	 as	 one	 of	 the	 molecules	 with	 the	 highest	 therapeutic	potential	 to	 ameliorate	 the	 adverse	 effects	 of	 both	 skeletal	 muscle	 and	 heart	 injury.	Interestingly,	 all	 the	 studies	 performed	 using	 IGF-1	 have	 shown	 how	 remarkable	 and	versatile	this	molecule	is	in	triggering	cardiac	repair	as	described	in	Section	1.5.2.	Thus,	if	tuned	properly,	it	could	potentially	lead	to	complete	cardiac	repair.		
1.5.5	IGF-1	therapeutic	applications	There	are	several	FDA	approved	IGF-1-based	drugs	for	the	treatment	of	diseases.	IGF-1	treatment	 is	 usually	 in	 combination	with	 IGF	binding	protein	 in	 order	 to	 increase	 the	half-life	 of	 IGF-1	 in	 circulation.	 The	most	 common	 drugs	 currently	 in	 use	 to	 date	 are	Mecasermin	 (Increlex	 ®)	 and	 Mecasermin	 rinfabate	 (IPLEX	 ®),	 a	 binary	 protein	complex	of	human	recombinant	IGF-1	and	human	recombinant	IGFBP-3	prescribed	for	long-term	treatment	of	growth	failure	in	children	with	severe	IGF-1	deficiency.			Interestingly,	Raffay	 S.	Khan	 in	2013	presented	a	novel	delivery	vehicle	 to	deliver	 the	IGF-1	 protein.	 The	 preclinical	 studies	 in	 rat	 showed	 that	 IGF-1	 conjugated	 to	 a	 DNA	binding	agent	improved	IGF-1	retention	at	sites	of	myocardial	injury	following	ischemia	reperfusion	injury	(Khan	et	al.	2014).	Despite	the	fact	that	IGF-1	treatment	has	overall	beneficial	 effects,	 there	are	 concerns	 regarding	 the	 safety	of	 chronic	elevated	 levels	of	systemic	 IGF-1	 (Castellano	 et	 al.	 2009).	 The	 main	 disadvantage	 of	 these	 drugs	 is	 the	increase	 in	 the	half-life	 of	 IGF-1,	 thus	 increasing	 the	 levels	 of	 IGF-1	 in	 the	 circulation;	this	has	been	associated	with	severe	adverse	effects,	such	as	an	increased	risk	of	cancer	(Gallagher	et	al.	2010).			However,	 pharmaceutical	 companies	 have	 not	 yet	 achieved	 a	 fully	 functional	 IGF-1	isoform	 that	 could	 be	 used	 as	 a	 therapeutic	 treatment	 for	 MI.	 The	 problem	 is	 in	reproducing,	 in	 vitro,	 the	 IGF-1Ea	 glycosylation	 pattern	 in	 artificial	 bacterial	 or	 yeast	
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organism,	 which	 so	 far	 it	 has	 not	 been	 yet	 achieved.	 Although,	 no	 function	 for	glycosylation	 of	 the	 Ea-peptide	 (Eb-peptide	 has	 no	 glycosylations)	 has	 so	 far	 been	reported.	 The	 glycosylation	 patter	 varies	 the	 affinity	 of	 these	 positively	 charged	peptides	to	the	negatively	charged	ECM	(Hede	et	al.	2012).	 It	has	also	been	speculated	that	 the	 E-peptides	 may	 have	 a	 specific	 receptor	 independent	 of	 IGF-1,	 which	 may	confer	 new	 actions	 to	 IGF-1.	 Consequently,	 IGF-1Ea	 gene	 therapy,	 rather	 than	 the	protein	itself,	is	currently	the	best	approach	to	deliver	IGF-1	and	the	Ea-peptide.	
	1.5.5.1	Viral	delivery	of	IGF-1	As	 discussed	 in	 the	 previous	 section,	 the	 challenges	 that	 compromise	 the	 design	 of	 a	fully	 functional	 IGF-1	 isoform	 have	 directed	 IGF-1Ea	 research	 towards	 viral	 delivery.	Research	 performed	 in	 rodents	 showed	 that	 intramuscular	 injection	 of	 an	 adeno-associated	virus	serotype	5	encoding	IGF-1	rat	cDNA	under	Tet	regulation,	AAV5.IGF1-tet,	 improved	 left	 ventricular	 function	 after	 MI	 (Lai	 et	 al.	 2012).	 Although	 the	 study	highlighted	 the	 beneficial	 effects	 of	 IGF-1,	 it	 also	 presented	 several	 limitations.	 The	serotype	 5	 works	 well	 in	 rodents,	 however,	 is	 highly	 immunogenic	 in	 humans,	 thus	exhaustive	 patient	 pre-screening	 for	 Nab	 should	 be	 taken	 into	 account	 to	 improve	efficacy.	In	addition,	AAV	vectors	were	delivered	via	intramuscular	injection	rather	than	intravenous	 injection	 limiting	 the	 translational	 scope	 as	 well	 as	 the	 efficacy.	Interestingly,	new	AAV	serotypes	such	as	AAV9	have	shown	 to	have	better	 tropism	to	the	heart	than	AAV5	(Fang	et	al.	2013).	Furthermore,	newly	formed	serotypes,	such	as	AAV8,	 AAV9,	 are	 capable	 of	 crossing	 the	 endothelial	 barrier	 to	 provide	 efficient	transgene	expression.	Regarding	cardiac	specificity	of	the	transgene,	Tet	expression	was	driven	 by	 the	 cytomegalovirus	 promoter	 (CMV),	 which	 limit	 heart	 specificity	 to	intramuscular	 injections	 only.	 Finally,	 the	 approach	 did	 not	 engaged	 de	 novo	vascularisation,	nonetheless,	reduced	apoptosis	was	achieved	(Lai	et	al.	2012).			Another	study	 focused	on	 IGF-1	angiogenic	capabilities,	using	microSPECT-CT	 imaging	in	 rats.	 Intramuscular	 injection	 of	 AAV2-mediated	 IGF-1	 gene	 transfer	 significantly	improved	 cardiac	 function	after	MI	 (Dobrucki	 et	 al.	 2010).	The	main	 limitation	of	 this	study	is	again	the	serotype	of	choice;	the	method	of	delivery	(intramuscular)	as	well	as	the	promoter	employed	(CMV)	which	does	not	confer	cardiac	specificity	(Dobrucki	et	al.	2010).	Successful	IGF-1	gene	therapies	must	combine	various	levels	of	IGF-1	specificity,	first,	limiting	the	expression	to	the	heart	with	a	cardiac	specific	promoter,	and	second	by	using	 a	 cardiac-specific	 serotype	 in	 order	 to	 achieve	 successful	 intravenous	 delivery	after	MI.		
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1.6	Hypothesis	and	aims	The	 escalating	 incidence	 of	 acute	 cardiovascular	 diseases	 leading	 to	 heart	 failure	underscores	 the	 increasingly	 urgent	 need	 for	 improved	 therapeutic	 strategies	 to	 limit	cardiac	tissue	damage	and	improve	functional	outcomes	in	a	translational	setting.			Insulin	 growth	 factor	 splicing	 variant	 4	 (IGF-1Ea)	 is	 a	 powerful	 enhancer	 of	 cardiac	muscle	 growth	 and	 regeneration,	 also	 blocking	 age-related	 atrophy	 and	 beneficial	 in	multiple	 skeletal	muscle	 diseases.	 In	 the	 heart,	 local	 expression	 of	 IGF-1Ea	 promoted	functional	restoration	associated	with	reduced	infarct	expansion,	 thinning	and	dilation	of	 the	 left	 ventricular	 wall.	 The	 therapeutic	 potential	 of	 IGF-1Ea	 compared	 to	 other	isoforms	 or	 the	 mature	 form	 mainly	 relies	 on	 its	 ability	 to	 act	 locally	 in	 the	 area	 of	administration.		This	thesis	examines	the	efficient	gene	transfer	of	IGF-1Ea	to	the	heart	and	 the	 effects	 of	 IGF-1Ea	 gene	 delivery	 on	 adverse	 ventricular	 remodeling	 after	ischemia/reperfusion	using	cell-	or	gene-based	approaches.		Considering	the	above	observations,	the	hypothesis	behind	this	thesis	is:	IGF-1Ea	 gene	 transfer,	 delivered	 either	 by	 cell-	 or	 viral-based	 approaches,	improves	 left	 ventricular	 function	and	 reduce	adverse	ventricular	 remodelling	after	myocardial	infarction.		If	 successful,	 the	 knowledge	 acquired	 will	 be	 useful	 to	 support	 IGF-1-based	 cardiac-specific	therapies	for	treatment	of	MI	through	the	design	of	new	approaches	to	deliver	beneficial	factors	with	the	reduced	need	to	perform	surgical	interventions.				Aims:	1. To	 understand	 the	 underlying	 mechanisms	 behind	 the	 enhanced	 repair	mediated	by	 IGF-1Ea	on	 inflammation	after	myocardial	 infarction	by	analysing	the	 subtypes	 of	 circulating	monocytes/macrophages	 attracted	 to	 the	 infarcted	area	in	our	cardiac-specific	IGF-1Ea	transgenic	mice	(αMHC.IGF1Ea).	2. To	assess	whether	 cultured	macrophages	 can	home,	 carry	and	deliver	 IGF-1Ea	into	the	injured	heart	and	investigate	their	potential	beneficial	effects	on	tissue	repair.	3. To	 determine	 whether	 intravenous	 delivery	 of	 AAV9-based	 IGF-1Ea	 gene	transfer	 can	 ameliorate	 the	 adverse	 effects	 of	 heart	 remodeling	 after	 ischemic	injury,	as	a	clinically	applicable	delivery	system.		
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Chapter	2	-	Methodology		
2.1	Mouse	model	
2.1.1	αMHC.IGF-1Ea	mice		The	αMHC.IGF-1Ea	transgenic	mice	line	on	under	the	FVB	background	was	generated	in	Nadia	 Rosenthal’s	 laboratory	 at	 the	 EMBL	 Monterotondo	 (Santini	 et	 al.	 2007).	 The	transgenic	 mouse	 line	 was	 used	 in	 Chapter	 3.	 Briefly,	 the	 rat	 IGF-1Ea	 consensus	sequence	 is	 under	 the	 control	 of	 αMHC	 promoter,	 limiting	 expression	 to	 the	 heart	muscle.	The	construct	was	inserted	into	the	genome	by	random	insertion.	
	
2.1.2	αMHC.IGF-1Ea	genotyping		Samples	for	genotyping	were	obtained	from	ear	notches.	Ear	samples	were	digested	at	56°C	 overnight	 in	 digestion	 buffer	 (0.5%	 Igepal	 CA-630	 	 (Sigma,	 UK,	 Cat.	 074K0577),	100	mM	Tris	pH	8,	0.5%	Tween	20)	with	0.2mg/ml	of	proteinaise	K	(Roche	Applied,	UK,	Cat.	03115801001).			Digested	 samples	 were	 vortexed	 and	 spinned	 down.	 The	 supernatant	 containing	 the	DNA	was	 directly	 used	 to	 amplify	 the	 IGF-1Ea	 gene	 by	 an	 standard	 polymerase	 chain	reaction	program	(Table	2.1).	For	IGF-1	genotyping	the	following	primers	were	used:		IGF-1	forward	primer:	5’-TTCCTGTCTACAGTGTCTGTG-3’	IGF-1	reverse	primer:	5’-GAGCTGACTTTGTAGGCTTCA-3’		Agarose	gel	electrophoresis	(1.5%)	were	prepared	using	1X	TAE	buffer	from	a	50x	TAE	stock,	 Tris	 base	 (C4H11NO3,	 MW:	 121.14	 g/mol),	 glacial	 acetic	 acid	 (CH3COOH,	 MW:	60.05g/mol),	0.5M	EDTA	stock	solution	(pH	8.0)	(Figure	2.1).		
Components		
final	concentration	
Volume	(µL)																								Thermocycler	conditions	
DNA	template	
DreamTaq	Green	PCR	Master	mix		(Thermo	Scientific.	Cat.K1081)	
Autoclaved,	distilled	water	
Primers			Final	volume	
1	12.5		10.5		1		25	
35	cycles	3	min	at	94°C	30	sec	at	94°C	40	sec	at	62°C	50	sec	at	50°C	2	min	at	72°C	∞	4°C	
	
Table	2.1.	Polymerase	chain-reaction	conditions	for	αMHC.IGF-1Ea.			
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Figure	2.1.	IGF-1Ea	genotyping	PCR	product.	Lane	1,	100	bp	molecular	weight	laddder.	Lane	2,	characteristic	 band	 at	 440	 bp	 for	 IGF-1Ea	 αMHC.IGF-1Ea	 mouse	 sample.	 Lane	 3,	 WT	 mouse	sample.	1.5%	agarose	electroforesis	gel.		
2.2	RNA	extraction	and	quantification	After	sacrificing	the	mice,	hearts	were	perfused	with	PBS,	and	samples	from	the	infarct	region,	border	zone,	and	remote	myocardium	were	harvested	and	snap-frozen	in	liquid	nitrogen.			In	Chapter	3	and	4,	 total	RNA	was	extracted	according	 to	 the	TRIzol	Reagent	protocol	(Invitrogen,	UK.	Cat.	10296028).	In	Chapter	5,	due	to	the	limited	amount	of	tissue,	total	RNA	was	isolated	using	the	RNeasy	kit	from	Qiagen,	with	DNAse	on	the	column	(Qiagen,	UK.	Cat.	74104)	which	allows	that	better	DNA	yields	can	be	extracted.			
2.2.1	RNA	isolation	from	cells	and	from	tissue	Total	 RNA	 from	 adherent	 cells	 (monolayer)	 was	 isolated	 by	 removing	 the	 culture	medium	from	the	culture	dish.	1ml	TRIzol	reagent/35mm	dish	was	directly	added	to	the	culture	dish	 surface	 area.	When	using	 either	60mm	or	100	mm,	3ml	or	8ml	of	TRIzol	were	added	respectively.	Cells	were	lysed	by	pipetting	up	and	down	several	times.				Total	 RNA	 from	mouse	 tissue	 was	 mechanically	 disrupted	 with	 surgical	 scissors	 and	placed	in	a	1.5	mL	tube,	an	appropriate	amount	of	TRIzol	was	added	accordingly,	1	ml	TRIzol	 reagent	 per	 50-100mg.	 Tissue	 samples	 were	 disrupted	 with	 a	 rotor-stator	homogeniser	 (Polytron	 PT	 2500	 E)	 for	 40-50	 seconds	 to	 disrupt	 and	 homogenize	 the	tissue	samples.			Samples	were	 incubated	at	RT	 for	5	minutes.	0.2	ml	of	chloroform	was	added	and	 the	samples	 were	 centrifuged	 at	 15000g	 for	 15min.	 The	 RNA	 in	 the	 aqueous	 phase	 was	
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precipitated	 with	 0.5ml	 isopropanol	 and	 washed	 with	 75%	 ethanol.	 The	 RNA	 was	pelleted,	air-dried	and	re-suspended	in	DNAse/RNAse	free	water.			
2.2.2	RNA	quantification	The	RNA	yield	was	quantified	using	Nanodrop®	(Thermo	Scientific,	Wilmington,	USA)	device	 at	 260	 nm	 and	 the	 purity	 by	 the	 ratio	 260/280	 nm	 and	 260/230nm.	 For	 RNA	samples,	 the	 ratio	 between	 the	 absorbance	 measured	 at	 260	 nm	 and	 280	 nm	(A260/A280)	 should	 ideally	 be	 2	 to	 indicate	 good	 RNA	 sample	 purity.	 Contaminating	proteins	 and	 some	 chemicals	 such	 as	 phenol	 absorb	 light	 at	 a	wavelength	 of	 230	 nm.	A260/A230	 ratio	 between	 2.0-2.2	 indicates	 sufficient	 purity	 of	 RNA	 from	 these	contaminants.			
2.2.3	cDNA	synthesis	The	cDNA	was	generated	according	to	Quantitect®	Reverse	Transcription	Kit	(QIAGEN,	UK.	Cat.	205313)	in	a	10μl	reaction	final	volume.	In	Chapter	3	and	4,	1	μg	of	total	RNA	was	retrotranscribed.	In	Chapter	5,	due	to	the	limited	amount	of	tissue,	100	ng	of	total	RNA	was	used	instead	of	1	μg.	
	
2.2.4	Quantitative	Real-Time	polymerase	chain	reaction	(qRT-PCR)	Following	 cDNA	 synthesis,	 TaqMan	 qRT-PCR	 was	 performed	 on	 an	 ABI	 7900HT	Sequence	 Detection	 System	 (Applied	 Biosystems,	 Carlsbad,	 CA,	 USA)	 platform	 using	either	 MicroAmp®	 Optical	 96-Well	 Reaction	 Plate	 or	 MicroAmp®	 Optical	 384-Well	Reaction	Plate	 (Applied	Biosystems,	 Cat.	 4306737	 and	4309849,	 respectively).	Master	mix	 for	 all	 samples	 and	 genes	 of	 interest	 (GOIs)	was	 prepared	 and	 aliquoted	 into	 the	reaction	plate-well	according	to	Table	2.2.	For	every	well,	1	µL	of	cDNA	was	loaded	on	triplicate.	 	Plates	were	sealed	with	optical	adhesive	film	(Applied	Biosystems,	USA.	Cat.	4311971)	and	spinned	down	for	a	few	seconds.	Taqman	FAM,	VIC	predesigned	probes	were	purchased	at	Applied	Biosystems	(http://bioinfo.appliedbiosystems.com/genome-database/gene-expression.html).			In	 this	 thesis,	 the	 TaqMan	 probes	 used	 for	 the	 relative	 quantification	 of	mRNA	 levels	were	as	follow	(Reference	code	of	predesigned	probes	in	brackets):	
Chapter	 3:	 IGF-1Ea	 (Mm00710307_m1),	 IL-10	 (Mm00439614_m1),	 IL-1β	(Mm00434228_m1),	 CCL2	 (Mm00441242_m1),	 CCL5	 (Mm01302427_m1),	 TGFβ	(Mm03024053_m1),	Collagen	Iα1	(Mm00801666_g1),	Collagen	Iα3	(Mm01254476_m1),	Lox	 	 (Mm00495386_m1),	 MMP2	 (Mm00439498_m1),	 MMP9	 (Mm00442991_m1),	
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TIMP1	(Mm00441818_m1),	TIMP2	(Mm004418225_m1),	actin,	alpha	1,	skeletal	muscle,	ACTA,	(Mm00808218_g1),	Atrial	Natriuretic	Peptide,	ANP	(Mm01255747_g1).			
Chapter	 4:	 IGF-1	 (Mm00439560_m1),	 IGF-1Ea	 (Mm00710307_m1),	 IGF-1Eb	(Mm01228180_m1),	 IGF-1R	 (Mm00802831_m1),	 Il-6	 (Mm00446190_m1),	 Il-10	(Mm00439614_m1),	TNF-α	(Mm00443258_m1),	CCL2-MCP1	(Mm00441242_m1).		
Chapter	 5:	 Actin,	 alpha	 1,	 skeletal	 muscle,	 Acta1	 (Mm00808218_g1),	 Nppb/brain	natriuretic	peptide	(BNP)	(Mm01255770_g1),	Collagen	Iα1	(Mm00801666_g1),	Collagen	Iα3	 (Mm01254476_m1),	 Lox	 (Mm00495386_m1),	 Thy1	 (Mm00493681_m1),	 IGF-1Ea	(transcript	 variant	 4)	 (Mm00710307-m1),	 Luciferase	 (Mr03987587_mr).	 GFP	expression	was	quantified	using	SYBR	green	primers:	FW	EGFP:	CCA	GGA	GCG	CAC	CAT	CTT	CTT	and	RV	EGFP:	GTA	GTG	GTT	GTC	GGG	CAG	CAG.		GAPDH	 	 (Applied	Biosystems,	USA,	Cat.	4310893E)	was	used	as	housekeeping	gene	 to	normalize	expression	levels.			
Components	-final	concentration	
For	a	96-well	plate	
Final	Volume	
(12.5	µL)	
Thermocycler	conditions	
Taqman	®	Gene	Expression	Master	Mix	GOI-FAM	(Reference	gene	GAPDH-VIC)	Autoclaved,	distilled	water	
6.25	0.625	4.625	
		 42	cycles	10	min	at	95°C	15	sec	at	95°C	1	min	at	60°C	∞	4°C		
Components	-final	concentration	
For	a	384-well	plate	
Final	Volume	
(10	µL)	Taqman	®	Gene	Expression	Master	Mix	GOI-FAM	(Reference	gene	GAPDH-VIC)	Autoclaved,	distilled	water	
5	0.5	3.5	
	
	
Table	 2.2.	 Reaction	 components	 and	 thermo	 cycler	 conditions	 for	 qRT-PCR	 reactions.	Master	 mix	 and	 samples	 were	 loaded	 on	 triplicates.	 Taqman	 ®	 Gene	 Expression	 Master	 Mix	(Applied	Biosystems,	USA.	Cat.	4369016).		
2.2.4.1	qPCR	data	analysis:	comparative	ΔΔCt	method	Once	the	PCR	cycle	 is	completed;	data	was	exported	 into	Excel	and	analysed	using	the	LinReg	software	in	order	to	estimate	the	efficiency	rates	and	the	Ct	values	(Ruitjer	et	al.	2009).	
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At	 some	 point	 of	 the	 PCR	 process,	 the	 accumulated	 fluorescent	 signal	 cross	 the	threshold	 (ie	exceeds	background	 level),	 called	 the	cycle	 threshold	value	 (Ct).	Ct	 levels	are	 inversely	 proportional	 to	 the	 amount	 of	 target	 nucleic	 acid	 in	 the	 sample	 (ie	 the	lower	 the	 Ct	 value	 the	 greater	 the	 amount	 of	 target	 nucleic	 acid	 in	 the	 sample).	 For	relative	quantification,	 the	Ct	 value	of	 the	GOI	 (Ct-GOI)	 is	 first	normalized	against	 the	Ct	value	of	a	reference	gene	(Ct-RG)	(i.e.	GAPDH	gene	in	this	thesis)	to	produce	the	ΔCt:			 ΔCt.	=		Ct-GOI	-	Ct-RG	
	Subsequently,	 the	 relative	 expression	 of	 the	 gene	 of	 interest	 for	 each	 sample	 is	calculated	using	 the	ΔCt	of	 the	 sample	 in	 the	 study	 group	 (ΔCt-ref),	 usually	 a	 control	 or	untreated	sample	and	applying	the	formula:			 ΔΔCt	(relative	expression	of	GOI)	=	2-ΔCt-ΔCt-ref		
2.2.4.2	Taqman®	probe-based	gene	expression	analysis	TaqMan®	 probes,	 also	 called	 double-dye	 oligonucleotides,	 consist	 of	 a	 fluorophore	attached	 to	 the	 5’	 end	 of	 the	 probe	 and	 a	 quencher	 to	 the	 3’	 end.	 The	 reporter	fluorescence	is	suppressed	by	the	proximity	to	the	quencher.	For	FAM	probes,	the	5’	end	emits	 light	 at	 520	 nm	 upon	 excitation	 whereas	 for	 VIC®	 probes,	 the	 fluorescence	reporter	dye	VIC®,	emits	light	580	nm	upon	excitation.	This	property	makes	possible	to	perform	analysis	of	two	genes	at	the	same	time	in	one	reaction	well.	During	synthesis,	the	5’	to	3’	nuclease	activity	of	the	DNA	polymerase,	contained	in	the	master	mix,	cleaves	the	 primer	 releasing	 the	 reporter	 dye	 and	 the	 quencher	 dye,	 resulting	 in	 increased	fluorescence	 by	 a	 mechanism	 known	 as	 Fluorescence	 Resonance	 Energy	 Transfer	(FRET).	 The	machine	 detects	 the	 accumulation	 of	 both	 the	 fluorophore	 and	 quencher	released	 into	 solution,	 quantifying	 the	 increase	 in	 fluorescence	 of	 the	 reported	 dye	(Taqman,	applied	biosystem	website)		
2.3	Protein	biochemistry		Animals	 were	 sacrificed	 using	 Schedule	 One	 approved	 methods.	 The	 hearts	 were	washed	with	cold	PBS	and	 immediately	removed	 from	carcasses,	 snap	 frozen	 in	 liquid	nitrogen	 and	 stored	 at	 -80C.	 Tissue	 samples	 were	 disrupted	 on	 500	 μl	 RIPA	 buffer	(Sigma,	UK.	Cat.	R0278)	with	a	rotor-stator	homogeniser	(Polytron	PT	2500	E)	for	40-50	seconds	to	disrupt	and	homogenize	the	tissue	samples.			
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2.3.1	Protein	extraction	and	quantification	Proteins	 were	 quantified	 using	 the	 DC	 colorimetric	 protein	 assay	 kit	 following	manufacturer’s	 instructions	 (Bio-Rad	 Laboratories,	 UK,	 Cat.	 500-0116)	 based	 on	standardised	 protocol	 from	 Nadia’s	 group.	 Briefly,	 protein	 samples	 are	 exposed	 to	copper	 tartrate	 solution	 in	an	alkaline	medium	 for	a	 subsequent	 reduction	of	protein-copper	 complexes	 of	 the	 reducing	 agent	 (Folin	 reagent).	 These	 two	 steps	 result	 in	 a	colorimetric	shift	to	blue,	with	a	peak	absorbance	at	750	nm	and	at	405	nm.	The	amount	of	Folin	reduced	in	the	reaction	is	proportional	to	the	amount	of	amino	acids,	 tyrosine	and	 tryptophan,	present	 in	 the	protein.	For	protein	quantification,	a	standard	curve	of	known	concentration	was	prepared	with	Bovine	Serum	Albumin	(BSA)	(Sigma,	UK.	Cat.	A9418).	Absorbance	values	were	plotted	against	the	amount	of	proteins	and	a	standard	curve	was	obtained	using	linear	regression	(Figure	2.2).	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2.2.	 Bovine	 Serum	 Albumin	 (BSA)	 representative	 standard	 curve.	 Concentration	curve,	from	0.2-2.5	μg/well,	of	BSA	with	linear	regression	analysis.	The	curve	equation	and	the	R2	are	 reported.	 The	 R-squared	 value	 is	 a	measure	 of	 goodness-of-fit	 of	 linearity.	When	 is	 >0.99,	means	 that	 the	 regression	 line	 gives	 correct	 predictions.	 Protein	 concentration	 (X)	 of	 the	unknown	samples	was	calculated	by	matching	their	absorbance	values	(Y)	against	the	standard	curve	using	the	graph	equation.	
	
2.3.2	Immunoblotting	After	quantification,	30-50	μg	of	protein	lysate	was	denaturalised	at	100ºC	for	5	min	in	SDS	blue	loading	buffer	(Cell	signalling,	USA,	Cat.	7722)	including	1/10	volume	30X	DTT	(Cell	 signaling,	USA,	 Cat.	 7016).	Denatured	 samples	were	 run	 in	 acrylamide	 20%	 tris-HCL/tris-tricine	 pre-cast	 gradient	 gels	 (Bio-Rad,	 UK.	 Cat.	 4561091)	 in	 running	 buffer	(25mM	Tris	base,	0.192M	Glycine,	0.1%	SDS).	Following	separation,	 the	 samples	were	transferred	on	a	nitrocellulose	membrane	 for	1	hour	at	4ºC.	Blotted	membranes	were	
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blocked	in	5%	skimmed	milk	in	PBS-T	and	incubated	with	the	primary	antibody	O/N	at	4ºC.	 Primary	 and	 secondary	 antibodies	were	 diluted	 1:1000	 in	 blocking	 solution.	 The	following	day,	blots	were	washed	with	PBS-Tween	20	and	incubated	with	the	secondary	antibody	 followed	 by	 a	 second	wash	 step.	 Nitrocellulose	 blots	were	 incubated	with	 a	luminol-based	detection	reagent	(ECL-Amersham/GE	healthcare	UK.	Cat.	RPN2232)	and	proteins	bands	visualised	on	an	film	developer.		In	Chapter	4,	western	blot	was	performed	using	the	following	primary	antibodies:	anti	mouse-IGF-1	 (Sigma,	 UK.	 Cat.	 I-8773),	 and	 the	 secondary	 antibody	 used	 was	 donkey	anti-goat	 IgG-HRP	(Santa	Cruz,	USA.	Cat,	SC-2020).	Alpha-tubulin	monoclonal	antibody	(Sigma,	UK.	Cat.	T6074)	was	used	as	a	loading	control.		In	Chapter	5,	western	blot	was	performed	using	the	following	primary	antibodies:	anti	mouse-IGF-1	(Sigma,	UK.	Cat.	I-8773),	anti-phospho-AktSer473	(Cell	signaling,	Cat.	9271),	anti-Akt	(Cell	Signaling,	Cat.	9272),	anti-phosphomTORSer	2448(Cell	Signaling,	Cat.	2971),	anti-mammalian	 target	 of	 rapamycin	 (mTOR)	 (Cell	 Signaling,	 Cat.	 2972)	 and	 alpha-tubulin	monoclonal	 antibody	 (Sigma,	UK.	Cat.	T6074)	as	described	 in	Blackstock	et	 al.	2014,	Panse	et	al.	2012	and	Felkin	et	al.	2011.	The	secondary	antibody	used	was	donkey	anti-rabbit	 IgG-HRP	 (GE	 Healthcare,	 USA,	 Cat.	 NA934).	 Brightness	 and	 contrast	 were	linearly	adjusted	using	power	point.		
2.4	Immune	single	cell	isolation	from	heart	To	 analyse	 neutrophils,	 monocytes,	 macrophages	 and	 dendritic	 cells,	 a	 single	 cell	suspension	was	prepared	from	hearts	before,	or	at	various	time	points	after	MI	(Day	1,	3,	5,	7,	and	28	post-operation).		The	hearts	were	mechanically	dissociated	using	surgical	scissors	and	subsequently	treated	with	4	cycles	of	10	min	each	at	37oC	with	a	1X	Hank’s	Balanced	Salt	Solution	(HBSS)	(Invitrogen,	USA.	Cat.	14025092)	enzymatic	dissociation	buffer	 containing	0.1mg/mL	Liberase	TH	Research	Grade	 (Roche	Diagnostics,	 UK.	 Cat.	05401151001),	50	ug/mL	of	DNaseI	(Roche	Diagnostics,	UK.	Cat.	11284932001),	10mM	HEPES	(Invitrogen,	USA.	Cat.	15630-080),	and	30mM	Taurine	(Sigma,	UK.	Cat.	T0625).	After	each	10	min	incubation	cycle,	the	cells	were	pelleted	at	320g	for	7min	at	4oC	and	washed	with	the	1X	HBSS	media	solution	containing	20%	FBS.	Cells	were	collected	and	filtered	 using	 a	 70	 µm	 cell	 strainer	 (BD	 Pharmingen,	 USA.	 Cat.	 08-771-2).	 An	 equal	volume	 of	 ice	 cold	 1X	 HBSS	 containing	 10mM	HEPES,	 30mM	 Taurine,	 and	 20%	 Fetal	Bovine	Serum	(FBS)	(GE	Healthcare,	USA.	Cat.	SH30084.02),	was	added	to	 the	enzyme	dissociation	 buffer.	 Under	 these	 specific	 cellular	 isolation	 conditions,	 the	 adult	
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cardiomyocytes	 are	 predominately	 lysed,	 as	 the	 enzymatic	 dissociation	 buffer	 is	potentially	toxic	to	these	large,	fragile	cell	types	(Oh	et	al.	2003).		For	preparing	single	cell	suspension	from	other	organs	such	as	kidney,	liver,	lungs,	and	skeletal	 muscle	 tissues,	 samples	 were	 harvested	 and	 placed	 on	 cold	 RPMI	 medium.	Thereafter,	tissue	was	finely	minced	with	scalpel	and	incubated	in	cell	digestion	medium	containing	Collagenase	F	 (Sigma,	UK.	Cat.	 C7926)	 and	RPMI,	 in	 gentle	 agitation	 for	30	minutes	at	room	temperature	(RT).	After	digestion,	4%	of	FBS	and	300U	of	DNAseI	were	added	to	the	solution.	Cell	suspension	was	then	filtered	through	70	µm	cell	strainer	and	centrifuged	1500rpm	for	5min	at	4ºC.	 	Resulting	pellets	were	resuspended	 in	PBS	and	and	 the	 number	 of	 cells	 were	 counted	 in	 a	 Beckman	 Coulter	 Vi-Cell	 XR	 cell	 counter	(Beckman	Coulter).			
2.4.1	Flow	cytometry	and	cell	sorting	Single	cells	were	 incubated	 in	1X	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	solution	(Gibco,	 Life	 technologies,	 UK.	 Cat.12491-015)	 containing,	 2%	 FBS,	 10mM	 HEPES	 and	incubated	for	30	min,	on	ice,	in	the	dark	with	the	following	antibodies:	CD11b-PE	(BD	Biosciences,	USA.	Cat.	553311),	F4/80-Biotin	(eBioscience,	USA.	Cat.	13-4801-85),	 CD45-APC-Cy7	 (BioLegend,	 USA.	 Cat.	 103116),	 CD206-PerCP-Cy5.5	(BioLegend,	USA.	Cat.141716),	Ly6C-APC	(eBioscience,	USA.	Cat.	17-5932-82)	and	Ly6G-AlexaFluor700	(BioLegend,	USA.	Cat.	127622).			Samples	 stained	 with	 biotin-labelled	 primary	 antibody	 were	 incubated	 with	streptavidin-PE-Cy7	 secondary	 antibody	 (eBioscience,	 USA.	 Cat.	 25-4317-82)	 for	 30	min,	 on	 ice,	 in	 the	 dark,	 with	 the	 1X	 DMEM	media	 solution	 as	mentioned	 above.	 The	samples	were	washed	and	re-suspended	in	fresh	1X	DMEM	media	solution	with	1.5	µM	Sytox	Blue	(Invitrogen,	USA.	Cat.	S34857).	Cells	were	re-filtered	using	5mL,	35	µm	filter	cap	tubes	 just	prior	to	sample	acquisition.	Flow	cytometric	cell	sorting	was	preformed	using	a	BD	FACSAriaI	 cell	 sorter	 (BD	Biosciences)	equipped	with	a	355nm	UV	 laser,	 a	405	nm	Violet	 laser,	a	488	nm	Blue	 laser,	a	561	nm	Yellow-Green	 laser	and	a	640	nm	Red	 laser.	The	antibody	cocktail	 fluorescence	minus	one	 (FMO)	controls	were	used	as	gating	 controls	 for	analyses	 to	distinguish	positive	 from	negative	 cell	 staining	 (Figure	
2.3	and	2.4).					
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Figure	2.3.	Identification	of	positive	stained	cells	using	the	Fluorescence	Minus	One	(FMO)	
strategy	 for	 Ly6G,	 CD11c	 and	 CD11b.	 	 The	FMO	strategy	was	used	 to	 appropriately	 identify	positive	 stained	 cells	 and	 differentiate	 them	 from	 background	 autofluorescence.	 Single	 cell	suspensions	isolated	from	hearts	of	mice	uninjured	and	post-MI	were	stained	with	anti-CD11b,	-CD45,	–Ly-6G,	–Ly-6C,	-F4/80,	-CD206	-CD11c	and	analyzed	by	FACS.	
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Figure	2.4.	Identification	of	positive	stained	cells	using	the	Fluorescence	Minus	One	(FMO)	
strategy	 for	 F4/80,	 Ly6C	 and	 CD206.	 The	 FMO	 strategy	was	 used	 to	 appropriately	 identify	positive	 stained	 cells	 and	 differentiate	 them	 from	 background	 autofluorescence.	 Single	 cell	suspensions	isolated	from	hearts	of	mice	uninjured	and	post-MI	were	stained	with	anti-CD11b,	-CD45,	–Ly-6G,	–Ly-6C,	-F4/80,	-CD206	-CD11c	and	analyzed	by	FACS.		
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Immune	 cells	were	defined	 as	 follows:	Total	 leukocytes	 (CD45+),	 neutrophils	 (CD45+,	CD11b+,	F4/80-,	CD11c-,	Ly6G+),	monocytes	(CD45+,	CD11b+,	CD11c-,	Ly6G-,	F4/80-),	macrophages	 (CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	 F4/80+)	 and	 dendritic	 cells	 (CD45+,	CD11b+,	 F4/80-,	 CD11c+,	 Ly6G-).	 Monocytes	 were	 further	 classified	 as	 Ly6Chigh	 and	Ly6Clow	monocytes	on	the	basis	of	the	Ly6C	expression	levels.	Macrophages	were	further	characterized	 on	 the	 basis	 of	 Ly6C	 and	 CD206	 expression,	 [i.e.	 Ly6Chigh/CD206low	(inflammatory	macrophages)	and	Ly6Clow/CD206high	(reparative	macrophages)].	Flow	Jo	software	(version	9.	8.5)	(Tree	Star,	Ashland,	OR)	was	used	for	analysis.			
2.5	Generation	and	differentiation	of	bone	marrow-derived	macrophages	
2.5.1	Mouse	bone	marrow	cell	isolation	After	 euthanasia,	 C57/BL6	mice	were	 sprayed	with	 70%	 ethanol	 and	 the	 femurs	 and	tibias	from	both	legs	were	removed.	Fresh	muscle	was	removed	using	surgical	scissors	and	clean	gauze	to	help	with	muscle	removal.	The	femurs	and	tibias	were	placed	in	10	cm	plate	with	cold	PBS.		Under	a	tissue	culture	cabinet,	the	bones	were	washed	for	less	than	 a	minute	with	 70%	 ethanol.	 Afterwards,	 the	 end	 of	 the	 bones	were	 cut	 off	with	scissors	 and	 the	bone	marrow	was	 flushed	using	a	1	ml	 syringe	 filled	with	RPMI.	The	fresh	 bone	 marrow	 suspension	 was	 homogenized	 by	 pipetting	 up	 and	 down	 then	filtered	using	 a	 70	µm	cell	 strainer	 (BD	Pharmingen,	USA.	 Cat.	 08-771-2)	 to	 bring	 the	cells	 into	 a	 single-cell	 suspension.	 Finally,	 cells	 were	 counted	 and	 cryopreserved	(Section	2.5.2)	or	differentiated	into	macrophages	(Section	2.5.3).	
	
2.5.2	Cryopreservation	of	mouse	bone	marrow	cells	Isolated	bone	marrow	cells	(Section	2.5.1)	were	centrifuged	for	10	minutes	at	250g,	5ºC.	After	 centrifugation,	 cells	were	 resuspended	 in	 1	ml	 of	 cell	 freezing	medium	 at	 a	 cell	concentration	of	6x106	cells/ml	(Sigma,	UK,	Cat.	C6164).	The	freezing	aliquots	were	kept	at	-80	ºC	for	a	period	no	longer	than	1	month.	
	
2.5.3	Differentiation	and	culture	of	bone	marrow-derived	macrophages	(BMdMs)	Freshly	 or	 frozen	 isolated	bone	marrow	 cells	were	plated	 at	 a	 concentration	 of	 6x106	cells	 per	 75cm2	 flask	 with	 10	 ml	 of	 differentiation	 medium	 containing,	 RPMI	 1640	(Lonza,	 UK.	 Cat.	 BE12-702F/U1)	 supplemented	 with	 20%	 FBS	 (Life	 technology,	Invitrogen,	 Gibco,	 UK.	 Cat.	 10270-106),	 penicillin/streptomycin	 (P/S)	 mix	 (Sigma-Aldrich,	 Gillingham,	 UK,	 Cat.	 P4333),	 Sodium	 pyruvate,	 2mM	 L-glutamine	 (Sigma,	Gillingham,	UK.	Cat.G8540),	20ng/ml	of	M-CSF	 (Preprotech,	UK.	Cat.AF-315-02),	50μM	of	β-mercaptoethanol	(Sigma,	Gillingham,	UK.	Cat.	M6250).	
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At	 day	 2,	 another	 further	 10	 ml	 of	 differentiation	 medium	 was	 added.	 At	 day	 4,	 the	medium	was	completely	 removed	and	a	new	 fresh	20	ml	differentiation	medium	with	half	 concentration	 of	 M-CSF	 was	 added.	 At	 day	 6,	 the	 medium	 was	 changed	 to	 fresh	medium	 with	 no	 M-CSF.	 Finally,	 at	 day	 7,	 non-polarized	 bone	 marrow-derived	macrophages	 were	 either	 stimulated	 with	 IL-4	 or	 IFNγ	 were	 used	 for	 transfection	experiments.	 The	 schematics	 of	 the	 BMdM	 differentiation	 process	 can	 be	 found	 in	Chapter	4,	Figure	4.7A.			
2.5.4	M1/M2	polarization	of	bone	marrow-derived	macrophages		At	 day	 7	 of	 differentiation,	 macrophages	 were	 stimulated	 with	 10	 ng/ml	 of	 IL-4	(Peprotech,	 UK.	 Cat.	 214-14)	 to	 differentiate	macrophages	 towards	 an	M2	 phenotype.	Alternatively,	macrophages	were	stimulated	with	100U/ml	of	IFN-ϒ	(Peprotech,	UK.	Cat.	200-02)	 and	 1	 μg/ml	 of	 LPS	 (Sigma,	 UK.	 Cat.	 L3012)	 to	 differentiate	 macrophage	towards	an	M1	phenotype.		
2.5.5	Monocyte	isolation	from	blood	and	spleen	Monocytes	 from	 spleen	 and	 blood	 were	 isolated	 from	 C57/BL6	 mice	 using	 magnetic	CD11b	 positive	 selection	 beads	 (MACS-Miltenyi	 biotech,	 UK.	 Cat.	 130-049-601).	 To	increase	the	yield	prior	isolation	the	cells	from	spleen	and	blood	were	centrifuged	on	a	Bicoll	 gradient	 (Biochrome,	UK.	Cat.	L6115),	 thus	 the	polymorphonuclear	 (PMN)	 layer	can	 be	 obtained.	 Splenocytes	 were	 mashed	 using	 the	 inner	 rod	 of	 a	 syringe.	 The	suspension	was	 then	 homogenised	 by	 passing	 the	 cells	 through	 a	 70	 μm	 cell	 strainer	(BD	Pharmingen,	USA.	Cat.	08-771-2).			
2.5.6	Bone	marrow-derived	macrophage	flow	cytometry	characterisation.	BMdMs	 were	 suspended	 in	 1X	 Dulbecco’s	 Modified	 Eagle	 Medium	 (DMEM)	 solution	(Gibco,	 Life	 technologies,	 UK.	 Cat.12491-015)	 containing,	 2%	 FBS,	 10mM	 HEPES	 and	incubated	for	30	min,	on	ice,	in	the	dark,	with	the	following	antibodies:		CD11b-PE	(eBioscience,	USA.	Cat.	Cat.	553311),	F4/80-APCeF780	(eBioscience,	USA.	Cat.	47-4801-80),	CD45-PECy7	(Biolegend,	USA.	Cat.1031114),	Ly6C-APC	(eBioscience,	USA.	Cat.	 17-5932-82)	 and	 CD206-488	 (eBioscience,	 USA	 Cat.53-2069-41).	 Thereafter,	macrophages	were	 centrifuged	and	washed	 three	 times	 in	PBS,	1500rpm	 for	5	min	at	4ºC.	All	the	samples	were	analysed	by	flow	cytometry	on	a	BD	FACS	Scan.	At	least,	1x103	events	were	collected	per	sample.	Flow	Jo	software	(Version	9.	8.5)	(Tree	Star,	Ashland,	OR)	was	used	for	analysis.		
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2.5.7	Bone	marrow-derived	macrophage	CFSE	staining	BMdMs	 were	 resuspended	 in	 a	 dilution	 1:1	 of	 5	 µM	 CFSE	 (Life	 technology,	 UK,	 Cat.	C34554)	 in	 warm	 serum-free	 RPMI.	 Then,	 incubated	 for	 5	 min	 at	 37ºC.	 Immediately	after,	BMdMs	were	put	on	ice.	Precooled	RPMI	medium	was	added	to	dilute	the	CFSE	to	reduce	cell	death.	BMdMs	were	centrifuged,	1500	rpm	for	5	minutes	at	4ºC,	and	washed	three	times	in	PBS.	After	centrifugation,	BMdMs	were	used	for	infusion	into	mice	or	for	flow	cytometry	analysis	(Chapter	4,	Figure	4.7).		CellTrace™	 CFSE	 Cell	 Proliferation	 Kit,	 for	 flow	 cytometry,	 (Life	 technology,	 UK,	 Cat.	C34554)	is	widely	used	for	cell	tracking	and	proliferation	studies.	CFSE	readily	crosses	intact	 cell	membranes.	 Once	 inside	 the	 cells,	 intracellular	 esterases	 cleave	 the	 acetate	groups	 to	 yield	 the	 fluorescent	 carboxyfluorescein	 molecule.	 The	 succinimidyl	 ester	group	reacts	with	primary	amines,	 crosslinking	 the	dye	 to	 intracellular	proteins.	After	the	acetate	groups	are	cleaved,	it	has	a	peak	excitation	of	494	nm	and	peak	emission	of	521	nm.			
2.6	Bone	marrow-derived	macrophages	transfection	BMdMs	 were	 transfected	 using	 the	 Amaxa	 Macrophage	 Nucleofection	 Kit	 (Amaxa	Biosystems,	USA.	Cat.	VPA-1009).	The	day	of	 the	experiment	75	cm2	dishes	of	BMdMs	were	 washed	 twice	 with	 cold	 PBS	 and	 trypsinased	with	 Trypsin/EDTA	 solution	 (Life	technologies,	UK.	Cat.	R001100).	BMdMs	were	 then	 incubated	 for	5	min	at	37ºC,	 then	differentiation	 medium	 was	 added	 to	 stop	 the	 trypsination	 process.	 BMdMs	 were	counted	 and	 cell	 density	 was	 determined.	 For	 transfection,	 1x106	 BMdMs	 were	resuspended	 in	 100μl	 of	 Nucleofector	 Solution	 and	 the	 appropriate	 concentration	 of	either	 pIRES2.eGFP	 plasmid	 or	 pGFP	 control	 vector.	 BMdMs	 were	 transferred	 into	 a	cuvette	and	placed	into	the	Nucleofector	device,	Y-001	program.	After	transfection,	the	cell	suspension	was	pre-equilibrated	with	culture	medium	and	gently	transferred	into	a	12-well	 plate.	 GFP	 expression	 was	 detected	 after	 2	 hours	 and	 for	 up	 to	 72	 hours.	Optimal	BMdMs	transfection	was	determined	by	comparison	with	the	GFP	levels	of	the	control	group	using	the	pGFP	vector	provided	by	the	manufacturer.	BMdM-GFP	positive	cells	were	also	analysed	by	flow	cytometry,	on	the	488-525/50	laser	on	a	BD	FACS	Scan.	At	least,	1x103	events	were	collected	per	sample.	Flow	Jo	software	(version	9.	8.5)	(Tree	Star,	Ashland,	OR)	was	used	for	analysis.	
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2.7	In	vivo	model	of	cardiac	injury	
2.7.1	Left	descending	coronary	artery	ligation	as	model	myocardial	infarction	Myocardial	infarction	by	permanent	left	coronary	artery	occlusion	was	induced	in	wild-type	(WT)	and	αMHC.IGF-1Ea	male	mice,	8	to	12	weeks	old.		Surgeries	were	performed	under	 mechanical	 ventilation	 with	 1–2.5%	 isofluorane.	 The	 chest	 cavity	 was	 opened	through	 the	 left	 fourth	 intercostal	 space.	The	heart	was	exposed	and	 the	 left	 coronary	artery	 was	 ligated	 using	 8.0	 mm	 non-absorbable	 suture	 (Ethicon-Johnson&Johnson,	Germany,	 Cat.	 W2808).	 The	 coronary	 artery	 can	 be	 found	 at	 1-2mm	 below	 the	 left	atrium,	ligation	at	this	point	should	produce	a	20-30%	ischemic	region.	The	chest	cavity,	and	skin	were	sutured	using	5.0mm	silk	 sutures	 (Ethicon-Johnson&Johnson,	Germany,	Cat.	W581).	Mortality	rate	ranged	 from	20	 to	40%,	observed	between	3	and	5	days	 in	WT	 mice.	 Mortality	 in	 the	 αMHC.IGF-1Ea	 was	 minimum.	 Mice	 received	 analgesic	treatment	 with	 buprenorphine	 (0.3	 mg/kg,	 s.c.)	 before	 and	 after	 surgery.	 Mice	 were	housed	in	individually	ventilated	cages	in	temperature-controlled	facilities	on	a	12-hour	light/dark	cycle	on	standard	diet.	All	mouse	procedures	were	approved	by	the	Imperial	College	 London	 Ethical	 Committee	 and	 were	 in	 accordance	 with	 national	 and	international	 regulations	 (UK	Home	 Office	 Project	 license	 70/7589).	 A	 representative	picture	of	an	infarcted	heart	by	this	method	can	be	found	in	Chapter	3,	Figure	3.3.	
	
2.7.2	Ischemia	reperfusion	injury	as	a	model	of	myocardial	infarction	Myocardial	infarction	was	induced	by	ischemia-reperfusion	(I/R)	in	C57/BL6	male	mice	(n=141),	 8	 to	 12	 weeks	 old,	 obtained	 from	 Charles	 River.	 Surgeries	 were	 performed	under	 general	 anesthesia	 with	 3–3.5%	 sevoflurane	 and	 mechanical	 ventilation	 was	provided	during	the	procedure.	Mice	received	analgesic	treatment	with	buprenorphine	(0.3	 mg/kg,	 s.c.)	 after	 surgery.	 The	 infarcts	 were	 performed	 by	 ligation	 of	 the	 left	coronary	artery	 for	45	minutes	 followed	by	reperfusion	of	 the	artery.	The	chest	cavity	was	opened	through	the	left	fourth	intercostal	space.	The	heart	was	exposed	and	the	left	coronary	 artery	 was	 ligated	 using	 8.0mm	 non-absorbable	 suture	 (Ethicon-Johnson&Johnson,	Germany,	Cat.	W2808).	The	coronary	artery	can	be	found	at	1-2mm	below	the	left	atrium,	ligation	at	this	point	should	produce	a	20-30%	ischemic	region.	A	plastic	canula	was	employed	an	knotted	along	with	the	left	descending	coronary	artery	to	 facilitate	 reperfusion.	 The	 chest	 cavity,	 and	 skin	 were	 sutured	 using	 5.0mm	 silk	sutures	 (Ethicon-Johnson&Johnson,	 Germany,	 Cat.	 W581).	 The	 chest	 cavity,	 and	 skin	were	sutured	with	5.0mm	silk	sutures	(Ethicon-Johnson&Johnson,	Germany,	Cat.W581).	The	 mortality	 rate	 in	 the	 first	 24	 h	 post-I/R	 was	 38%;	 no	 mortality	 was	 found	afterwards.	1mg/ml	of	bromodeoxyuridine,	BrdU,	was	administered	in	the	water	of	all	
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four	 groups	 and	 renewed	 every	 two	 days.	 Mice	 received	 analgesic	 treatment	 with	buprenorphine	 (0.3	 mg/kg,	 s.c.)	 before	 and	 after	 surgery.	 Mice	 were	 housed	 in	individually	 ventilated	 cages	 in	 temperature-controlled	 facilities	 on	 a	 12-hour	light/dark	cycle	on	standard	diet.		A	representative	picture	of	an	infarcted	heart	by	this	method	can	be	found	in	Chapter	5,	Figure	5.2.		
2.7.3	Skeletal	muscle	CTX	injury	as	model	for	muscle	regeneration	Surgical	 anaesthesia	was	 induced	with	3.5-4.5%	 isofluorane	 and	maintained	with	2.5-3%	during	 the	 procedure.	 At	 the	 beginning	 of	 the	 procedure,	mice	 received	 analgesic	treatment	with	buprenorphine	(0.1	mg/kg,	s.c.).	Fur	was	removed	and	Tibialis	Anterior	(TA)	 and	 quadriceps	 from	 7-8	 weeks-old	 mice	 were	 injected	 with	 5µl	 of	 cardiotoxin	(CTX)	at	10µM	(Latoxan,	France,	Cat.	L8102).	For	each	TA	and	quadriceps,	4	and	8	CTX	injections	of	5µl	were	perfomed	respectively.	Muscle	samples	were	harvested	at	various	timepoints	 after	 injury.	 In	 parallel,	 TA	 muscle	 was	 embed	 in	 paraffin	 for	 histological	analysis	and	quadriceps	were	collected	for	single	cell	separation.		
2.8	Echocardiography		
2.8.1	Transthoracic	echocardiography	with	Vevo	770	Echocardiographic	measurements	were	taken	using	a	high-frequency	ultrasound	system	Vevo	770	(VisualSonics,	Canada)	with	a	30-MHz	linear	transducer	and	recorded	images	were	 analyzed	 by	 using	 the	 Vevo	 770	workstation	 software.	 	Mice	were	 anesthetized	with	1-2%	isofluorane,	and	the	anesthetic	flow	rate	was	adjusted	to	maintain	heart	rate	of	approximately	450	±	50	beats	per	minute.	Furthermore,	warmed	ultrasound	gel	and	a	heating	 platform	were	 used	 to	maintain	 body	 temperature	 at	 37	 ±	 0.5ºC	 to	minimize	variation	between	mice.	The	functional	analysis	was	performed	at	basal	level,	1,	3,	5,	7	and	 28	 days	 post-MI	 in	 anesthetized	 mice	 to	 evaluate	 left	 ventricle	 cardiac	 function,	chamber	dimensions,	and	infarct	size.		From	these	analysis,	left	ventricular	end-systolic	volume	(LVESV),	left	ventricular	end-diastolic	volume	(LVEDV),	left	ventricular	internal-systolic	 diameter	 (LVIDS),	 left	 ventricular	 internal-diastolic	 diameter	 (LVIDD),	 left	ventricular	posterior	wall	in	diastole	(LVPWD),	left	ventricular	posterior	wall	in	systole	(LVPWS),	left	ventricular	ejection	fraction	(LVEF)	and	fractional	area	change	(FAC)	were	acquired	to	perform	the	analysis		
2.8.2	Transthoracic	echocardiography	with	Vevo	2100		Echocardiographic	 measurements	 were	 taken,	 by	 a	 blinded	 operator,	 using	 a	 high-frequency	 ultrasound	 system	 Vevo	 2100	 (VisualSonics,	 Inc)	 with	 a	 30-MHz	 linear	
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transducer	and	recorded	images	were	analysed	by	a	second	blinded	operator	using	the	Vevo	 2100	workstation	 software.	 	 Transthoracic	 echocardiography	was	 performed	 at	baseline,	 3	 and	 28	 days	 post-I/R	 injury	 in	 anesthetized	 mice	 to	 evaluate	 LV	 cardiac	function,	 chamber	dimensions,	wall	 thickness,	 infarct	 size	and	wall	motion.	Mice	were	anesthetized	 with	 1-2%	 isoflurane	 in	 oxygen,	 the	 anesthetic	 flow	 was	 adjusted	 to	maintain	heart	rate	in	approximately	450	±	50	beats	per	minute.	Furthermore,	warmed	ultrasound	gel	and	a	heating	platform	were	used	to	preserve	body	temperature	around	37	 ±	 0.5ºC	 to	 minimize	 variation	 among	mice.	 Standard	 2D	 and	M-mode	 parasternal	long	 and	 short	 axis	 (at	 mid-ventricle)	 views	 were	 obtained	 to	 assess	 left	 ventricular	function	 and	 chamber	 dimensions.	 From	 these	 modes,	 left	 ventricular	 end-systolic	volume	 (LVESV),	 left	 ventricular	 end-diastolic	 volume	 (LVEDV),	 left	 ventricular	 end-systolic	 diameter	 (LVESD),	 left	 ventricular	 end-diastolic	 diameter	 (LVEDD)	 and	 left	ventricular	ejection	fractional	(LVEF)	were	acquired	to	perform	the	analysis.			
Figure	 2.5.	 Echocardiographic	 representation	 of	 parasternal	 short	 and	 long	 axis	
orientation	and	schematics	of	LV	walls.	Global	and	regional	cardiac	function	was	assessed	by	a	12-based	segment	model,	considering	2D	short	axis	views	at	3	levels	(base,	middle	and	apex).	In	each	level,	the	left	ventricle	was	divided	in	4	segments	(anterior,	lateral,	inferior	and	septal)	and	each	 segment	 was	 score	 according	 to	 the	 American	 Society	 of	 Echocardiography	 (Lang	 et	 al.	2005).	Segment	analysis	and	motion	can	be	found	in	Chapter	5,	Figure	5.7.	
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Left	ventricle	wall	motion	score	index	(WMSI)	was	calculated	in	order	to	assess	global	and	 regional	 cardiac	motion	 by	 a	 12-based	 segment	model,	 considering	 2D	 short	 axis	views	at	3	levels	(base,	middle	and	apex).	In	each	level,	the	left	ventricle	was	divided	in	4	segments	(anterior,	lateral,	inferior	and	septal)	and	each	segment	was	scored	according	to	 the	American	Society	of	Echocardiography	(1:	normal,	2:	hypokinetic,	3:	akinetic,	4:	dyskinetic	and	5:	aneurysmal)	(Lang	et	al.	2005)(Figure	2.5	and	Chapter	5,	Figure	5.7).	
	WMSI	 is	 defined	 as	 the	 ratio	 of	 the	 sum	 of	 scored	 individual	 segment	 over	 the	 total	number	 of	 segments	 evaluated.	 Infarct	 size	was	 also	 estimated	 considering	 the	mean	score	of	 individual	 segments.	Only	mice	 that	presented	 two	or	more	cardiac	 segments	with	altered	motion	plus	a	 left	ventricular	ejection	fraction	below	45%	at	3	days	post-surgery	were	selected	for	the	study.	All	measurements	were	carried	out	 in	accordance	with	 the	 recommendations	 for	 chamber	 quantification	 from	 the	 American	 Society	 of	Echocardiography	 in	 conjunction	with	 the	 European	 Association	 of	 Echocardiography	(Lang	et	al.	2005).	
	
2.9	Histology	of	paraffin-embedded	tissue		After	sacrifying	the	mice,	the	hearts	were	perfused	with	PBS	and	KCL-arrested-perfused	hearts	 samples	were	 fixed	 in	 paraformaldehyde	 (4%	 in	 PBS)	 for	 48h,	washed	 in	 PBS,	dehydrated,	and	included	in	paraffin.		
2.9.1	Masson’s	Trichrome	Staining		Five-micron	thick	sections	were	stained	following	Masson’s	trichrome	protocol	(Masson	trichrome	Staining	reagents,	Sigma,	UK,	Cat.	HT15-1KT).	Paraffin	sections	were	stained	with	celestine	blue	for	5	minutes,	washed	in	tap	water,	and	incubated	in	haemotoxylin	for	 5	minutes.	 Slides	were	 incubated	with	 fucsin	 acid	 for	 5	minutes,	 rinsed	quickly	 in	distilled	water	and	differentiated	in	phosphomolybdic	acid	(1%)	for	3-5	minutes.	After	that,	 slides	 were	 rinsed	 briefly	 in	 water	 and	 stained	 in	 methyl	 blue	 for	 2-3	 minutes.	Finally,	 slides	 were	 washed	 briefly	 with	 distilled	 water	 and	 dehydrated	 in	 ascending	series	of	Methanol,	cleared	in	xylene	and	mounted	in	DPX	(VWR,	UK.	Cat.	100504-938).			
2.9.1.1	Determination	of	scar	length	and	total	fibrosis	Scar	length,	as	method	for	the	quantification	of	infarct	size,		was	determined	in	Masson’s	trichrome-stained	 sections	 by	 using	 the	 midline	 method,	 which	 best	 correlates	 with	functional	measurements	(Takagawa	et	al.	2007	and	Lopez-Olaneta	et	al.	2014).	In	this	method,	the	infarct	size	is	measured	as	the	length	of	the	midline	of	the	infarcted	wall,	in	
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which	50%	of	the	wall	thickness	is	composed	of	scar	tissue.	Scar	length	represents	the	percentage	 of	 infarct	 length	 with	 respect	 to	 the	 whole	 length	 of	 the	 left	 ventricular	circumference.	 Total	 fibrosis	 was	 quantified	 in	 whole	 heart	 images	 obtained	 at	 the	middle	section	by	ImageJ	software	(NIH,	USA)	.		
2.9.2	Picrosirius	red	staining	Five-micron	 thick	 sections	 were	 stained	 with	Weigart’s	 haematoxylin	 for	 10	 minutes	followed	by	a	wash	in	tap	water.	Sections	were	incubated	with	1%	Molybdophosphoric	acid	 for	20	minutes,	after	a	brief	wash	 in	distilled	water	sections	were	 incubated	with	Sirius	 red	 solution	 for	 60	 minutes.	 Slides	 were	 washed	 with	 distilled	 water	 and	dehydrated	in	ascending	series	of	Methanol,	cleared	in	xylene	and	mounted	in	DPX.			
2.9.3	Heart	immunohistochemistry	Prior	to	immunoperoxidase	staining,	five-micron	thick	sections	were	washed	in	PBS	for	5	minutes.	The	slides	were	then	immersed	in	0.1M	citrate	buffer	(pH	6)	and	microwaved	for	 10	 minutes	 before	 blocking	 for	 endogenous	 peroxidases	 using	 0.3%	 hydrogen	peroxide	 in	 PBS	 for	 10	minutes.	 Sections	were	washed	 3x5	minutes	 each	 in	 PBS	 and	blocked	with	3%	bovine	 serum	albumin	 (W/V)	 (BSA)	 in	PBS	 for	30	minutes.	 Sections	were	incubated	separately	overnight	with	the	antibodies	described	below.		The	 primary	 antibodies	 used	 were,	 IGF-1	 (Sigma,	 UK.	 Cat.	 I-8773)	 antibody	 1:100	dilution,	anti-α-smooth	muscle	actin	(Abcam,	UK.	Cat.	Ab5694)	1:400	dilution,	and	anti-Luciferease	 (Promega,	 USA.	 Cat.	 -G7451)	 1:300	 dilution	 was	 used.	 Vessels	 were	quantified	by	anti-α-smooth	muscle	actin	(αSMA,	Sigma,	UK,	Cat.	A5228)	1:200	dilution	was	used.	Mitosis	and	cell	division	was	quantified	by	Anti-Phospho-Histone	H3	(Ser10)	(Cell	Signalling,	UK,	Cat.9701)	in	a	1:200	dilution.		Primary	antibodies	were	removed	by	washing	the	sections	3	times	with	PBS	followed	by	a	second	incubation	of	Biotinylated	anti-goat	immunoglobulin	(Vector	laboratories,	UK.	Cat.	 I-5000)	diluted	1/250	in	PBS	for	1	hour	following	3	times	washes	in	PBS	before	1	hour	 incubation	with	Avidin-Biotin	 (Vector	 laboratories,	UK.	 Cat.	 PK-4000).	 Reactivity	was	 detected	 by	 using	 diaminobenzidine	 tetrahydrochloride	 (DAB	 tablets-25mg/ml)	(Sigma,	 UK	 Cat.	 D4293)	 and	 hydrogen	 peroxide	 (0.01%	 W/V).	 Sections	 were	 then	counter	stained	with	haematoxylin	and	viewed	on	Ziess	Axioskop	microscope.		
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The	number	of	vessels	was	determined	counting	the	number	of	αSMA+	vessels	divided	by	the	infarct	area.	Images	were	digitalised	by	using	a	NanoZommer	(Hamamatsu,	UK)	and	further	quantified	by	using	ImageJ	software	(NIH,	USA).		
2.9.4	Heart	immunofluorescence	Prior	 to	 immunoperoxidase	 staining,	 five-micron	 thick	 sections	 were	 washed	 in	phosphate	 buffered	 saline	 (PBS)	 for	 5	 minutes.	 The	 slides	 were	 immersed	 in	 0.1M	citrate	 buffer	 (pH	 6)	 and	 microwave	 for	 10	 minutes	 before	 blocking	 for	 endogenous	peroxidases	 using	 0.3%	 hydrogen	 peroxide	 in	 PBS	 for	 10	 minutes.	 Sections	 were	washed	3x5	minutes	each	 in	PBS-Triton	0.3%	and	blocked	with	blocking	solution	(3%	bovine	serum	albumin	(W/V)	(BSA),	20mM	MgCl2,	0.3%	Tween,	5%	goat	serum	in	PBS)	for	 1	 hour	 at	 RT.	 Samples	 were	 also	 blocked	 with	 Avidin/Biotin	 blocking	 kit	 (Vector	Labs,	USA,	SP-2001).	After	incubation	with	the	primary	antibody,	sections	were	washed	3x5	minutes	each	in	PBS-Triton	0.3%	and	incubated	O/N	at	4°C.			For	 BrdU	 and	 troponin	 I	 immunofluorescence	 were	 performed	 with	 the	 following	antibodies:	 Mouse	 anti-BrdU	 1:30	 dilution	 (BD	 Bioscience,	 USA,	 Cat.	 347580).	 Rabbit	Anti-cardiac	troponin	I	at	1:100	dilution	(Abcam,	UK,	Cat.	ab	47003).			The	 following	 day,	 the	 slides	 were	 incubated	 with	 biotinylated	 anti-rabbit	 secondary	antibody	 1:100	 (Jackson	 Immuno	 Research,	 USA,	 Cat.111-066-003)	 for	 1	 hour	 at	 RT.	Finally,	 slides	 were	 incubated	 with	 anti-mouse	 streptavidin-Alexa	 488	 1:200	(ThermoFisher,	 USA,	 Cat.	 A-11029)	 and	 anti-biotin	 Streptavidin-Cy3	 1:200	 (Jackson	Immuno	Research,	USA,	Cat.	016-160-084).	Sections	were	washed	3x5	minutes	each	in	PBS	 and	 DAPI	 in	 a	 1:1000	 dilution.	 Slides	 double-stained	 with	 anti-BrdU	 and	 anti-troponin	I	were	assessed	by	Zeiss	LSM	Confocal	Microscope	System.		
2.10.		Amplification	and	purification	of	IGF-1Ea	vector	from	E.coli	The	pIRES2.eGFP,	 in	Chapter	4,	 containing	 the	Mus	musculus	 IGF-1Ea	consensus	 cDNA	sequence	was	obtained	from	Nadia	Rosenthal’s	glycerol	stocks.	The	pIRES2.eGFP	vector	is	 a	 bi-cistronic	 gene	 expression	 cassette,	 which	 contains	 a	 Kanamycin/Neomycin	resistance	gene	(Kan-Neo).	These	two	genes	confers	the	bacterial	host	with	resistance	to	each	 antibiotic	 allowing	 artificial	 selection	 of	 those	 bacterial	 cells	 containing	 the	plasmid.	 In	 this	 plasmid,	 gene	 expression	 is	 driven	 by	 the	 cytomegalovirus	 promoter	(CMV),	 which	 regulates	 the	 expression	 of	 the	 IGF-1Ea	 gene	 and	 eGFP	 reporter	 gene.	Transcription	ends	at	a	SV40	polyA	terminator	signal	(Figure	2.6A).		
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pIRES2.eGFP	glycerol	stock	of	One	Shot®	TOP10	Chemically	Competent	Escherichia	coli	(E.	coli,	 Invitrogen,	USA.	Cat.	C404010)	containing	 IGF-1Ea	plasmid	was	reactivated	by	inoculation	 of	 60	 μl	 of	 glycerol	 stock	 into	 3	 ml	 of	 Luria-Bertani,	 LB,	 (Sigma,	 UK.	 Cat.	L3522)	and	30	μg/ml	of	Kanamycin	(Sigma,	UK.	Cat.	K1377).	After	O/N	culture	at	37	ºC,	the	bacterial	grow	was	divided	and	1	ml	was	plated	into	LB	Agar	plate	with	Kanamycin,	1	ml	was	stored	as	glycerol	stock.	Finally,	the	remaining	1	ml	was	used	for	isolating	the	plasmid.	The	 construct	was	 isolated	using	QIAGEN	Plasmid	Mini	or	Midi	Kit	 (QIAGEN,	UK.	Cat.	12143	and	12123,	respectively)	according	to	the	manufacture’s	protocol.	
	
Figure	2.6.	Schematic	illustration	of	pIRES2.eGFP	backbone	and	IGF-1Ea	PCR	product.	(A)	IGF-1Ea	 is	 flanked	 by	 the	 restriction	 sites	 EcoRI	 and	 BamHI.	 (B)	 Amplification	 of	 the	 IGF-1Ea	from	the	pIRES2.eGFP	by	high	efficiency	PCR.	Lane	1,	1	Kb	DNA	ladder.	Lane	2,	negative	control.	Lane	3,	IGF-1Ea	amplicon.	
	
2.11	IGF-1Ea	cloning	strategy:	from	pIRES2.eGFP	to	pAAV9.IGF-1Ea		In	Chapter	5,	the	Mus	musculus	IGF-1Ea	consensus	cDNA	sequence	was	subcloned	from	the	pIRES2.eGFP	(Section	2.10)	 into	the	destination	vector	pAC-cTNT	(provided	by	Dr.	Juan	 Bernal,	 CNIC,	 Madrid,	 Spain).	 The	 pAC-cTNT	 plasmid	 (not	 shown),	 later	 named	pAAV9.IGF-1Ea	(Figure	2.7A),	contains	all	the	elements	allowing	plasmid	replication	in	bacteria	as	well	as	serve	as	viral	genomic	payload	of	adeno-associated	viral	vehicle.	The	pAC-cTNT	plasmid	is	a	bi-cistronic	gene	expression	cassette	which	expression	is	driven	by	 the	 cardiac	 troponin	 promoter	 (cTNT)	 and	 an	 internal	 ribosomal	 entry	 site	 (IRES)	followed	by	the	firefly	luciferase	reporter	gene.	The	pAC-cTNT	also	contains	SV40	polyA	signal	and	the	bi-cistronic	cassette	is	flanked	by	inverted	terminal	repeats	(ITR),	shown	as	 hairpin	 loops	 (Figure	 2.7A).	 For	 bacterial	 amplification,	 the	 pAC-cTNT	 vector	 also	contains	a	SV40	replication	promoter	and	the	Ampicilin	resistance	gene	that	confers	to	the	bacterial	host	resistance	to	the	antibiotic.	
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The	cloning	strategy	was	designed	based	on	the	restriction	enzyme	sites	present	in	the	pAC-cTNT	 limited	 to	 EcoRI	 and	 NotI	 restriction	 sites.	 Consequently,	 IGF-1Ea	 cloning	strategy	is	a	two-step	cloning	strategy	as	follows,	(i)	PCR	amplification	of	Mus	musculus	IGF-1Ea	 consensus	 sequence	 in	 the	 pIRES2.eGFP	 by	 high	 efficiency	 PCR	with	 primers	containing	EcoRI	and	NotI	 restriction	sites	 (Section	2.11.1)	and	(ii)	cloning	of	 the	 IGF-1Ea	insert	into	the	plasmid	pAC-cTNT	destination	vector	(Section	2.11.2).		
	
2.11.1	Amplification	and	purification	of	IGF-1Ea	PCR	product	The	IGF-1Ea	sequence,	from	pIRES2.eGFP,	was	amplified	using	the	components	and	PCR	cycle	 described	 in	 Table	 2.3.	 In	 order	 to	 avoid	 mutations	 during	 IGF-1Ea	 PCR	amplification,	 Platinum®	 Pfx	 High	 fidelity	 DNA	 polymerase.	 The	 following	 primers,	showing	in	bold	EcoRI	and	NotI	restriction	sites	were	used:	Forward	primer:	5’-GCTTCGAATTCTGCAGTCGACGC-3’.	In	bold,	EcoRI	sequence.	Reverse	primer:	5’-CCGCGGCCGCCTACATTCTGTAGG	-3’.	In	bold,	NotI	sequence.		
	
Table	 2.3.	 Components	 and	 thermocycler	 conditions	 for	 IGF-1Ea	 PCR.	 Agarose	 gel	electrophoresis	 (2%)	 was	 used	 to	 run	 the	 PCR	 product	 at	 100	 Volts	 to	 verify	 that	 a	 single,	discrete	band	of	the	correct	size	was	present.	Platinum®	Pfx	High	fidelity	DNA	polymerase	was	used	(Invitrogen	®,	UK,	Cat	No.	11708-013).			The	 IGF-1Ea	PCR	product	 (462	bp)	was	 then	 subcloned	 into	 the	pAC-cTNT.	After	PCR	amplification	(Figure	2.6B)	of	IGF-1Ea	and	before	cloning	into	the	pAC-cTNT,		the	PCR	product	was	purified	according	to	the	manufacturer’s	protocol	using	the	QIAquick®	Kit	(QIAGEN,	 UK.	 Cat.	 28104).	 The	 PCR	 purification	 kit	 is	 based	 on	 a	 bind-wash-elute	procedure	where	impurities	such	as	primers,	nucleotides,	enzymes,	minerals,	oils,	salts,	which	may	inhibit	the	restriction	enzyme	digestion	process,	are	washed	away	and	pure	DNA	is	eluted	with	a	small	volume	of	water.	
Component	
(final	concentration)	
Volume	(µL)																										
50	µL	reaction	
Thermocycler	conditions	
35	cycles	
DNA	template	(200ng)	
MgSO4(1mM)	
Pfx	Amplification	Buffer	(1X)	
dNTPs	(0.3mM	each)	
Primer	mix	(0.3µM	Each)	
Autoclaved,	distilled	water	
Platinum	Pfx	DNA	polymerase	(1unit/µL)	
PCR	Enhancer	solution	
1	3	5	1.5	1.5	35	0.4	5	
	5	min	at	94°C	35X									15	sec	at	94°C																		30	sec	at	55°C																		1	min	sec	at	68°C	10	min	at	72°C	∞	4°C		
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2.11.2	IGF-1Ea	PCR	product	digestion	and	ligation	into	the	pAC-cTNT	Following	IGF-1Ea	PCR	amplification	and	purification,	both	the	PCR	insert	and	the	pAC-cTNT	 destination	 vector	 were	 digested	 for	 1	 hour	 with	 EcoRI	 and	 NotI	 restriction	enzymes	as	described	in	Table	2.4.	
	
REAGENT	 AMOUNT	(µL)	
Plasmid	DNA	
EcoRI	
NotI	
NEBuffer	CutSmart*	
Total	reaction	volume	
	
Incubation	Temperature	
Incubation	time	
Inactivation	
1	μg	1	µL	1	µL	5	µL	50	µL		37°C	1	hour	65°C	–	20min.	
	
Table	 2.4.	 IGF-1Ea	 plasmid	 and	 pAC-cTNT	 restriction	 enzyme	
digestion	 protocol.	 *CutSmart:	 50mM	 Potassium	 Acetate,	 20mM	Tris-acetate,	10mM	Magnesium	Acetate	and	100μg/ml	BSA	(pH	7.9	at	 25°C).	 EcoRI	 (New	 England	 BioLabs,	 USA.	 	 Cat.	 R0101S).	 NotI	(New	England	BioLabs,	USA.		Cat.	R0189S)		The	digestion	process	generated	cohesive	5’	and	3’	ends	in	both	the	pAC-cTNT	plasmid	and	 the	 IGF-1Ea	 insert.	Therefore,	 in	order	 to	 facilitate	 the	cloning	of	 the	 insert	 in	 the	vector,	 T4	 ligase	was	used.	T4	 ligase	 seals	 the	nicks	between	 adjacent	 residues	 of	 the	double-strand	break	by	forming	a	phosphodiester	bond	between	the	3'	hydroxyl	and	5'	phosphate	 of	 adjacent	 DNA	 residues.	 	 Restriction	 enzyme	 digested	 products,	 IGF-1Ea	insert	and	pAC-cTNT	vector,	were	ligated	as	described	in	Table	2.5.			
REAGENT	 									AMOUNT	(µL)	
Insert:Vector	ratio	
Ligase	Reaction	Buffer	
Total	DNA	
T4	DNA	Ligase	
Distilled	water	
	
Incubation	temperature	
Incubation	time	
3:1	4	µL	<100ng	0.1	Units	Up	to	20	µL		23-26°C	1h	–	O/N	
Table	2.5.	Ligation	protocol.	T4	DNA	ligase	kit	(Life	technologies,	Thermo	Fisher	Scientific,	UK.		Cat.	15224-017).		The	final	product	is	the	pAAV9.IGF-1Ea	plasmid	shown	in	Figure	2.7.	
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2.11.3	One	Shot®	Stbl3	Transformation		The	pAAV9.IGF-1Ea	plasmid	(Figure	2.7)	was	then	used	to	transform	STBL3	competent	cells.	 This	 step	 is	 required	 to	 obtain	 a	 reasonable	 amount	 of	 pAAV9.IGF-1Ea	 for	downstream	protocols.		Transformation	was	performed	according	to	the	manufacturer’s	protocol	using	the	One	Shot®Stbl3™	 Chemically	 competent	 E.Coli	 (Invitrogen,	 USA.	 Cat.	 C7373-03)	 using	 the	heat-shock	 technique	(42°C	 for	45	seconds	and	 then	 immediately	placed	on	 ice).	After	transformation,	 the	 cells	 were	 seed	 on	 a	 pre-warmed	 Ampicilin	 resistant	 plate	 and	incubated	 O/N	 at	 37°C.	 This	 particular	 strain	 of	E.Coli	 is	 recommended	when	 cloning	vectors	with	 inverted	 terminal	 repeats	 (ITR).	 	The	strain	has	been	designed	 to	 reduce	the	 frequency	of	homologous	 recombination	preventing	 intermolecular	 recombination	of	 the	 ITR	 regions,	 which	 may	 compromise	 vector	 integrity.	 	 As	 described	 in	 the	Introduction,	Section	1.4.2.2,	ITR	regions	facilitate	recombination	and	DNA	packing	into	the	viral	vehicle	(Figure	2.8).			The	 following	day,	 one	half	 of	positive	 resistant	 colonies	were	 incubated	 in	2ml	of	LB	medium,	 and	 the	 other	 half	 of	 the	 colony	 was	 screened	 for	 positive	 insert/plasmid	insertion.	The	screening	was	performed	by	PCR	 for	 the	 IGF-1Ea	gene	and	by	digesting	the	vector	as	described	in	Sections	2.11.4	and	2.11.5.		
2.11.4	Amplification	of	positive	clones,	bacterial	amplification	and	plasmid	isolation	After	 O/N	 culture,	 the	 pAAV9.IGF-1Ea	 plasmid	 was	 isolated	 using	 QIAGEN	 plasmid	purification	Kit	according	to	the	manufacturer’s	instructions	(QIAGEN,	UK.	QIAprep	Spin	Miniprep	Kit	Cat.	27106	and	Endofree	Plasmid	Maxi	Kit.	Cat.	12362).	Purified	plasmids	were	eluted	with	sterile	milliQ	water	and	stored	at	-20°C.	The	DNA	yield	was	quantified	by	Nanodrop®	(Thermo	Scientific,	Wilmington,	USA)	measuring	absorbance	at	260	nm	and	280	nm.			
2.11.5	Confirmation	of	correct	IGF-1Ea	cloning:	PCR	and	restriction	enzyme	digestion	In	 order	 to	 verify	 the	 correct	 cloning	 of	 the	 IGF-1Ea	 insert	 into	 the	 pAC-cTNT	destination	 vector,	 the	DNA	was	digested	using	EcoRI	 and	NotI	 as	described	 in	Table	
2.5.	 Following	 endonuclease	 digestion,	 20µL	 of	 plasmid	 was	 mixed	 with	 6X	 loading	buffer	(New	England	Bio	Labs,	USA,	Cat.	B7021S)	and	loaded	on	a	1.5%	agarose	gel	as	shown	Figure	 2.7B.	The	digested	 IGF-1Ea	product	band	observed	 indicates	successful	cloning.	
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Figure	 2.7.	 Schematic	 illustration	 of	 pAAV9.IGF-1Ea	 vector	 backbone	 and	 IGF-1Ea	
restriction	 enzyme	 digestion.	 	 (A)	 IGF-1Ea	 was	 cloned	 inside	 a	 pAAV9.IGF1Ea	 under	 the	control	of	the	cardiac	troponin	promoter.	A	bi-cistronic	gene	expression	cassette	with	allows	the	expression	of	 IGF-1Ea	 and	 luciferase	 via	 an	 internal	 ribosomal	 entry	 site	 (IRES).	Transcription	ends	 by	 a	 SV40	 polyA	 terminator	 signal.	 The	 IGF-1Ea	 gene	 is	 flanked	 by	 the	 restriction	 sites	EcoRI	and	NotI.	The	vector	also	contains	an	ampicilin	resistance	gene	that	confers	to	the	bacterial	host	 antibiotic	 resistance.	 (B)	 Cloning	 validation	 of	 the	 recombinant	 pAAV9.IGF-1Ea	 plasmid	vector	 by	 EcoRI	 and	 NotI	 digestion.	 Lane	 1,	 1	 Kb	 DNA	 ladder.	 Lane	 2,	 original	 pAAV9	 with	another	GOI.	Lane	3,	restriction	enzyme	digestion	with	the	IGF-1Ea	gene.	1	Kb	plus	DNA	ladder™	(Invitrogen,	USA.	Cat.	10787018).	EcoRI	 (New	England	BioLabs,	USA.	 	Cat.	R0101S).	NotI	 (New	England	BioLabs,	USA.		Cat.	R0189S).		
2.11.6	pIRES.eGFP	and	pAAV9.IGF-1Ea	sequencing	For	 sequencing,	 150ng	 per	 Kb	 (500-600ng	 for	 plasmid	 over	 3Kb),	 1	 µl	 of	 sequencing	primer	(at	~3.2	pmole)	and	water	was	added	up	to	a	 final	volume	of	10	ul.	Sequences	were	 sent	 to	 the	 MRC	 sequencing	 facility.	 ApE	 software	(http://biologylabs.utah.edu/jorgensen/wayned/ape/)	 was	 used	 for	 the	 analysis	 and	comparison	of	the	sequences.			For	the	pIRES.eGFP,	the	following	primers	flanking	the	IGF-1Ea	were	designed:		IGF-1	forward	primer:	5’-CGTCTTCACACCTCTTCTACC-3’	IGF-1	reverse	primer:	5’-GGTAGAAGAGGTGTGAAGACG-3’		For	the	pAAV9.IGF-1Ea,	primers	were	design	to	cover	the	DNA	region	from	ITR1	to	ITR2	(Figure	2.7),	which	is	the	region	that	will	be	incorporated	inside	the	adeno-associated	viral	vehicle,	thus,	no	mutation	will	pass	onto	the	viral	production	step.				
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The	primers	sequence	used	for	sequencing	based	on	pAAV9.IGF-1Ea	backbone,	Figure	
2.7A,	were	the	following:	5’	ITR1	forward	primer:	5’-GGTGTCGGGGCTGGCTTAACTATGC-3’	5’	cTNT	forward	primer:	5’-CAGTCTGGGCTTTCACAAGACA-3’	5’	IGF1.1	forward	primer:	5’-GCACATTCCTGCTGGCTCTGCC-3’	3’	IGF1.1	reverse	primer:	5’-CACTAGTCCAGTGTGGTGGAAT-3’	5’	ITR2.1	forward	primer:	5’-CCGAAAGGTCTTACCGGAAAAC-3’	5’	ITR2.2	forward	primer:	5’-GTCGACCGTAGATAAGTAGCATGGCG-3’		Samples	 for	 sequencing	 were	 submitted	 to	 the	 MRC	 sequencing	 facility.	 Only	 those	samples	with	no	mutations,	inverted	or	deleted	regions	neither	at	promoter	nor	at	IGF-1Ea	gene	level,	were	carried	forward	for	viral	production.			Most	 importantly,	 I	 experienced	 serious	 difficulties	when	 sequencing	 the	 ITR	 regions,	which	delayed	the	project	 for	months.	 I	seek	the	assistance	of	MRC	facility	people	that	eventually	 allowed	 me	 to	 properly	 sequence	 the	 ITR	 regions	 and	 make	 sure	 that	 no	mutations	were	carried	forward.	The	approach	is	described	in	the	following	section.		
2.11.7	Sequencing	GC-rich	regions	of	the	ITRs	As	 described	 in	 the	 Introduction,	 section	 1.4.2.2,	 the	 inverted	 terminal	 repeats	 (ITRs)	flanking	 the	 pAAV9.IGF-1Ea	 genome	 are	 repeated	 DNA	 regions	 with	 high	 GC-rich	content	 forming	 strong	 hydrogen	 bounds	 and	 secondary	 structures,	 which	 prevents	proper	 amplification	 (Figure	 2.8).	 These	 regions	 are	 not	 easily	 denatured	 during	 the	sequencing	process.										
Figure	2.8.	Predicted	structure	of	the	inverted	terminal	repeats	(ITR)	in	the	pAAV.IGF-1Ea.	3D	T-shape	structure	of	the	ITR	after	AAV9.IGF-1Ea	delivery	into	the	heart.	In	the	pAAV.IGF-1Ea	plasmid,	ITR	sequences	are	linear	sequences	flanking	the	IGF-1Ea	at	5’	and	3’	(Figure	2.7).	Inside	the	virus	AAV9,	at	each	end	of	the	genome	the	ITR	form	3D	T-shape	structures	(Chapter	5,	Figure	
5.2).	
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At	MRC	facility,	we	came	up	with	the	idea	of	amplifying	the	ITR	regions	by	PCR	prior	to	sequencing	rather	than	sending	the	whole	plasmid	(Kieleczawa	et	al.	2006).	Therefore,	a	new	 protocol	 was	 designed	 to	 improve	 amplification	 efficiencies.	 A	 new	 polymerase,	TaKaRA	 La	 Taq®	 (Clontech,	 France.	 Cat.	 RR013A)	was	 used	 as	 described	 to	 be	more	efficient	when	amplifying	DNA	targets	with	high	GC	content.	Besides	the	high	efficiency	of	 the	 TaKaRA	 La	 Taq®	 polymerase,	 7-deaza-dGTP	 was	 used	 instead	 of	 dGTP.	 The	structure	of	this	GTP	analogue	stabilizes	the	hairpin	and	prevents	compressions	of	the	DNA	during	the	amplification	phase.	The	components	and	the	PCR	cycle	are	described	in	
Table	2.6.	
	After	ITR	PCR	amplification,	the	sample	was	purified	from	enzymes	and	nucleotides.	For	that,	ExoSAP	mix,	containing	1U	each	of	FastAP	and	ExoI,	was	added	directly	to	the	PCR	tube.	 The	 components	 and	 reaction	 protocol	 is	 described	 in	 Table	 2.7.	 For	 ITR	amplification	the	following	primers	were	used:			ITR1	forward	primer:	5’-GGTTCAGGGGGAGGTGTGGGAGG-3’	ITR1	reverse	primer:	5’	GGAAGCGGAAGAGCGCCCAATAC-3’		ITR2	forward	primer:	5'-TGGCTTAACTATGCGGCATCAG-3’	ITR2	reverse	primer:	5’-CCAGCCTTTTGTCACCTCCCAG-3’		ITR	regions	were	then	sequenced	as	described	in	Section	2.11.6	with	the	same	primers	as	described	above.		 		
	
	
	
	
	
	
	
	
Table	2.6.	GC-	rich	PCR	components.	*	7-deaza-dGTP:		75%	7-deaza-dGTP	and	25%	dGTP.						
Component	
(final	concentration)	
Volume																										
50	µL	reaction	
Thermocycler	conditions	
35	cycles	
DNA	template	(100ng)	
GC	Buffer	I	
dNTP	mixture*	400µM	each	
Primer	mix	(0.2-1	µM	each)	
Autoclaved,	distilled	water	
TaKaRa	LA	Taq		(2.5	units/50µl)	
1	µL	25	µL	8	µL	10-50	pmol	10-50	pmol	Up	to	50	µL	0.5	µL	
																	1	min	at	94°C	30X									30	sec	at	94°C																		30	sec	at	60°C																		1	min	at	72°C																			5	min	at	72°C																			∞	4°C		
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Table	 2.7.	 ExoSAP	 sequencing	 protocol	 components.	 For	 each	PCR,	5µl	of	ExoSAP	mix	was	added.	 Exonuclease	 I	 (New	 England	 BioLabs,	 Ipswitch,	 MA,	 USA.	 Cat.	 M0293S)	 was	 used	 to	remove	overhanging	and	 single	 stranded	DNA	 fragments.	 (B)	FastAP	Thermosensitive	Alkaline	Phosphatase	 (Thermo	 Scientific,	Wilmington,	 USA.	 Cat.	 EF06511000)	 was	 used	 to	 remove	 the	primers,	and	to	dephosphorylate	the	DNA	and	dNTPs.								
	
	
	
	
	
	
Figure	2.9.	ITR	PCR	product	agarose	gel.	1.5%	Agarose	gel	showing	the	ITR	PCR	product.	Lane	1,	 100	 bp	 ladder.	 Lane	 2,	 5’ITR1	 expected	 size	 434	 bp.	 Lane	 3,	 3’	 ITR2	 expected	 size	 382	 bp.	Quick-Load®	100	bp	DNA	Ladder	(New	England	BioLabs,	Ipswitch,	MA,	USA.		Cat.	N0467S).		
2.11.8	pAAV9.IGF-1Ea	vector	quality	control,	construction,	production,	and	purification	As	described	 in	 Section	2.11.2,	Mus	musculus	 IGF-1Ea	 consensus	 sequence	was	 ligated	into	 the	 pAC-cTNT	 backbone	 and	 construct	 integrity	 was	 confirmed	 by	 restriction	enzyme	digestion	 and	 sequencing.	AAV9	viruses	were	produced	 and	purified	by	Penn	Vector	 Core	 	 at	 the	 University	 of	 Pennsylvania	 (Gao	 et	 al.	 2006).	 Prior	 packing,	 the	vector	was	subjected	to	a	series	of	digestion	enzyme	quality	controls	in	order	to	check	for	vector	integrity	(Appendix	1).	The	vector	was	later	subjected	to	genome	titrations,	sodium	 dodecyl	 sulfate–polyacrylamide	 gel	 electrophoresis	 analysis	 for	 purity,	 and	transgene	expression	analysis	in	HL-1	cells.		
ExoSAP	Mix	
Final	Concentration	
Final	volume	
(30	µL)	
Thermocycler	conditions	Water	10x	SAP	Buffer	Exonuclease	I	(20	U/	µL)		FastAP	(1	U/	µL)			
37	µL	30	µL	8	µL	25	µL	
	 37˚C,	45	min	80˚C,	15	min	4˚C	hold	
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2.12	In	vivo	injections	of	both	GFP-	and	CFSE-macrophages	after	CTX	injury	CTX	injured	mice	received	1-2	x	106	BMdMs/50μl	injected	intravenously,	24	hours	after	CTX	 injury.	BMdMs	were	 labelled	with	either	GFP,	as	described	 in	Section	2.6,	or	with	CFSE.	
	
2.13	AAV9.IGF-1Ea	in	vivo	gene	transfer	Five	hours	after	ischemic	injury,	mice	were	anesthetized	with	1.5–2.5%	sevoflurane	and	50μl	of	AAV9	virus	(in	saline)	was	injected	intravenously	through	the	femoral	vein	using	a	 29-gauge	 insulin	 syringe.	 AAV9	 treatment	 was	 performed	 as	 follows:	 one	 group	received	3.5x1011	genome	copies	(GC)	of	AAV9.GFP	as	AAV	control.	For	the	IGF-1Ea	gene	transfer,	 two	 different	 viral	 titers	 were	 administered,	 3.5x1010	 GC	 and	 3.5x1011	GC	 of	AAV9.IGF-1Ea.	After	post-viral	transfer	IGF-1Ea	levels	were	determined	by	qTR-PCR	and	western	blot.	
	
2.13.1	IVIS	-	Bioluminescence	analysis	of	in	vivo	gene	transfer	Mice	were	 anesthetized	with	 1.5-2%	 isoflurane	 in	 oxygen.	 D-luciferin	 (Promega,	 USA.	Cat.	 E1601)	 at	 100	 mg/kg	 in	 saline	 was	 administered	 to	 mice	 via	 intraperitoneal	injection	 (i.p).	 5-10	minutes	 after	 D-luciferin	 administration,	 all	mice	were	 imaged	 in	supine	 position	 using	 a	 Xenogen	 IVIS100	 imaging	 system	 (Caliper	 Life	 Sciences,	Hopkinton,	MA,	USA).	Organs	were	immersed	in	D-luciferin	for	1	min	and	bioluminesce	was	 imaged	 immediately	 after	 using	 the	 IVIS	 100	 imaging	 system.	 Images	 were	processed	 using	 Living	 Image	 software	 (Caliper	 Life	 Sciences).	 Mean	 luminescence	intensities	 (photons/s·cm2·sr)	 were	 measured	 from	 the	 regions	 of	 interest	 over	 the	mouse	hearts.	
	
2.13.2	Detection	of	serum	IGF-1	protein	In	Chapter	5,	 the	sera	from	I/R,	AAV9.GFP	and	AAV9.IGF-1Ea	groups	were	purified	for	measurements	of	total	IGF-1	using	a	commercially	available	ELISA	kit	specific	for	rodent	IGF-1	 (Peprotech	 900-K170).	 IGF-1	 serum	 levels	 were	 based	 on	 a	 standard	 curve	generated	 from	 recombinant	 mouse	 IGF-1,	 according	 to	 the	 manufacturer’s	 protocol.	The	assay	can	accurately	detects	IGF-1	concentrations	ranging	from	62–6,000	pg/ml.	
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2.14	Statistics		In	Chapter	3,	Two-tailed	Student’s	 t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	time	points	after	MI.			In	Chapter	4,	One-way	ANOVA	followed	by	Dunnett’s	post-test	at	different	conditions.		In	 Chapter	 5	 the	 following	 statistical	 packages	 were	 used:	 One-way	 ANOVA	 with	Dunnett's	 Multiple	 Comparison	 post-test	 to	 compare	 I/R	 vs	 AAV9.GFP,	 AAV9.IGF-1Ea	groups.	Two-way	ANOVA	to	compare	the	4	groups	with	Bonferroni	post-tests.	Two-way	ANOVA	to	compare	3	days	vs.	28	days	with	Bonferroni	post-tests.	Group	differences	in	qRT-PCR	and	histological	quantifications	were	analysed	by	one-way	ANOVA	followed	by	Dunnett’s	post-test	to	untreated	mice.	Vessels	were	analysed	by	Student’s	t-test.		Data	 is	 presented	 as	 mean	 ±	 SEM.	 	 Data	 was	 analyzed	 with	 GraphPad-Prism	 5.0	(Graphpad	 Software,	 Inc.,	 www.graphpad.com),	 and	 differences	 were	 considered	statistically	significant	at	P	<0.05.					
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Chapter	3	–	Study	of	 IGF-1Ea-mediated	 inflammatory	response	and	extracellular	
matrix	remodeling	after	myocardial	infarction	in	αMHC.IGF-1Ea	
	
3.1	Introduction	After	 myocardial	 infarction,	 the	 damaged	 myocardium	 releases	 inflammatory	 signals	that	trigger	a	cascade	of	cellular	processes	in	order	to	repair	damaged	tissue,	leading	to	the	formation	of	scar	tissue	and	left	ventricular	(LV)	dysfunction	(Introduction,	Section	1.3.2).	 Tissue	 restructuring	 after	 infarction	 involves	 the	 breakdown	 of	 the	 ECM	 by	proteolytic	 enzymes,	 mainly	 the	 metalloproteinases	 MMP-2	 and	 MMP-9,	 balanced	 by	interaction	with	tissue	inhibitors	of	metalloproteinases	(TIMPs)(Vanhoutte	et	al.	2006).	Initially	a	temporary	matrix	is	formed,	primarily	composed	of	collagen	type	III	(Col	Iα3),	providing	 a	 scaffold	 for	 the	 replacement	 of	 cells	 and	 structural	 integrity	 to	 the	 heart,	thereby	reducing	the	risk	of	LV	dilation	and	rupture	(Caulfield	et	al.	1979	and	Jugdutt	et.	al.	 2003).	 This	 is	 later	 replaced	 by	 collagen	 type	 I	 (Col	 Iα1)	which	will	 constitute	 the	permanent	ECM	(Jugdutt	et	al.	2003).	Col	Iα1	confers	tensile	strength	and	resistance	to	stretch	 and	 deformation,	 while	 Col	 Iα3	 confers	 compliance.	Their	 balance	 determines	cardiac	 tissue	 stiffness	 with	 increased	 Col	 Iα3	 to	 Col	 Iα1	 ratio	 generating	 a	 more	resilient	 left	 ventricle	 (Jugdutt	 et	 al.	 2003	and	 Jugdutt	 et	 al.	 2003).	The	newly	 formed	scar	 tissue	 acts	 as	 scaffold	 in	 order	 to	 preserve	 cardiac	 function	 due	 to	 the	 loss	 of	contractile	myocardium.		Innate	 immune	 cells	 recruited	 to	 the	 injured	 myocardium	 from	 the	 blood	 include	neutrophils,	 monocytes,	 macrophages	 and	 dendritic	 cells	 (Nahrendorf	 et	 al.	 2013,	Leuschner	 et	 al.	 2012	 and	 Yan	 et	 al.	 2013).	 	 These	 cells	 play	 a	 prominent	 role	 in	remodeling,	 producing	 the	MMPs	 that	 break	 down	 the	matrix,	 synthesizing	 new	 ECM	components	 and	 activating	 fibroblasts	 to	 myofibroblasts	 which	 will	 later	 in	 the	inflammatory	process	be	the	main	producers	of	matrix	proteins	(Jugdutt	et	al.	2003	and	Jugdutt	et	al.	2003).			The	 tissue	 micro-environment	 at	 a	 given	 time	 after	 MI	 influences	 the	 recruitment	 of	immune	 cells	 as	well	 as	 their	 phenotypic	 and	 functional	 properties.	 This	 is	 especially	relevant	 for	 the	 macrophage	 population,	 which	 undergoes	 a	 time-dependent	 shift	between	inflammatory	and	reparative	functions	(Frangogiannis	et	al.	2014	and	Frantz	et	al.	 2014).	 At	 early	 timepoints	 after	 injury	 the	 majority	 of	 macrophages	 produce	inflammatory	 cytokines	 and	 ROS	 including	 interleukin	 IL-1β,	 IL-12,	MMP-9	 and	 nitric	oxide.	 These	 are	 termed	 inflammatory	 or	 M1-like	 macrophages,	 which	 express	 high	
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levels	 of	 Ly6C	 marker,	 and	 function	 to	 recruit	 more	 inflammatory	 cells,	 phagocytose	cellular	debris	and	produce	growth	factors	(Vanhoutte	et	al.	2006).	As	repair	proceeds	reparative	 macrophages	 predominate,	 many	 of	 which	 express	 the	 CD206	 marker.	 In	contrast	to	the	inflammatory	macrophages,	reparative	macrophages	are	involved	in	the	suppression	 of	 inflammation	 due	 to	 high	 production	 of	 IL-10	 and	 TGF-β	 (Bujak	 et	 al.	2007,	Frangogiannis	et	al.	2014	and	Cao	et	al.	2010)	and	assist	in	the	progression	from	inflammation	 to	 repair.	 They	 also	 perform	 reparative	 roles	 promoting	 cell	 growth,	angiogenesis	and	remodeling	of	 the	ECM.	Additionally,	different	monocyte	populations	can	be	distinguished	by	the	Ly6C	marker	in	the	mouse	and	may	preferentially	give	rise	to	inflammatory	versus	reparative	macrophages.		Understanding	the	signaling	pathways	and	the	lineage	relationships	of	monocytes	after	MI	will	support	the	search	for	specific	therapies,	Introduction,	Figure	1.3	(Nahrendorf	et	al.	2013).			As	discussed	in	the	Introduction,	Section	1.5.4,	IGF-1Ea	and	its	mature	circulating	form	can	 modulate	 immune	 responses	 and	 suppress	 pathological	 inflammation	 by	modulating	 regulatory	 cytokines	 (Johannesson	 et	 al.	 2014	 and	 Bilbao	 et	 al.	 2014).	Expressed	as	a	cardiomyocyte-specific	transgene	(αMHC-IGF.1Ea)	or	delivered	locally	to	the	mouse	heart,	IGF-1Ea	improves	functional	recovery	after	cardiac	injury,	however	the	cellular	 and	molecular	mechanisms	 behind	 the	 enhanced	 repair	 in	 αMHC-IGF.1Ea	 are	not	fully	understood.			This	chapter	 focuses	on	 investigating	whether	 there	 is	a	difference	 in	 the	 immune	cell	dynamics	after	myocardial	infarction	in	αMHC-IGF.1Ea	hearts	and	the	potential	carry-on	effect	on	tissue	remodeling.	
	
3.2 IGF-1Ea	improves	cardiac	function	after	myocardial	infarction	In	αMHC.IGF-1Ea	hearts,	the	baseline	expression	of	transgenic	IGF-1Ea	was	much	higher	than	 the	 expression	 of	 endogenous	 IGF-1Ea	 in	 WT	 hearts	 (Average	 286-fold)	 at	 all	experimental	time	points	(Figure	3.1A	and	3.1B).			Although	 far	 exceeding	 the	 expression	 of	 endogenous	 IGF-1Ea,	 the	 αMHC.IGF-1Ea	transgenic	 mice	 provide	 a	 suitable	 model	 of	 IGF-1Ea	 at	 supraphysiological	concentrations	of	possible	therapeutic	relevance.	
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Figure	3.1.	 IGF-1Ea	relative	mRNA	levels	 in	 the	heart	after	myocardial	 infarct	 in	WT	and	
αMHC.IGF-1Ea	mice	compared	 throughout	a	28-day	 timecourse.	(A)	infarct	and	(B)	remote	area	 (non-ischemic).	 Infarcted	 and	 remote	 regions	 were	 separated	 using	 a	 scalpel	 and	 a	stereoscopic	microscope.	Remote	regions	are	septal	or	 inferior	non-infarcted	areas	of	the	heart	as	 in	Figure	 2.5.	 Solid	 lines	 represent	WT	mice.	 	 Dashed	 lines	 represent	 αMHC.IGF-1Ea	mice.		n=3	per	group.	Results	are	expressed	as	mean	fold	induction	±	SEM	over	the	values	of	uninjured	hearts.		Endogenous	 IGF-1Ea	expression	 in	WT	hearts	was	measured	at	1,	3,	5,	7	 and	28	days	after	MI	in	both	ischemic	and	remote	(Non-ischemic)	regions.	IGF-1Ea	levels	increased	in	 both	 the	 ischemic	 and	 remote	 regions	 (Figure	 3.2A)	with	 a	 substantially	 stronger	induction	in	the	ischemic	area	(8-fold	over	uninjured	levels).	These	results	indicate	that,	similar	 to	 other	 organs,	 endogenous	 IGF1-Ea	 expression	 is	 up-regulated	 after	 cardiac	tissue	damage	(Philippou	et	al.	2009,	Sanz	et	al.	2005	and	Santini	et	al.	2007).		To	 pinpoint	 the	 start	 of	 functional	 improvement,	 echocardiographic	 analysis	 was	performed	before,	and	1,	3,	5,	7	and	28	days	after	MI	(Table	3.1).	One	day	following	MI	both	groups	displayed	a	reduction	in	left	ventricular	ejection	fraction	(LVEF),	however,	αMHC.IGF-1Ea	 hearts	 showed	 significant	 improvement	 in	 LVEF	 by	 day	 7	 after	 MI	(Figure	 3.2B	 and	 Table	 3.1).	 Left	 ventricular	 end	 systolic/diastolic	 volumes	significantly	increased	after	MI	in	WT	hearts,	indicating	a	sign	of	left	ventricular	dilation,	while	the	αMHC.IGF-1Ea	hearts	did	not	display	any	such	signs	(Figure	3.2C	and	Table	
3.1).			In	 support	 of	 the	 functional	 data,	 the	 expression	 of	 molecular	 markers	 for	 cardiac	damage	 such	 as	 actin-alpha	 1	 skeletal	 muscle	 	 (ACTA)	 and	 atrial	 natriuretic	 peptide	(ANP)	 (Cameron	 at	 al.	 2000	 and	 Sergeeva	 et	 al.	 2012)	 were	 significantly	 reduced	 in	αMHC.IGF-1Ea	compared	to	WT	mice	28	days	after	MI	(Figure	3.2D	and	3.2E).	The	peak	
Imperial	College	London	 	 Chapter	3	-	IGF-1Ea	in	cardiac	repair	
Enrique	Gallego-Colon	 85	
of	 endogenous	 IGF-1Ea	 in	 the	 ischemic	 region	 of	 WT	 mice	 by	 day	 7,	 along	 with	 the	improvement	in	cardiac	function	in	αMHC.IGF-1Ea	as	early	as	day	7,	indicates	that	IGF-1Ea	signalling	at	early	time	points	is	key	for	cardiac	repair.	
	
Figure	3.2.	Expression	of	IGF-1Ea	improves	cardiac	function	and	reduces	dilation	as	early	
as	7	days	after	myocardial	 infarction.	(A)	mRNA	levels	of	IGF-1Ea	in	the	ischemic	and	in	the	remote	area	of	WT	hearts	at	1,	3,	5,	7	and	28	days	 following	MI.	 Infarcted	and	remote	 regions	were	 separated	 using	 a	 scalpel	 and	 a	 stereoscopic	 microscope.	 Remote	 regions	 are	 septal	 or	inferior	non-infarcted	areas	of	 the	heart	 as	 in	Figure	 2.5.	 (B)	Left	 ventricular	ejection	 fraction	(LVEF)	 and	 (C)	 left	 ventricular	 end	 systolic	 volume	 (LVESV)	 after	myocardial	 infarction.	 Solid	lines	represent	WT	mice.		Dashed	lines	represent	αMHC.IGF-1Ea	mice.	Levels	of	(D)	actin-alpha	1	skeletal	muscle	(ACTA	1)	and	(E)	atrial	natriuretic	peptide	(ANP)	mRNA	expression	28	days	after	MI.	Results	are	expressed	as	mean	fold	induction	±	SEM	over	the	values	of	uninjured	hearts.	n=	4-6	per	group.	*	p<0.05,	**	p<0.005.	Two-tailed	Student’s	t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.		
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Table	3.1.	Echocardiographic	measurements	and	analysis	performed	at	1,	3,	5,	7	and	28	
days	after	MI.	LVEDV,	left	ventricular	end-diastolic	volume;	LVESV,	left	ventricular	end-systolic	volume;	 LVIDD,	 left	 ventricular	 internal	 diameter	 in	 diastole;	 LVIDS,	 left	 ventricular	 internal	diameter	 in	 systole;	 LVPWD,	 left	 ventricular	posterior	wall	 in	 diastole;	 LVPWS,	 left	 ventricular	posterior	 wall	 in	 systole;	 LVEF,	 left	 ventricular	 ejection	 fraction;	 FAC,	 Fractional	 area	 change.	Mean	values	±	SE	are	shown.	n=	4-6	per	group.*P<0.05.	Two-tailed	student	t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea.	&P<0.05.	One-way	ANOVA	 for	condition	 time	on	each	group	and	compared	with	the	uninjured	group	on	that	column.		
	 	 	 	 	
	
WT	 αMHC-IGF-1Ea	 WT	 αMHC-IGF-1Ea	
	
Uninjured	 1	Day	
LVEDV	 52,82±5,246	 70,05±10,54	 55,09±8,99	 67,83±7,35	
LVESV	 18,91±3,93	 32,79±9,10	 39,31±9,35	 44,57±12,51	
LVIDD	 3,71±0,26	 4,08±0,18	 3,44±0,29	 3,75±0,30	
LVIDS	 2,47±0.182	 3,01±0,29	 3,05±0,52	 3,24±0,40	
LVPWD	 0,83±0,33	 1,02±0,07	 0,95±0,07	 0,85±0,05	
LVPWS	 1,10±0,071	 1,18±0,11	 1,07±0,14	 0,98±0,19	
LVEF	 64,652±2,72	 67,57±3,21	 37,24±8,11&	 29,96±9,266&	
%FAC	 38,80±1,91	 37,43±2,36	 18,83±4,35&	 23,52±7,91	
	 	 	 	 	
	 	 	 	 	
	
3	Days	 5	Days	
LVEDV	 57,13±5,271	 57,14±4,26	 75,610±15,68	 59,930±10,355	
LVESV	 34,97±4,01	 26,48±3,14	 50,66±6,51	 34,82±9,22	
LVIDD	 3,78±0,07	 3,59±0,452	 4,06±0,427	 3,69±0,24	
LVIDS	 2,92±0.15	 2,75±0,31	 3,11±0,33	 2,99±0,36	
LVPWD	 0,86±0,08	 0,74±0,04	 0,67±0,09	 0,88±0,17	
LVPWS	 1,00±0,09	 0,94±0,25	 0,70±0,08	 1,09±0,18	
LVEF	 43,72±2,851&	 54,17±2,80	 34,80±4,24&	 46,51±7,95	
%FAC	 22,51±2,27	 28,90±3,11	 16,60±2,34&	 23,43±4,59&	
	 	 	 	 	
	
7	Days	 1	Month	
LVEDV	 78,95±14,71	 56,88±11,5	 101,88±20,54&	 63,29±6,34	
LVESV	 76,61±10,81&	 27,133±5,793*	 73,72±14,80&	 29,08±3,37*	
LVIDD	 4,31±0,32	 3,63±0,35	 4,38±0,31	 3,80±0,16	
LVIDS	 4,26±0,21&	 2,88±0,53*	 3,85±0,27&	 2,65±0,14*	
LVPWD	 0,62±0,03	 0,70±0,07	 0,71±0,05	 0,80±0,06	
LVPWS	 0,60±0,03	 0,96±0,96	 0,65±0,03	 1,05±0,11*	
LVEF	 24,35±6,52&	 53,16±10,24*	 35,24±3,38&	 59,244±3,949*	
%FAC	 16,69±4,106&	 36,340±3,31*	 15,636±2,06&	 32,783±2,38*	
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3.3 Altered	tissue	remodeling	in	αMHC.IGF-1Ea	after	injury	Three	days	after	myocardial	infarction,	WT	and	αMHC.IGF-1Ea	hearts	displayed	infarcts	of	equal	size,	quantified	by	Masson’s	trichrome	staining	(Figure	3.3A).	However,	by	28	days	 after-MI,	 αMHC.IGF-1Ea	 hearts	 exhibited	 smaller	 scar	 areas	 compared	 to	 WT	(Figure	 3.3B,	 3.3C	 and	 3.3D).	 This	 was	 observed	 as	 a	 reduction	 in	 scar	 length	 but	increased	scar	thickness,	consistent	with	reduced	infarct	expansion.		
	
Figure	 3.3.	 IGF-1Ea	 enhanced	 repair	 after	 myocardial	 infarction.	 Quantification	 of	 the	infarcted	area	at	(A)	3	days	and	(B)	28	days	after	MI.	n=3.	Representative	histological	sections	of	(C)	WT	and	 (D)	αMHC.IGF-1Ea	hearts	 stained	with	Masson’s	 trichrome	28	days	 after	MI.	 Scale	bar,	 1mm.	Mean	 fold	 induction	 ±	 SEM.	 *	 p<0.05.	 Two-tailed	 Student’s	 t-test	was	 performed	 to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.		As	a	molecular	measurement	of	fibrosis,	TGF-β	mRNA	levels	were	significantly	lower	in	αMHC.IGF-1Ea	than	in	WT	mice	after	MI	(Figure	3.4A).	Therefore,	expression	of	genes	involved	 in	 ECM	 turnover	 and	 synthesis	 such	 as	MMP-9,	MMP-2,	 TIMP-2,	 TIMP-1,	 Col	Iα1,	Col	Iα3	and	lysyl	oxidase	(Lox)	at	1,	3,	5,	7	and	28	days	after	MI	were	quantified.	In	WT	hearts,	MMP9	was	up-regulated	3	days	after	MI,	followed	by	MMP2	at	day	7	(Figure	
3.4B	and	 3.4C).	 Interestingly,	neither	MMP9	nor	MMP2	was	significantly	up-regulated	in	αMHC.IGF-1Ea	hearts	at	any	time-point.	Inhibitors	of	matrix	degradation,	TIMP-1	and	
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TIMP-2,	had	similar	expression	in	WT	and	αMHC.IGF-1Ea	hearts	at	all	timepoints	except	for	 day	 7	 when	 TIMP-2	 was	 significantly	 up-regulated	 in	 αMHC.IGF-1Ea	 hearts	compared	to	WT	(Figure	3.4D	and	3.4E).	Several	studies	have	provided	proof	that	ECM	dissolution	 promotes	 LV	 dilation	 (Jugdutt	 et	 al.	 2003	 and	 Vanhoutte	 et	 al.	 2008).	Consequently,	 these	 results	 supports	 the	 idea	 of	 a	 net	 overall	 reduction	 in	 matrix	breakdown	(Figure	3.4A),	may	contribute	to	the	reduced	fibrosis	and	dilation	observed	in	αMHC.IGF-1Ea	hearts	(Bujak	et	al.	2007).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 3.4.	 Changes	 in	 gene	 expression	 of	 extracellular	 matrix	 suggesting	 a	 distinct	
remodeling	 in	 αMHC.IGF-1Ea	 mice	 after	 myocardial	 infarction.	 (A-E)	 mRNA	 relative	expression	was	measured	at	the	infarct	region.	(A)	transforming	growth	factor	beta	(TGF-β),	(B)	matrix	 metalloproteinase	 9	 (MMP-9),	 (C)	 matrix	 metalloproteinase	 2	 (MMP-2),	 (D)	 tissue	inhibitor	of	metalloproteinase	 (TIMP)	2	and	 (E)	TIMP1.	Mean	 fold	 induction	±	SEM.	Solid	 lines	represent	WT	mice.	 	Dashed	lines	represent	αMHC.IGF-1Ea	mice.	n=	4-6	per	group.	*	p<0.05,	**	p<0.005.	Two-tailed	Student’s	t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.	
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Consequently,	 the	 composition	 of	 the	 newly	 synthesised	 matrix	 was	 analysed	 by	measuring	mRNA	expression	of	the	most	abundant	cardiac	ECM	collagens,	Col	 Iα1	and	Col	 Iα3,	 as	well	 as	 the	 collagen	 cross	 linker,	 lox,	which	 increases	matrix	 stiffness.	 Up-regulation	of	both	collagens	was	detected	by	day	3,	peaking	at	day	7	(Figure	3.5A	and	
3.5B).	At	this	timepoint,	WT	hearts	expressed	significantly	more	of	both	collagens	than	did	 αMHC.IGF-1Ea	 hearts.	 Interestingly,	 a	 difference	 in	 the	 ratio	 of	 the	 collagens	was	noted;	αMHC.IGF-1Ea	hearts	expressed	more	Col	Iα3	than	Col	Iα1	(Figure	3.5C).	At	the	peak	of	collagen	up-regulation,	lox	was	also	up-regulated	in	WT	hearts,	yet	this	was	not	observed	 in	 αMHC.IGF-1Ea	 hearts	 (Figure	 3.5D).	 These	 results	 indicate	 that	 IGF-1Ea	overexpression	reduces	ECM	turnover	(Figure	3.4)	after	MI	and	alters	the	composition	of	 the	newly	 formed	matrix	 (Figure	 3.5),	with	preferential	 expression	of	Col	 Iα3	over	Col	Iα1	and	less	crosslinking,	which	likely	alters	the	mechanical	properties	of	the	fibrotic	area	Jugdutt	et	al.	2003	and	Vanhoutte	et	al.	2008).		
	
	
Figure	 3.5.	 Infarct	 region	 mRNA	 levels	 of	 matrix	 genes	 of	 the	 newly	 synthesised	
extracellular	matrix	of	αMHC.IGF-1Ea	mice.	(A-D)	mRNA	relative	expression	was	measured	at	the	infarct	region.	(A)	Collagen	(Col)	Iα1,	(B)	Col	Iα3,	(C)	ColIα1/ColIα3	ratio,	(D)	lysyl	oxidase	in	the	 infarct	 area.	 Mean	 fold	 induction	 ±	 SEM.	 Solid	 lines	 represent	 WT	 mice.	 	 Dashed	 lines	represent	αMHC.IGF-1Ea	mice.	n=	4-6	per	group.	*	p<0.05,	***	p<0.001.	Two-tailed	Student’s	t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.		
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3.4	 Distinct	 chemokine	 and	 cytokine	 production	 in	 αMHC-IGF-1Ea	 hearts	 after	
myocardial	infarct.	Tissue	remodeling	after	injury	is	closely	tied	to	the	inflammatory	process.	Therefore,	the	inflammatory	status	of	the	αMHC.IGF-1Ea	and	WT	hearts	was	compared,	monitoring	the	production	 of	 key	 immune	 genes	 IL-1β,	 IL-10,	 MCP-1	 and	 CCL5.	 Expression	 of	 the	inflammatory	 cytokine	 IL-1β	 was	 rapidly	 induced	 upon	 injury	 in	 WT	 hearts	 (66-fold	over	uninjured)	yet	was	not	increased	as	strongly	in	αMHC.IGF-1Ea	hearts	(19-fold	over	uninjured;	Figure	3.6A).	Similarly	the	strong	up-regulation	of	MCP-1	in	WT	hearts	was	not	 observed	 in	 αMHC.IGF-1Ea	 hearts	 (Figure	 3.6B).	 By	 contrast,	 the	immunosuppressive	cytokine	IL-10	was	rapidly	up-regulated	in	αMHC.IGF-1Ea	hearts,	peaking	1	day	after	MI,	with	3-fold	higher	up-regulation	compared	to	WT	controls.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 3.6.	 Cytokine	 dynamics	 in	 infarcted	 hearts	 of	 αMHC.IGF-1Ea.	 (A-D)	mRNA	 relative	expression	was	measured	at	the	infarct	region.	(A)	Interleukin	(IL)-1β,	(B)	MCP-1,	(C)	IL-10	and	(D)	CCL5	at	several	time-points	after	permanent	ligation.	Solid	lines	represent	WT	mice.		Dashed	lines	 represent	 αMHC.IGF-1Ea	 mice.	 Mean	 fold	 induction	 ±	 SEM	 over	 the	 values	 of	 uninjured	hearts.	 n=	 3	 per	 group.	 *	 p<0.05,	 **	 p<0.005.	 Two-tailed	 Student’s	 t-test	 was	 performed	 to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.		Although	 a	 second	 peak	 of	 IL-10	 mRNA	 was	 detected	 at	 7	 days	 after	 MI,	 it	 was	comparable	 in	 both	 WT	 and	 αMHC.IGF-1Ea	 hearts	 (Figure	 3.6C).	 CCL5,	 which	 is	involved	 in	 the	 recruitment	 of	 Ly6Clow	monocytes	 (Tacke	 et	 al.	 2007	 and	 Carlin	 et	 al.	
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2013)	was	up-regulated	 in	αMHC.IGF-1Ea	hearts,	7	days	after	MI	 (Figure	 3.6D).	These	data	 suggest	 an	 early	 bias	 towards	 a	 less	 inflammatory	 environment	 potentially	modulating	 the	 recruitment	 of	 monocytes	 in	 αMHC.IGF-1Ea	 hearts	 after	 myocardial	infarction.		
3.5 IGF-1Ea	modulates	myeloid	cell	recruitment	after	myocardial	infarction.	To	 document	 accumulation	 of	 the	 main	 innate	 immune	 cell	 populations	 involved	 in	cardiac	 inflammation	 after	 infarct,	 single	 cell	 suspensions	 (Methodology,	 Section	 2.4)	were	 prepared	 from	 whole	 mouse	 hearts	 and	 analyzed	 by	 flow	 cytometry	 using	 the	gating	 strategy	 shown	 in	 Figure	 3.7A-E.	 Macrophages	 were	 identified	 as	 CD45+,	CD11b+,	 CD11c-,	 Ly6G-,	 F4/80+	 (Figure	 3.7F),	 Monocytes,	 CD45+,	 CD11b+,	 CD11c-,	Ly6G-,	 F4/80-,	 Ly6Chigh/Ly6Clow	 (Figure	 3.7G),	 DC,	 Dendritic	 Cells	 as	 CD45+,	 CD11b+,	F4/80-,	CD11c+,	Ly6G-	and	neutrophils,	CD45+,	CD11b+,	F4/80-,	CD11c-,	Ly6G+	(Figure	
3.7H).	 Inflammatory	 macrophages	 as	 CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,F4/80+Ly6Chigh/CD206low	 and	 	 reparative	 macrophages	 as	 CD45+,	 CD11b+,	 CD11c-,	Ly6G-,	F4/80+,	Ly6Clow/CD206high	(Figure	3.7I).		In	WT	 and	 αMHC.IGF-1Ea	 hearts	 the	 total	 number	 of	 infiltrating	 leukocytes	 (CD45+)	gradually	increased	after	MI,	both	reaching	comparable	peak	numbers	at	day	5	(Figure	
3.8A).	However	at	the	earlier	3-day	timepoint,	αMHC.IGF-1Ea	hearts	contained	49%	less	leukocytes	 per	milligram	of	 tissue	 than	WT	hearts.	 In	 examining	 specific	 immune	 cell	populations,	 the	 difference	 is	 partly	 explained	 by	 a	 75%	 reduction	 in	 neutrophils	(CD45+,	CD11b+,	F4/80-,	CD11c-,	Ly6G+;	186	versus	46	cells/mg	of	tissue,	Figure	3.8B)	and	a	67%	reduction	in	monocytes	(CD45+,	CD11b+,	CD11c-,	Ly6G-,	F4/80-;	191	versus	62	cells/mg	of	heart,	Figure	 3.8C),	however	 it	 is	mostly	due	 to	a	 reduced	presence	of	macrophages	(CD45+,	CD11b+,	CD11c-,	Ly6G-,	F4/80+;	58%,	2276	versus	949	cells/mg	of	heart,	Figure	3.8D).			These	data	agree	with	the	reduced	MCP-1	expression	observed	in	αMHC.IGF-1Ea	hearts	(Figure	3.6B),	as	it	is	the	principal	chemokine	involved	in	monocyte	recruitment	(Tacke	et	al.	2007	and	Serbina	et	al.	2006).						
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Figure	3.7.	Gating	strategy	for	infiltrating	immune	cells	after	myocardial	infarct.	Single	cell	suspensions	isolated	from	hearts	of	mice	uninjured	and	after-MI	were	stained	with	anti-CD11b,	-CD45,	 –Ly-6G,	 –Ly-6C,	 -F4/80,	 -CD206	 -CD11c	 and	 analyzed	 by	 FACS.	 (A)	 live	 cells,	 (B	 and	 C)	Singlets,	 (D)	 FSC-SSC	 scatter,	 (E)	 CD45+,	 (F)	 Macrophages,	 CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	F4/80+,	 (G)	 Monocytes,	 CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	 F4/80-,	 Ly6Chigh/Ly6Clow,	 (H)	 DC,	Dendritic	Cells,	CD45+,	CD11b+,	F4/80-,	CD11c+,	Ly6G-	and	neutrophils,	CD45+,	CD11b+,	F4/80-,	CD11c-,	 Ly6G+,	 (I)	 CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,F4/80+Ly6Chigh/CD206low	 (Inflammatory	macrophages)	 and	 CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	 F4/80+,	 Ly6Clow/CD206high	 (Reparative	macrophages)	based	on	FMO	controls	shown	in	Methodology,	Section	2.4.1.	Representative	plots	from	WT	hearts	3	days	after	infarction	are	presented.					
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Figure	 3.8.	 Characterization	 and	 temporal	 dynamics	 of	 immune	 cell	 populations	 in	
αMHC.IGF-1Ea	 hearts	 after	 myocardial	 infarction.	 Quantification	 of	 (A)	 total	 leukocytes	(CD45+),	 (B)	 neutrophils	 (CD45+,	 CD11b+,	 F4/80-,	 CD11c-,	 Ly6G+),	 (C)	 monocytes	 (CD45+,	CD11b+,	 CD11c-,	 Ly6G-,	 F4/80-),	 (D)	 Macrophages	 (CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	 F4/80+).	Data	 is	 presented	 as	 the	 total	 number	 of	 cells	 per	 mg	 of	 heart.	 n=	 4-6	 per	 group.	 Solid	 lines	represent	WT	mice.		Dashed	lines	represent	αMHC.IGF-1Ea	mice.	Mean	values	±	SEM	are	shown.*	p<0.05,	**	p<0.005.	Two-tailed	Student’s	t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI	.			The	 Ly6C	 surface	 marker	 distinguishes	 two	 different	 subsets	 of	 monocytes	(Frangogiannis	 et	 al.	 2014	 and	 Frangogiannis	 et	 al.	 2012).	 Analysis	 of	 the	 Ly6Chigh		(CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	 F4/80-	 and	 Ly6Chigh)	 and	 Ly6Clow	 (CD45+,	 CD11b+,	CD11c-,	 Ly6G-,	 F4/80-	 and	 Ly6Clow)	 populations	 revealed	 that	 the	 reduction	 of	 total	monocyte	 numbers	 at	 day	 3	 was	 attributable	 to	 a	 20%	 decrease	 of	 the	 Ly6Chigh	population	(102	versus	32	cells/mg	of	heart),	whereas	the	Ly6Clow	population	was	not	significantly	different	in	WT	compared	to	αMHC.IGF-1Ea		(Figure	3.9A	and	3.9B).							
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Figure	3.9.	Temporal	dynamics	of	monocytes	subpopulations	in	αMHC.IGF-1Ea	hearts	after	
myocardial	 infarction.	 Monocytes	 (CD45+,	 CD11b+,	 CD11c-,	 Ly6G-,	 F4/80-)	 were	 further	classified	as	(A)	Ly6Chigh	and	(B)	Ly6Clow	monocytes.	Data	is	presented	as	the	total	number	of	cells	per	 mg	 of	 heart.	 n=	 4-6	 per	 group.	 Solid	 lines	 represent	 WT	 mice.	 	 Dashed	 lines	 represent	αMHC.IGF-1Ea	mice.	Mean	values	±	SEM	are	shown.	*	p<0.05,	**	p<0.005.	Two-tailed	Student’s	t-test	was	performed	to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.		To	 differentiate	 between	 inflammatory	 and	 reparative	macrophage	 populations,	 Ly6C	and	 CD206	 markers	 were	 used.	 Both	 Ly6C+	 inflammatory	 (CD45+,	 CD11b+,	 CD11c-,	Ly6G-,	 F4/80+	 and	 Ly6C+/CD206-)	 and	 CD206+	 reparative	 (CD45+,	 CD11b+,	 CD11c-,	Ly6G-,	F4/80+	and	Ly6C-/CD206+)	macrophage	normalized	cell	numbers	were	reduced	by	 71%	 and	 48%	 respectively,	 in	 αMHC.IGF-1Ea	 hearts	 at	 the	 3	 day	 timepoint	 (522	versus	153	and	596	versus	310	cells/mg	of	tissue	of	heart,	respectively;	Figure	3.10A	and	3.10B),	however	this	was	significant	only	for	the	Ly6C+	population.	By	day	7	after	MI,	 macrophage	 dynamics	 changed	 and	 a	 greater	 number	 of	 total	 macrophages	 in	αMHC.IGF-1Ea	hearts	compared	to	WT	was	observed,	which	was	mainly	due	to	a	155%	preferential	increase	in	the	CD206+	population	(575	versus	1468	cells/mg	heart,	Figure	
3.10B).	For	this	work,	only	cells	that	were	either	Ly6C+/CD206-	or	Ly6C-/CD206+	were	analyzed,	 although	 a	 double	 positive	 cell	 population	 was	 found	 (i.e.	 CD206+,	 Ly6C+).	However	no	changes	were	observed	over	time	between	WT	and	αMHC.IGF-1Ea	for	the	double	 positive	 population	 (Figure	 3.10C).	 Dendritic	 cells	 (CD45+,	 CD11b+,	 F4/80-,	CD11c+,	Ly6G-)	were	increased	by	48%	in	αMHC.IGF-1Ea	hearts	compare	to	WT	5	days	after	MI	(168	versus	248	cells/mg	heart;	Figure	3.10D).							
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Figure	 3.10.	Temporal	 dynamics	 of	 macrophages	 subpopulations	 and	 dendritic	 cells	 in	
αMHC.IGF-1Ea	 hearts	 after	 myocardial	 infarction.	 Macrophages	 (CD45+,	 CD11b+,	 CD11c-,	Ly6G-,	 F4/80+)	 were	 characterized	 on	 the	 basis	 of	 Ly6C	 and	 CD206	 expression	 as	 (A)	Ly6Chigh/CD206low	 (Inflammatory	 macrophages)	 and	 (B)	 Ly6Clow/CD206high	 (Reparative	macrophages).	(C)	Double	CD206+/Ly6C+	population.	(D)	Dendritic	cells	were	defined	as	CD45+,	CD11b+,	F4/80-,	CD11c+,	Ly6G-.	Data	is	presented	as	the	total	number	of	cells	per	mg	of	heart.	n=	4-6	per	group.	Solid	lines	represent	WT	mice.		Dashed	lines	represent	αMHC.IGF-1Ea	mice.	Mean	values	 ±	 SEM	 are	 shown.	 *	 p<0.05,	 **	 p<0.005.	 Two-tailed	 Student’s	 t-test	 was	 performed	 to	compare	WT	vs	αMHC.IGF-1Ea	at	selected	timepoints	after	MI.			In	 summary,	 cardiac-restricted	 expression	 of	 an	 IGF-1Ea	 transgene	 limited	 the	 early	accumulation	of	innate	immune	cells	at	day	3	after	MI,	with	a	bias	towards	the	reduction	of	inflammatory	myeloid	populations	in	favour	of	reparative	populations.	This	reduction	paralleled	with	the	lower	expression	of	myeloid	chemokines	and	the	less	inflammatory	milieu	observed	in	the	αMHC.IGF-1Ea	hearts.	
	
3.6 Discussion	Previous	work	in	our	lab	showed	that	local	expression	of	IGF-1Ea	promoted	functional	restoration	 after	MI,	 and	observed	 reduced	 infarct	 expansion,	 thinning	 and	dilation	of	
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the	left	ventricular	wall	(Santini	et	al.	2007).		The	work	in	this	chapter	indicates	that	the	transcriptional	 modulation	 of	 key	 ECM	 remodeling	 genes,	 in	 the	 IGF-1Ea	 hearts,	 is	associated	with	a	tempering	of	the	inflammatory	myeloid	cell	response.			Increased	 MMP	 expression	 after	 injury	 has	 been	 implicated	 in	 contributing	 to	 scar	destabilisation,	 as	 transgenic	 animal	model	 knockouts	 of	 either	MMP2	 or	MMP9	have	been	 shown	 to	 attenuate	 LV	 dilation,	 rupture	 and	 impairment	 of	 cardiac	 function	(Hayashidani	 et	 al.	 2003	 and	 Ducharme	 et	 al.	 2000).	While	 MMP2	 and	MMP9	mRNA	expression	 levels	 were	 up-regulated	 in	 injured	 WT	 hearts,	 this	 increase	 was	 not	observed	 in	 αMHC.IGF-1Ea	 hearts.	 In	 line	 with	 reduced	 matrix	 breakdown,	 mRNA	expression	 of	 the	MMP	 inhibitor,	 TIMP2,	was	 significantly	 increased	 in	αMHC.IGF-1Ea	hearts	at	day	7	after	myocardial	 infarction.	Thus	IGF-1Ea	may	prevent	adverse	cardiac	remodeling,	in	part,	by	modulating	transcription	of	MMPs/TIMPs.			The	production	of	new	matrix	components	was	also	altered	by	the	presence	of	the	IGF-1Ea	transgene	with	an	overall	reduction	in	collagen	synthesis,	confirmed	in	histological	stains,	and	a	bias	towards	expression	of	Col	Iα3	over	Col	Iα1.	In	MI	patients,	turnover	of	cardiac	 extracellular	matrix	 can	 be	 assessed	 by	 using	 circulating	 collagen	 peptides	 as	blood	biomarkers	and	high	 type	 I	 collagen	 is	associated	with	adverse	clinical	outcome	(Weber	 et	 al.	 1997	 and	 Iraqi	 et	 al.	 2009).	 A	 prospective	 multicentre	 study	 further	showed	 that	 especially	 a	 low	 type	 III/type	 I	 collagen	 ratio	 at	 1	 month	 after	 MI	 is	predictive	 of	 detrimental	 left	 ventricular	 remodeling	 as	well	 as	 cardiovascular	 deaths	and	hospitalizations	for	heart	 failure	(Eschalier	et	al.	2013).	Changes	in	collagen	ratios	are	 known	 to	 affect	 the	 strength	 and	 tensile	 properties	 of	 the	 ECM.	 It	 would	 be	interesting	 to	 determine	whether	 these	 properties	 are	modified	 in	 the	 αMHC.IGF-1Ea	hearts.			Additionally,	 IGF-1Ea	 could	 promote	 the	 changes	 in	 collagen	 deposition	 by	 directly	acting	 on	 fibroblasts	 as	 it	 promotes	 both	 their	 proliferation	 and	 activation	 to	myofibroblasts	(Simmons	et	al.	2002	and	Hung	et	al.	2013).	Alternatively,	IGF-1Ea	may	influence	 accumulation	 and	 activation	 of	 immune	 cells	 present	 at	 the	 infarct	which	 in	turn	regulate	myofibroblast	activation.	 Indeed,	this	 fact	was	observed	by	a	modulation	of	 the	 inflammatory	 process	 in	 αMHC.IGF-1Ea	 hearts,	 with	 less	 monocyte	 (Ly6Chigh)	infiltration	 into	 the	 injured	 myocardium.	 This	 effect	 is	 associated	 with	 reduced	expression	 of	 the	monocyte	 chemo-attractant	MCP-1,	 although	 no	 significant	 changes	were	observed	in	the	Ly6Clow	monocyte	population	 in	 infarcted	hearts,	possibly	due	to	
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CCL5	up-regulation.	It	is	interesting	that	while	complete	depletion	of	monocytes	at	any	stage	 of	 repair	 leads	 to	 poor	 recovery	 (Nahrendorf	 et	 al.	 2007),	 a	 more	 subtle	modulation	of	the	monocyte	population	in	the	αMHC.IGF-1Ea	hearts	 is	associated	with	improved	 heart	 function.	 Studies	 abrogating	 monocyte	 recruitment	 using	 a	 selective	CCR2	inhibitor	have	resulted	in	reduced	IL-1β,	IL-6,	MCP-1	and	TNFα	levels	(Chen	et	al.	2008).	 IGF-1Ea	 influences	 macrophage	 polarization	 in	 skeletal	 muscle	 (Tonkin	 et	 al.	2015)	 and	 we	 similarly	 found	 reduced	 Ly6Chigh	 monocyte	 and	 Ly6C+	 macrophage	normalized	cell	numbers	while	CD206+	macrophage	numbers	were	increased	by	day	7,	suggesting	that	IGF-1Ea	promoted	a	quick	progression	to	the	reparative	phase	of	repair	by	 modulating	 macrophage	 phenotype.	 In	 the	 αMHC.IGF-1Ea	 hearts,	 we	 observed	 a	decrease	 in	 MCP-1,	 which	 is	 the	 chemokine	 for	 CCR2,	 recently	 shown	 to	 distinguish	infiltrating	 monocytes	 from	 the	 resident	 macrophage	 (cTM)	 population	 which	 has	 a	different	embryological	origin	and	expresses	CD206	(Tacke	et	al.	2007,	Heidt	et	al.	2014,	Epelman	et	 al.	 2014	and	Pinto	et	 al.	 2012).	We	noted	a	 reduction	 in	 the	 IL-1	β	mRNA	levels	24	hours	after	MI.	This	reduction	occurs	before	the	major	inflammatory	infiltrate.	Although,	 many	 cells	 can	 produce	 IL-1β,	 we	 hypothesised	 that	 the	 activation	 of	 cTM	towards	 a	 more	 anti-inflammatory	 environment	 may	 lead	 to	 the	 reduction	 in	 the	inflammatory	 cytokine	 IL-1β.	 It	 is	 therefore	 possible	 that	 in	 our	 αMHC.IGF-1Ea	transgenic	 mouse	 model,	 IGF-1Ea	 reduces	 the	 infiltration	 of	 inflammatory	 Ly6Chigh	monocytes	by	preventing	up-regulation	of	MCP-1	while	 still	 allowing	 for	 expansion	of	the	resident	macrophage	population.			In	summary,	 the	αMHC.IGF-1Ea	mouse	model	can	modulate	several	associated	aspects	of	 the	 cellular	 repair	 process	 after	 MI,	 including	 immune	 cell	 recruitment,	 cytokine	expression,	 and	matrix	 turnover.	 All	 of	 these	 changes	 occur	mainly	within	 the	 first	 7	days	after	myocardial	infarction,	at	which	time	a	functional	improvement	can	already	be	measured	 in	αMHC.IGF-1Ea	hearts	 compared	 to	WT	controls.	These	data	provide	new	insights	into	the	mechanism	of	IGF-1Ea	and	suggest	that	early	immunodulation	is	key	to	successful	cardiac	repair	after	injury.			3.6.1 Limitation	of	the	project	The	 main	 limitation	 of	 this	 study	 is	 the	 fact	 that	 the	 heart-specific	 transgene	 is	expressed	from	the	time	of	embryonic	cardiac	myogenesis	onward,	and	therefore,	does	not	 simulate	 delivery	 to	 humans	 in	 a	 clinically	 relevant	 setting.	 	 Additionally,	 the	beneficial	 effects	 observed	 in	 the	 αMHC.IGF-1Ea	 hearts,	 could	 be	 explained	 by	 either	preconditioning	effects	or	by	enhancing	reparative	processes	after	cardiac	injury.	In	this	
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thesis,	 Chapter	 5	 further	 addresses	 these	 questions	 as	 supplemental	 IGF-1Ea	 is	administered	 5	 hours	 after	 injury,	 indicating	 that	 IGF-1Ea	 does	 not	 have	 a	preconditioning	effect.		3.6.2	Outcomes	The	study	of	 the	 immune	cell	dynamics	and	 the	positive	remodeling	mediated	by	 IGF-1Ea	in	response	to	myocardial	infarct	indicates	that		IGF-1Ea	plays	a	more	active	role	on	modulating	the	spatial	containment	of	inflammatory	cascades	leading	to	effective	repair.	IGF-1Ea,	 by	 reducing	 infarct	 expansion,	 limits	 the	 extension	 of	 the	 inflammatory	response	into	the	viable	myocardium,	therefore,	limiting	fibrosis	to	the	infarcted	region.	In	 parallel,	 IGF-1Ea	 prevents	 prolonged	 or	 excessive	 induction	 of	 pro-inflammatory	signalling	reducing	the	risk	of	an	accentuated	injury	hence	adverse	remodeling.			Furthermore,	 this	 work	 suggests	 that	 complete	 cardiac	 regeneration	 may	 not	 be	necessary,	 but	 a	 fine	 modulation	 of	 the	 inflammatory	 response	 may	 be	 essential	 to	induce	an	effective	repair	and	a	reduction	of	the	fibrotic	tissue.	In	light	of	these	results,	supplemental	 IGF-1Ea	 gene	 therapy,	 studied	 in	 Chapter	 4	 and	 5,	 is	 assessed	 as	 it	contributes	 to	 local	 long-term	 beneficial	 remodeling	 of	 the	 heart	 in	 response	 to	myocardial	infarct.							
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Chapter	4	 –	Delivery	 of	 therapeutic	 growth	 factors	 to	 the	 injured	heart	 by	bone	
marrow-derived	macrophages		
	
4.1	Introduction	As	 described	 in	 the	 Introduction,	 Section	 1.3.2,	 monocytes	 and	 macrophages	 are	principally	 recognised	 for	 their	 housekeeping	 roles,	 modulating	 inflammation,	 and	comprise	the	major	infiltrating	cell	population	following	tissue	injury	(Nahrendorf	et	al.	2013,	 Frantz	 et	 al.	 2014	 and	 Nahrendorf	 et	 al.	 2010).	 The	 intrinsic	 injury-homing	capacity	 of	 macrophages	 makes	 them	 ideal	 vectors	 for	 the	 delivery	 of	 salutary	 and	immunomodulatory	payloads	to	the	site	of	 injury,	with	the	potential	to	augment	tissue	repair	 and	 regeneration	 (Burke	 et	 al.	 2002).	Moreover,	 using	 the	 body’s	 own	 homing	cells	 to	deliver	 regenerative	gene	products	 to	 the	site	of	 injury	might	 lead	 to	new	and	powerful	cell	therapies	for	heart	diseases	and	other	chronic	diseases	(Tong	et	al.	2014).		The	studies	performed	in	this	chapter	exploit	the	homing	properties	of	macrophages	to	develop	 tools	 for	 the	 delivery	 of	 therapeutic	 growth	 factors	 to	 an	 injury	 site.	 This	chapter	 assesses	whether	 cultured	macrophages	 can	 home	 to	 the	 injured	muscle	 and	investigates	 their	 potential	 beneficial	 effects	 on	 tissue	 repair	 by	 (1)	 the	 generation	of	homing-competent	 macrophage	 cells	 from	 the	 bone	 marrow,	 and	 (2)	 the	characterisation	of	homed	transplanted	macrophages	following	injury.	The	chapter	also	explores	 whether	 macrophages	 can	 deliver	 an	 IGF-1Ea	 therapeutic	 payload	 by	 (1)	stimulating	endogenous	IGF-1Ea,	or	(2)	by	‘priming’	macrophages	with	cytokines.		The	 proposed	 work	 supports	 the	 development	 of	 novel	 tools	 to	 deliver	 therapeutic	factors	 to	 injured	 tissue,	 which	 is	 particularly	 useful	 for	 treatment	 of	 injured	 hearts	since	 no	 surgical	 intervention	 will	 be	 necessary,	 following	 cardiac	 injury,	 to	 deliver	beneficial	 factors.	While	 proof-of-principle	 for	 this	 approach	will	 be	 demonstrated	 in	injured	 skeletal	 muscle,	 this	 approach	 can	 be	 applied	 to	 a	 range	 of	 disease	 contexts	where	inflammation	plays	a	prominent	role.	These	include	rheumatoid	arthritis,	chronic	inflammation	and	stroke.			
4.2	Rationale	behind	the	skeletal	muscle	injury	model		Although	 extensive	 experience	 in	 myocardial	 infarction	 (MI)	 injury	 models	 were	acquired,	 the	 experiments	 to	 characterise	 the	 homing	 competency	 of	 cultured	macrophages	 were	 conducted	 using	 the	 Tibialis	 Anterior	 (TA)	 injury	 model	 for	 the	following	 reasons,	 (i)	 the	 inflammatory	 and	 leukocyte	 infiltration	 kinetics	 are	 almost	
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identical	 between	 the	 injured	 TA	 and	 MI	 injury	 models	 (Arnold	 et	 al.	 2007	 and	Nahrendorf	et	al.	2007).	The	TA	injury	model	leads	to	a	local	necrotic	lesion	resulting	in	a	 robust	 inflammatory	 response,	which	 is	 a	 similar	 response	 as	myocardial	 infarction	(Figure	4.1);	(ii)	using	the	 in	vivo	GFP	or	CFSE	labelling	reporter	approach,	homing	to	the	 injured	 TA	 and	 uninjured	 TA	 can	 be	 assessed	 simultaneously	 to	 determine	 the	homing	 specificity	 to	 injury;	 (iii)	TA	 injuries	do	not	 result	 in	mouse	 lethality,	whereas	lethality	 following	 cardiac	 injury	 can	 range	 between	 20-40%	 after	 surgery	 (Gao	 et	 al.	2010);	 (iv)	 TA	 injuries	 can	 be	 conducted	 more	 rapidly	 than	 MI,	 approximately	 12	injuries/hour	 vs	 2	 injuries/hour,	 respectively	 (Arnold	 et	 al.	 2007	 and	 Tidball	 et	 al.	2004).		
	
Figure	 4.1.	 Representative	 haematoxylin	 and	 eosin	 staining	 of	 TA	 injured	 muscle	 and	
cardiac	injured	muscle	two	days	after	injury.	(A)	Uninjured	TA	muscle,	(B)	injured	TA	muscle,	(C)	 uninjured	 myocardium	 and	 (D)	 injured	 myocardium.	 TA	 injury	 is	 characterise	 by	 a	 large	accumulation	of	inflammatory	cells	shown	here	in	blue/purple.	Scale	bar:	250	um.		
4.3	IGF-1Ea	levels	in	macrophages	and	monocytes	To	investigate	the	therapeutic	potential	of	the	immune-mediated	cell-based	therapy,	the	mRNA	levels	of	IGF-1Ea	and	IGF-1	receptor	(IGF-1R)	were	assessed	in	various	cell	types.	BMdMs	(Methodology,	Section	2.5.3,	2.5.4	and	2.5.5),	were	the	cell	type	that	expressed	the	 highest	 levels	 of	 IGF-1Ea	when	 compared	with	 either	 blood	 or	 spleen	monocytes.	IFN-γ/LPS-polarization	of	BMdMs,	which	 induces	an	M1-like	 inflammatory	phenotype,	drastically	 down-regulated	 the	 expression	 of	 IGF-1Ea	 whereas	 IL-4-polarization	 of	BMdM,	which	promotes	differentiation	 into	M2-like	reparative	phenotype,	 induced	the	
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expression	of	IGF-1Ea	by	1.5-fold	when	compared	with	control	BMdM	and	15-fold	when	compared	 to	 blood	monocytes	 (Figure	 4.2A).	 Interestingly,	 the	 expression	 of	 IGF-1R	inversely	 correlated	 with	 IGF-1Ea	 expression	 after	 polarization	 with	 either	 stimulus,	whereas	blood	monocytes	expressed	higher	levels	of	IGF-1R	(Figure	4.2B).		
	
Figure	4.2.	IGF-1Ea	and	IGF-1R	mRNA	levels	in	blood	monocytes,	spleen	monocytes,	BMdM,	
LPS/IFNγ-polarized	 BMdM	 and	 IL-4-polarized	 BMdM.	 (A)	mRNA	 levels	 of	 IGF-1Ea	 and	 (B)	mRNA	levels	of	IGF-1	receptor	in	monocytes	and	macrophages.	Mean	values	±	SEM	are	shown.	*	p<0.001.	One-way	ANOVA	plus	Dunnett’s	multiple	comparison	test.	n=3	each	group.		
	The	 results	 indicated	 that	M2-polarized	BMdM	were	 the	highest	producers	of	 IGF-1Ea	(in	mRNA	levels)	in	this	context,	therefore	supporting	the	hypothesis	that	either	BMdM	or	M2-polarised	macrophages	may	be	considered	as	vectors	for	the	delivery	of	salutary	payloads.	 Furthermore,	 IGF-1Ea	 expression	 appears	 to	 be	modulated	 according	 to	 the	inflammatory	 environment	 that	 the	 cells	 encounter.	 Further	 in	 vivo	 studies	 in	 this	chapter,	Section	4.6,	will	address	the	engraftment	of	these	cells	after	injury	as	well	as	the	beneficial	effect	of	IGF-1Ea	delivery	on	tissue	repair.		
4.4	Bone	marrow-derived	macrophage	characterisation	for	transplantation		Before	proceeding	with	the	in	vivo	experiment	and	due	to	the	heterogeneity	of	the	bone	marrow	population,	the	purity	of	the	in	vitro	generated	macrophages	was	evaluated	by	flow	 cytometry	 phenotypic	 analysis	 of	 cell-specific	 surface	 markers	 6	 days	 after	differentiation.	Analysis	confirmed	that,	after	differentiation,	96.5%	of	in	vitro	generated	macrophages	 were	 positive	 for	 the	 macrophages	 markers	 CD11b	 and	 F4/80	 (Figure	
4.3).				
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This	data	indicates	that	generating	BMdMs	from	the	bone	marrow	results	in	a	basically	pure	population	that	can	be	directly	transfected	without	any	further	purification	step.				
	
Figure	 4.3.	 In	 vitro	 bone	 marrow-derived	 macrophages	 characterization.	 (A)	 10x	representative	Ph2	bright	field	image	of	BMdM,	(B)	flow	cytometry	plot	of	BMdM,	F4/80-CD11b	positive	cells	after	7	days	in	vitro	differentiation.		~100000	events.	
	
4.5	Bone	marrow-derived	macrophage	immunotherapy		To	 investigate	 the	 therapeutic	 relevant	 effect	 of	 BMdM-mediated	 IGF-1Ea	 delivery,	endogenous	 levels	 of	 IGF-1Ea	 were	 augmented	 by	 transfecting	 BMdMs	 with	 the	pIRES.eGFP	vector	(Methodology,	Section	2.6).	In	the	pIRES.GFP,	the	IGF-1Ea	expression	is	driven	by	the	strong	CMV	promoter.	The	plasmid	also	contains	an	internal	ribosome	entry	site	(IRES)	followed	by	the	GFP	reporter	gene.			BMdM	 were	 transfected	 with	 the	 pIRES.eGFP	 plasmid	 to	 investigate	 whether	 ex	 vivo	manipulated	 macrophages	 can	 deliver	 reparative	 factors	 to	 improve	 wound	 healing.	Because	 transfection	 of	 non-dividing	 cells,	 by	 which	 exogenous	 DNA	 is	 incorporated	inside	of	cells,	 is	considered	a	difficult	 technique	and	 is	associated	with	significant	cell	death,	 the	 following	 experiment	 aimed	 to	 optimise	 the	 transfection	 process,	 thus	improving	cell	viability	and	increasing	IGF-1Ea	expression.				BMdMs	were	 transfected	 at	 day	 6	 of	 differentiation	with	 increasing	 concentrations	 of	the	IGF-1Ea.GFP	vector,	up	to	a	maximum	of	5	μg.	Twenty-four	hours	after	transfection,	the	 transfection	 efficiency	 was	 validated	 by	 fluorescence	 microscopy	 analysis	 of	 GFP	fluorescence	as	shown	in	Figures	4.4A	and	4.4B.	The	analysis	demonstrated	a	variable	intensity	 of	 GFP	 fluorescence	 in	 the	 transfected	 BMdM.	 This	 is	 probably	 due	 to	 the	differing	number	of	vector	copies	that	can	be	transfected	into	each	cell.	The	transfection	
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efficiency	 was	 also	 validated	 by	 flow	 cytometry	 comparing	 the	 GFP	 expression	 of	untransfected	BMdM	(Figure	4.4C)	and	transfected	BMdM	with	the	pIRES.eGFP	plasmid	(Figure	 4.4D).	 Finally,	 cell	 viability	 following	 transfection	 was	 assessed	 by	 Sytox	staining.	Overall,	the	transfection	process	itself	reduced	viability	to	approximately	60%,	which	 remained	 the	 same	 at	 all	 plasmid	 concentrations	 (Figure	 4.4E).	 From	 the	 four	DNA	concentrations	tested,	a	concentration	of	5	μg	of	plasmid	was	found	to	be	optimal,	balancing	 viability	 and	 IGF-1Ea	 expression	 (Figure	 4.4F).	 In	 absolute	 numbers,	 only	4.8x105	 out	 of	 1x106	BMdM	 transfected	were	 found	 to	 be	GFP	positive	(Total	 BMdM	x	cell	 viability	 x	 %GFP	 =	 1x106	 x	 0.6	 x	 0.8).	 Although	 M1-	 and	 M2-like	 macrophage	transfection	efficiencies	were	similar	to	the	BMdM	efficiencies	(not	shown),	all	cell	types	showed	a	transfection	efficiency	very	variable	ranging	from	45%	to	80%.			IGF-1Ea	 mRNA	 levels	 were	 also	 quantified	 by	 qPCR.	 Transfection	 with	 the	 highest	concentration	of	the	vector	(5	μg),	induced	up	to	a	100-fold	increase	in	the	levels	of	IGF-1Ea	 when	 compared	 with	 control	 non-transfected	 macrophages	 and	 macrophages	transfected	with	 the	pGFP	vector	provided	by	 the	manufacturer	of	 the	 transfection	kit	(Figure	4.4E).																				
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Figure	 4.4.	 Assessment	 of	 BMdM	 transfection	 efficiency	 through	 various	 techniques	 24	
hours	 after	 transfection.	 Overlay	 of	 bright	 field	 and	 fluorescence	 field	 of	 pIRES2.eGFP	transfected	 macrophages	 at	 (A)	 100x	 and	 (B)	 40x	 magnification.	 Scale	 bar,	 50	 μm.	 Flow	cytometry	 plot	 depicting	 BMdM-GFP	 positive	 populations,	 (C)	 untransfected	 (D)	 with	 5	 μg	 of	pIRES.eGFP	vector.	(E)	GFP	fluorescence	(left	Y	axis)	versus	IGF-1Ea	mRNA	levels	(left	Y	axis)	in	pIRES2.eGFP	 transfected	 BMdM,	 24h	 after	 transfection.	 (F)	 Percentage	 viable	 cells	 by	 Sytox	negative	staining	(left	Y	axis)	and	GFP	fluorescence	(right	Y	axis).	n=12	wells	each	group.	Mean	values	±	SEM	are	shown.	
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To	assess	IGF-1	protein	production,	immunoblot	analysis	was	performed	as	described	in	Methodology,	Section	2.3.	BMdMs	transfected	with	5	μg	resulted	in	a	100-fold	increase	in	 IGF-1Ea	 expression	 (Figure	 4.5A).	 This	was	mirrored	 by	 an	 increase	 in	 detectable	IGF-1	protein	levels	analysed	by	western	blotting	(Figure	4.5B).	Interestingly,	the	IGF-1Ea	propeptide	 produced	by	macrophages	was	 initially	 secreted	 to	 the	medium,	 thus,	the	 mature	 form	 was	 not	 found	 in	 transfected	 BMdMs	 (Figure	 4.5B).	 An	 IGF-1	immunoblot	of	conditioned	medium	from	pIRES.eGFP	transfected	BMdM	showed	higher	levels	of	IGF-1Ea	than	the	IGF-1	mature	form	during	the	first	8-24	hours,	however,	at	72	hours	post-transfection,	 IGF-1Ea	could	not	be	detected	by	western	blot	and	only	IGF-1	mature	 form	was	 found	(Figure	4.5C).	A	possible	explanation	 for	 this	result	 is	 that,	at	this	timepoint,	the	lifespan	of	transfected	BMdMs	is	limiting	IGF-1Ea	synthesis.	The	IGF-1Ea	 produced	was	 eventually	 processed	 and	 cleaved,	 consequently,	 the	mature	 IGF-1	was	the	only	isoform	observed	72	hours	after	transfection.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.5	 IGF-1Ea	 expression	 levels	 in	 transfected	 BMdM.	 (A)	 IGF-1Ea	 mRNA	 levels	 in	BMdM	 transfected	 with	 5	 μg	 of	 pIRES2.eGFP.	 (B)	 Western	 blot	 of	 IGF-1	 and	 IGF-1Ea	 protein	levels	in	BMdM	transfected	with	5	μg	of	pIRES2.eGFP.	Additional	bands	likely	reflect	differential	glycosylation	 states,	 since	 the	 rodent	 Ea-peptide	 contains	 two	N-linked	 glycosylation	 sites.	 (C)	IGF-1	and	IGF-1Ea	protein	levels	present	in	the	conditioned	medium	of	transfected	macrophages	at	8,	24	and	72	hours	post-transfection.	1x106	macrophages	were	transfected.	Mean	values	±	SEM	are	shown.	*	p<0.001	1-way	ANOVA	plus	Dunnett’s	multiple	comparison	test.	n=3	each	group.		
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4.5.1	Effect	of	IGF-1Ea	on	transfected	BMdM	in	vitro	Previous	 results	 from	 our	 group	 have	 shown	 that	 IGF-1Ea	 overexpression	 in	 skeletal	muscle	and	heart	dampens	pro-inflammatory	activity	and	promotes	anti-inflammatory	responses	(Pelosi	et	al.	2007	and	Santini	et	al.	2007)	Thus,	the	expression	levels	of	the	main	 cytokines	 modulated	 by	 IGF-1Ea,	 TNF-α	 and	 IL-10,	 were	 analysed.	 After	transfection,	 the	 inflammatory	cytokine	TNF-α	was	up-regulated	 in	both	 the	pGFP	and	the	 pIRES2.eGFP	 group.	 Interestingly,	 the	 levels	 of	 TNF-α	 in	 BMdMs	 transfected	with	IGF-1Ea.GFP	were	markedly	 lower	 (Figure	 4.6A).	 Conversely,	 levels	of	 the	 IL-10	anti-inflammatory	 cytokine	 were	 increased	 150-fold	 when	 compared	 with	 either	 non-transfected	BMdMs	or	 the	pGFP	group	(Figure	 4.6B).	Although	 these	results	allude	 to	an	 apparent	 direct	 autocrine	 and	 paracrine	 effect	 on	 BMdMs	 modulated	 by	 IGF-1Ea,	further	 in	 vivo	 analyses	 are	 required	 to	 demonstrate	 specific	 modulation	 of	 the	inflammatory	process	by	IGF-1Ea	or	by	the	in	vitro	generated	BMdMs.											
	
Figure	4.6.	Effects	of	 IGF-1Ea	overexpression	 in	vitro	BMdMs.	BMdM	cultured	for	24	hours.	mRNA	relative	levels	of	(A)	TNF-α	and	(B)	IL-10	genes	analysed	by	qPCR.	Mean	values	±	SEM	are	shown.	*	p<0.001	1-way	ANOVA	plus	Dunnett’s	multiple	comparison	test.	n=3	each	group.		
4.6	 Homing	 of	 transplanted	 bone	 marrow-derived	 macrophages	 following	 TA	
injury	and	the	effect	of	‘priming’	macrophages	with	cytokines	In	parallel	to	the	work	carried	out	in	Section	4.5,	the	Tibialis	Anterior	muscle	(TA)	injury	model	(Methodology,	Section	2.7.3	and	2.12)	was	performed	to	evaluate	BMdM	homing	competency.	The	TA	model	involves	the	injection	of	the	snake	venom	cardiotoxin	(CTX)	into	 the	 right	 tibialis	 anterior	 muscle	 (Hirata	 et	 al.	 2003).	 The	 homing	 capacities	 of	BMdMs	 were	 determined,	 before	 and	 after	 priming	 the	 cells	 with	 LPS/IFN-γ	 or	 IL-4	(Methodology,	 Section	 2.5.4).	 As	 shown	 in	 Section	 4.3,	M2-like	macrophages	were	 the	main	producers	of	IGF-1Ea	from	the	selected	populations.	In	order	to	determine	optimal	
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homing	 parameters,	 infusion	 of	 both	 M1-	 and	 M2-like	 BMdMs	 transfected	 with	pIRES2.eGFP	vector	as	well	as	BMdM	cells	at	7	days	of	differentiation	(Figure	4.7A),	24	hours	 post-TA	 injury	 (Figure	 4.7B)	 were	 performed.	 	 The	 infusion	 time	 was	 chosen	based	 on	 leukocyte	 infiltration	 kinetics	 during	 the	 acute	 phases	 of	 muscle	 injury	(Nahrendorf	 et	 al.	 2013	 and	 Tonkin	 et	 al.	 2015).	 As	 described	 in	 detail	 in	 the	Introduction,	Section	1.3.2,	after	MI,	inflammatory	macrophages	(M1-like	macrophages)	infiltrate	 into	 the	 injury	 site	 in	 great	 numbers	 between	 days	 1-3	 post-injury,	 while	reparative	macrophages	 (M2-like	macrophages)	macrophages	 predominate	 from	 days	3-7	post-injury.	Therefore,	the	proposed	transplantation	window	should	permit	entry	of	both	M1	and	M2	polarised	macrophages.			
	
Figure	 4.7.	 Experimental	 design	 for	 in	 vivo	 IGF-1Ea	 BMdM	 immunotherapy.	 (A)	 Bone	marrow-derived	macrophages	differentiation	process.	Red	 sphere	 indicates	 the	 cells	 that	were	selected	to	assess	BMdM	homing	competency.	(B)	TA	injury	timecourse.	Selected	BMdMs	either	IGF-1Ea.GFP	 M1-like	 BMdMs,	 IGF-1Ea.GFP	 M2-like	 BMdMs	 and	 CFSE-labelled	 BMdMs,	 were	infused	 intravenously	via	 vein	 tail	 24	hours	 after	TA	 injury.	At	 either	24	hours	or	6	days	 after	infusion,	macrophages	from	the	injured	TA	and	uninjured	TA	were	isolated	and	GFP+	cells	were	analysed	 by	 flow	 cytometry	 for	 the	 expression	 of	 cell	 surface	markers	markers,	 CD45,	 CD11b,	F4/80,	Ly6C,	CD206.	
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4.6.1	Homing	of	IGF-1Ea.GFP	M1-	and	M2-like	macrophages	In	 order	 to	 assess	 BMdMs	 homing	 competencies,	 2x106	 of	 BMdM	 cells	 were	 infused	intravenously	 (i.v.)	 (Methodology,	 Section	 2.5	 and	 2.12),	 24	 hours	 after	 TA	 injury	(Figure	 4.7A	 and	 4.7B).	 Prior	 infusion,	 M1-and	 M2-like	 BMdMs	 were	 transfected	 as	described	in	Methodology,	Section	2.6,	transfected	BMdMs	are	named	IGF-1Ea.GFP	M1-and	M2-like	macrophage,	respectively.		Twenty-four	 hours	 after	 infusion,	 TA	 from	 both	 legs,	 injured	 and	 uninjured,	 were	obtained	and	analysed	by	flow	cytometry	for	GFP	fluorescence	(Chapter	2,	Section	2.12.		In	order	to	assess	BMdM	homing,	several	organs	such	heart,	kidney	and	lung	were	also	harvested	 as	 controls.	Macrophages	were	 analysed	 according	 to	 the	 expression	 of	 the	cell	surface	markers	CD45,	CD11b	and	F4/80	(Figure	4.8A,	Figure	4.8B	and	Table	4.1).	GFP	fluorescence	can	be	detected	in	the	488	nm	blue	 laser	using	a	BD	FACS	ARIAI	cell	sorter.	 After	 infusion,	 neither	 IGF-1Ea.GFP	 M1-	 nor	 M2-like	 BMdM	 showed	 any	engraftment	 into	 the	 injured	muscle	 (Figure	 4.8C	 and	Figure	 4.8D,	 respectively	 and	
Table	 4.1).	 Surprisingly,	 IGF-1Ea.GFP	M1-like	macrophages	preferentially	migrated	 to	the	kidney	(Figure	4.8E	and	Table	4.1),	but	not	the	lung	(Figure	4.8F	and	Table	4.1).	Conversely,	 IGF-1Ea.GFP	 M2-like	 macrophages	 preferentially	 migrated	 to	 the	 lung	(Figure	4.8G	and	Table	4.1),	but	not	the	kidney	(Figure	4.8H	and	Table	4.1).			 								
Table	 4.1.	 Percentage	 of	 macrophages	 CD45,	 CD11b,	 F4/80	 in	 several	 organs	 24	 hours	
after	 i.v	 infusion.	 Total	 macrophages	 were	 calculated	 from	 the	 total	 of	 alive	 events	 in	 the	selected	tissue	(Figure	4.8A).	IGF-1Ea.GFP	M1-	or	M2-GFP	macrophages	were	calculated	from	the	 total	 macrophage	 populations	 (Figure	 4.8B).	 Macrophage	 populations	 are	 depicted	 as	CD45+,	CD11b+,	F4/80+.	n=4	mice	per	group.	
	Considering	 the	 probability	 of	 detecting	 GFP+	 cells	 using	 this	 delivery	 method,	 the	number	of	GFP-positive	cells	in	lung	(for	IGF-1Ea.GFP	M2-like	macrophages)	and	in	the	
	 %	Total		Macrophages	 %	Total	IGF-1Ea.GFP	M1-like	macrophages	 %	Total		Macrophages	 %	Total		IGF-1Ea.GFP	M2-like	macrophages	Heart	 0.44	 0	 0.42	 0	
Kidney	 0.54	 0.12	 0.59	 0	
Lung	 2	 0	 2.93	 0.14	
TA	injury	 50.7	 0	 49.7	 0	
TA	uninjured	 2	 0	 1.86	 0	
	 	 	 	 	No	cells	TA	injury	 48.3	 0	 	 	No	cell	no	injury	 1.45	 0	 	 		 	 	 	 	
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kidney	 (for	 IGF-1Ea.GFP	M1-like	macrophages)	was	2400	and	2800	cells,	 respectively.	The	 number	 of	 events	 was	 calculated	 as	 follows:	 IGF-1Ea.GFP	 M1-like	 macrophages;	2x106	 x	 0.0012.	 IGF-1Ea.GFP	 M2-like	 macrophages;	 2x106	 x	 0.0014.	 Therefore,	 the	homing	efficiency	 to	 lung	and	kidney	 is	between	0.12-0.14%	 for	 IGF-1Ea.GFP	M1/M2-like	macrophages	(Table	4.1).		
	
Figure	4.8.	Representative	flow	cytometry	plots	of	GFP+	positive	BMdM	in	skeletal	muscle	
24	 hours	 after	 i.v.	 infusion,	 48	 hours	 after	 CTX	 injury.	 (A)	 Total	 alive.	 (B)	 F4/80-CD11b	positive	macrophages.	(C)	IGF-1Ea.GFP	M1-like	macrophages	in	CTX	injured	TA.	(D)	IGF-1Ea.GFP	M2-like	macrophages	 in	 CTX	 injured	 TA.	 (E)	 IGF-1Ea.GFP	M1-like	macrophages	 in	 kidney.	 (F)	IGF-1Ea.GFP	M1-like	macrophages	in	lung.	(G)	IGF-1Ea.GFP	M2-like	in	lung.	(H)	IGF-1Ea.GFP	M2-like	in	kidney.	2x106	total.	1x106	events	acquired.	n=3	each	group.	Macrophages	populations	are	depicted	as	CD45+,	CD11b+,	F4/80+,	GFP+/-.	
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4.6.2	Homing	of	CFSE-positive	bone	marrow-derived	macrophages	In	parallel	with	Section	4.6.1,	 an	additional	 strategy	was	 implemented	 to	 test	whether	non-polarised	BMdMs	could	be	a	better	therapeutic	vehicle	than	the	ex	vivo	manipulated	IGF-1Ea.GFP	 M1-/M2-BMdMs.	 First,	 the	 number	 of	 macrophages	 to	 be	 infused	 was	increased	 5-fold	 (10×106).	 Secondly,	 day-7	 non-polarised	 BMdMs	 were	 chosen	 since	differentiated	 macrophages	 might	 have	 reduced	 plasticity	 relative	 to	 non-polarised	BMdMs.	Indeed,	this	is	supported	by	the	fact	that	unfractionated	bone	marrow	cells	have	improved	migration	 to	 organs	 as	 discussed	 in	 the	 Introduction,	 Section	 1.4.1.	 Thirdly,	CSFE	 fluorescence-labelled	BMdMs	represent	a	much	more	direct	method	 to	 label	and	track	 BMdMs	 without	 the	 need	 of	 transfection,	 which	 in	 turn	 will	 increase	 survival.	These	modifications	 should	 facilitate	 trafficking	and	homing	of	BMdMs,	 as	BMdMs	are	less	affected	by	ex	vivo	manipulations.			Consequently,	 approximately	 10×106	CSFE	 fluorescence-labelled	 BMdM	 were	 injected	i.v.	as	described	in	Methodology,	Section	2.12.	Twenty-four	hours	after	infusion,	the	TA	from	both	 legs,	 injured	and	uninjured,	were	obtained	and	analysed	by	 flow	cytometry	for	 CFSE	 fluorescence.	 Spleen	 and	 lung	 were	 taken	 as	 positive	 controls	 since	 these	organs	 have	 been	 shown	 (Section	 4.6.1)	 to	 strongly	 retain	 migrating	 cells.	 Flow	cytometry	 analysis	 indicated	 that	 approximately	 1500	 CFSE-labelled	 BMdM	 events	(0.004%	total	macrophages)	at	the	injured	site	preferentially	homed	to	the	injury	site	as	shown	 in	Figure	 4.9A	 (as	 a	percentage	of	 total	macrophages)	and	 in	Figure	 4.9B	 (as	absolute	 numbers).	 Retention	 was	 also	 observed	 in	 spleen	 and	 lung,	 with	 0.07%	 of	CFSE-labelled	BMdM	retained	in	the	lungs	and	0.03%	in	the	spleen.	Thus,	in	the	lung,	up	to	 40–fold	more	 CFSE-labelled	BMdM	were	 detected	when	 compared	with	 TA-injured	muscle.	These	data	demonstrate	that	BMdMs	can	preferentially	home	to	sites	of	muscle	injury;	however	numbers	are	very	low.		Surprisingly,	 6	days	 after	TA	 injury,	 the	number	of	 engrafted	CFSE-labelled	BMdMs	 in	the	 TA	 injured	 muscle	 considerably	 increased	 (Figure	 4.9C	 and	 Figure	 4.9D).	Furthermore,	CFSE-labelled	BMdM	retention	was	not	observed	 in	 the	 liver	or	 the	 lung	(not	 shown).	 In	 summary,	 six	days	 after	 infusion,	 approximately	60,000	CFSE-labelled	BMdMs	were	recruited	at	the	injured	site	(Figure	4.9C),	representing	0.5	%	of	the	total	macrophages	at	the	given	time	(Figure	4.9D).				 	
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Figure	4.9.	Adoptive	immunotherapy	of	CFSE-labeled	BMdMs	into	CTX	injured	muscle	24h	
and	6	days	after	 injury.	 	Analysis	was	performed	comparing	the	capacity	of	BMdM	to	migrate	into	 the	 damaged	muscle.	 (A)	 Percentage	 CFSE-labeled	BMdM	 and	 (B)	 total	 numbers	 of	 CFSE-labeled	BMdMs	in	the	skeletal	muscle,	spleen	and	lung,	24	hours	after	 injection	(72	hours	after	TA	muscle	injury).	(C)	Percentage	CFSE-labeled	BMdM	(D)	total	numbers	of	CFSE-labeled	BMdMs	in	 the	 skeletal	muscle,	 6	 days	 after	 injection.	Macrophage	 populations	 are	 depicted	 as	 CD45+,	CD11b+,	F4/80+,	CFSE+.	Mean	percentage	±	SEM.	n	>	4	mice	per	group.		
	
4.7	Discussion		The	 ultimate	 aim	 of	 this	 chapter	was	 to	 develop	 a	 strategy	 to	 expand	 a	 population	 of	macrophages	in	vitro	to	be	used	for	transplantation	into	an	injured	host	and	evaluate	the	efficacy	of	immune-cell	mediated	delivery	of	IGF-1Ea	to	counteract	the	effects	of	muscle	injury.			Studies	performed	 in	vitro	 showed	that	 the	environment	encountered	by	macrophages	modulated	the	expression	of	IGF-1Ea	isoform.	Interestingly,	upon	stimulation	with	IL-4	or	reparative	environment,	macrophages	respond	by	up-regulating	the	mRNA	levels	of	IGF-1Ea.	 The	 opposite	 trend	 was	 observed	 when	 macrophages	 were	 stimulated	 with	
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IFNγ.	Regarding	the	role	of	the	IGF-1R	in	the	IGF-1-mediated	immune	response,	further	investigations	are	required	to	understand	the	role	of	the	receptor	as	a	down-regulation	of	the	receptor	was	observed	upon	stimulation	with	TNF-α/LPS	but	not	IL-4.			The	 in	vitro	 studies	 presented	 in	 this	 chapter	 indicate	 that	 BMdM	 can	 be	 successfully	transfected	and	 secrete	 IGF-1Ea	 into	 the	 culture	medium,	however,	 the	 lifespan	of	 the	BMdMs	after	transfection	limits	their	action	after	infusion.	Furthermore,	in	vitro	and	in	
vivo	studies	 presented	 in	 this	 chapter	 show	 that	 overexpressing	 IGF-1Ea	 in	BMdMs	 is	possibly	 not	 the	 best	 approach	 for	 the	 delivery	 of	 salutary	 factors	 into	 the	 injured	muscle.	 Particularly,	 the	 cell-based	 protocol	 using	 IGF-1Ea.GFP	 M1-/M2-like	 BMdMs	demonstrated	that	these	cells	do	not	home	to	injured	muscles;	rather,	IGF-1Ea.GFP	M1-/M2-like	BMdMs	differentially	homed	to	either	kidney	or	 lung,	however,	 it	 is	most	 like	these	cells	are	retained	in	such	organs.	The	results	shown	in	Section	4.6	taken	together	with	 the	 fact	 that	 the	 lifespan	 of	 IGF-1Ea.GFP	 M1-/M2-like	 BMdMs	 is	 limited	 after	transfection,	restricted	the	use	of	IGF-1Ea.GFP	M1-/M2-like	BMdMs	for	the	treatment	of	muscle	 injuries,	 and	 specially	 the	 heart.	 Nevertheless,	 the	 fact	 that	 these	 cells	preferentially	home	to	either	lungs	or	the	kidney	could	open	a	new	line	of	research	for	the	use	of	IGF-1Ea.GFP	M1-/M2-	like	BMdMs	as	desirable	cell	vehicles	for	inflammatory-driven	 diseases	 affecting	 these	 organs.	 One	 of	 the	 reasons	 that	 might	 explain	 the	reduced	homing	competency	of	macrophages	can	be	 the	cell	 type	chosen.	 IGF-1Ea.GFP	M1-/M2-like	 BMdMs	 are	 fully	 differentiated	 cells	 with	 limited	 migratory	 capacities.	Consequently,	 in	Section	4.6.2,	non-polarised	bone	marrow-derived	macrophages	were	used.	 Experiments	 using	 CFSE-labelled	 BMdMs	 showed	 that	 this	 population	preferentially	homed	to	the	injured	muscle.	However,	similar	to	the	results	presented	in	Section	 4.6.1,	 these	 cells	 were	 retained	 in	 great	 measure	 in	 organs	 such	 as	 liver	 and	spleen.	Interestingly,	six	days	after	infusion,	no	retention	was	observed	in	these	organs	and	 a	 relative	 increase	 in	 CFSE-labelled	 BMdMs	 number	 was	 found	 at	 the	 injured	muscle.	 Consequently,	 Analysis	 of	 IGF-1	 overexpression	 in	 injured	 TA	 after	 BMdMs	infusion	was	not	evaluated	because	of	the	low	engraftment.		Considering	 all	 the	 data	 reported	 in	 this	 chapter,	 it	 could	 be	 concluded	 that	 from	 a	therapeutic	 point	 of	 view	 the	 use	 of	 BMdMs	 as	 a	 vehicle	 has	 proven	 to	 be	 very	inefficient,	with	more	 than	90%	of	 IGF-1Ea.GFP	M1-/M2-like	BMdMs	or	CFSE-labelled	BMdMs	disappearing	or	undetectable	after	injection.			
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The	 main	 conclusions	 of	 this	 chapter	 are	 that	 (i)	 the	 more	 differentiated	 the	macrophages	become,	the	less	migratory	they	are.	(ii)	IGF-1Ea.GFP	M1-/M2-like	BMdMs	transfected	with	the	IGF-1Ea	plasmid	do	not	exhibit	migration	capacity	whatsoever	but,	instead	 lung	 and	 kidney	 retention	 is	 observed.	 (iii)	 Using	 a	 CFSE-labelled	 approach,	BMdMs	displayed	some	homing	capacities	although	not	in	adequate	numbers	to	cause	a	therapeutic	 effect	 and,	 therefore,	 should	 not	 be	 considered	 for	 further	 translational	studies.			One	of	the	hypotheses	to	explain	the	disappearance	of	the	majority	of	the	infused	cells	was	 that	 survival	 might	 have	 been	 compromised	 due	 to	 temperature	 changes,	 use	trypsin	 for	 cell	 detachment,	 transition	 from	 PBS	 to	 blood,	 or/and	 the	 transfection	process	itself	as	well	as	BMdMs	are	in	a	more	differentiated	state	than	other	cells	such	as	 monocytes	 and	 bone	 marrow	 cells.	 Furthermore,	 technical	 difficulties	 were	experienced	 during	 the	 development	 of	 this	 approach	 including	 BMdM	 culture,	transfection	efficiencies,	non-homogenous	GFP	expression,	IGF-1Ea	production,	and	cell	survival.	Because	of	 these	 setbacks,	proof	 that	engineered	macrophages	are	 functional	and	 could	 potentially	 enhance	 healing	 to	 injured	muscle	 was	 ultimately	 not	 explored	due	 to	 technical	difficulties	described	above.	 Indeed,	 this	work	was	abandoned	at	 this	stage	 in	order	to	explore	other	suitable	vehicles	 for	 IGF-1Ea.	Consequently,	more	cost-effective	 and	 time-efficient	 strategy	 was	 pursued,	 developed	 and	 achieved,	 which	 is	described	in	Chapter	5.			Nonetheless,	 if	the	BMdMs	system	had	succeeded,	several	techniques	would	have	been	used	 to	 assess	 the	 beneficial	 effects	 of	 this	 approach.	 For	 instance,	 skeletal	 muscle	regeneration	 would	 have	 been	 judged	 as	 a	 significant	 increase	 in	 the	 cross-sectional	area	of	newly	 formed	multinucleated	myotubes	 in	 skeletal	muscle	 following	TA	 injury	(Barton-Davis	 et	 al.	 1998).	 Furthermore,	 flow	 cytometry	 analysis	 studies	 would	 have	been	valuable	to	characterise	macrophage	relationships	and,	to	identify	the	percentage	of	M1	and	M2	macrophages	after	1,	3,	5	and	7	days	after	injury	coinciding	with	M1,	M1	to	M2	shift,	and	M2	macrophages,	respectively.	Finally,	real	time	PCR	would	have	been	used	 to	 study	 whether	 the	 BMdM	 therapy	 modulates	 the	 inflammatory	 response,	 by	studying	 changes	 in	 inflammatory	mediators	 including	 Il-1β,	 IL-6,	TNF-α,	 IFN-γ,	 IL-10,	and	IL-13.			In	addition	to	this,	the	extent	of	skeletal	muscle	regeneration	would	have	been	analysed	by	 quantification	 of	 collagen	 content	 (fibrosis)	 using	 picrosirius	 red	 staining,	 and	
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quantifying	the	proportion	of	multinucleated	fibers	generated	after	injury	(a	marker	of	extent	of	regeneration).		
 4.7.1	Limitation	of	the	approach	The	 idea	behind	 this	 approach	was	 indeed	very	 appealing	 from	a	 therapeutic	point	of	view;	however,	 the	main	 limitations	were	already	encountered	at	 the	planning	 stages,	beginning	 at	 the	 time	 of	 selecting	 a	 suitable	 cell	 type	 as	 vehicle.	 Ideally,	 monocytes	should	have	been	 the	 cell	 of	 choice.	Unfortunately,	monocyte	 isolation	procedures	 are	still	 not	 well	 refined,	 and	 sufficient	 numbers	 cannot	 be	 realistically	 isolated.	Furthermore,	given	that	adequate	numbers	could	be	isolated,	the	best	available	protocol	for	 monocyte	 transfection	 has	 an	 efficiency	 of	 10-30%,	 causing	 high	 mortality	 rates	(Burke	 et	 al.	 2002).	 These	 two	 obstacles	 were	 one	 of	 the	 main	 reasons	 for	 choosing	macrophages	instead	of	monocytes	in	this	chapter.		In	summary,	both	in	vivo	and	in	vitro	studies	have	shown	that	BMdMs	are	less	suited	as	vectors	for	gene	therapy	than	initially	thought.	In	vitro,	one	of	the	main	limitations	is	the	yield	of	viable	BMdMs	positively	 transfected,	which	 is	 reduced	by	50%.	Moreover,	 the	heterogeneity	 in	 transfection	 efficiencies	 generates	 a	 less	 reliable	 homogenous	population,	 in	 terms	of	 IGF-1Ea	synthesis	and	delivery.	An	additional	 limitation	 is	 that	macrophage	 transfection	 is	 transient	 limiting	 BMdMs	 lifespan.	 In	 vivo,	 the	 main	limitation	was	 the	 (lack	 of)	 BMdMs	 homing	 efficiency	 and	 the	 retention	 in	 non-target	organs	such	us	spleen	and	lung.		4.7.2	Outcomes	Other	 macrophage-based	 approaches	 are	 being	 considered	 at	 the	 moment.	 In	 Nadia	Rosenthal’s	 group	 in	 Australia,	 luciferase-labelled	 macrophages	 (DKO-MΦs)	 as	 an	alternative	to	study.	They	have	shown	that	these	macrophages	can	home	to	the	sites	of	injury	when	primed	with	angiotensin	II.	Indeed,	priming	macrophages	with	angiotensin	II	 significantly	 improved	 the	homing	 competency	of	 these	 cells.	Another	aspect	 that	 is	being	 explored	 is	 how	 to	 minimise	 concerns	 regarding	 non-autologous	 allogeneic	transplantations,	such	as	rejection.			Additionally,	 Dr	 Rosenthal´s	 group	 in	 Australia	 is	 also	 exploring	 the	 generation	 of	myeloid	cells	from	iPSCs	and	testing	their	homing	competencies.	
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Chapter	5	 -	Adeno-associated	virus	type	9	(AAV9)	IGF-1Ea	gene	transfer	 into	the	
damaged	heart	after	ischemia/reperfusion	injury.	
	
5.1	Introduction	Cardiac	gene	transfer	serves	as	a	novel	therapeutic	approach	in	the	treatment	of	heart	diseases	(Introduction,	Section	1.4.2).	 In	recent	years,	the	use	of	AAV	has	proved	to	be	the	 most	 promising	 gene	 delivery	 system	 for	 transfer	 of	 genes	 to	 post-mitotic	 cells	(Gregorevic	 et	 al.	 2006,	 Wang	 et	 al.	 2005	 and	 Walker	 et	 al.	 2009).	 In	 1998,	 Prof.	Rosenthal	successfully	delivered	AAVs	loaded	with	IGF-1	to	aging	or	dystrophic	skeletal	muscle	(Barton-Davis	et	al.	1998).		In	that	paper,	IGF-1	expression	promoted	an	increase	of	15%	in	muscle	mass	and	14%	in	strength	in	old	adult	mice.		As	 described	 in	 the	 Introduction,	 Section	 1.4.2.2,	 AAV	 was	 selected	 above	 other	serotypes	due	 to	high	 tropism	 to	heart	 tissue	 as	well	 as	 the	 lack	of	 pathogenicity	 and	persistence	 of	 viral	 expression.	 There	 are	 several	 studies	 indicating	 that	 the	 newly	produced	 serotypes	 AAV,	 such	 us	 AAV5,	 AAV6,	 AAV8,	 AAV9,	 with	 so-called	 cardiac	tropism,	can	achieve	greater	transduction	into	the	heart	muscle	than	AAV1,	AAV2,	AAV3,	AAV4.	In	a	study	in	2012,	Hongfei	compared	intravenous	versus	intracoronary	delivery	of	 several	 of	 these	 AAV	 serotypes.	 Of	 all	 the	 serotypes	 tested,	 the	 highest	 cardiac	expression	was	achieved	via	intracoronary	delivery	of	AAV9	(Hongfei	at	al.	2012	and	Lai	et	al.	2012).	In	another	study,	Prasad	determined	that	AAV9	was	the	serotype	with	the	highest	transduction	efficiency	requiring	an	average	of	nearly	two	vector	genomes	per	cell	 to	 attain	 85%	 transduction	 efficiency	 (Prasad	 et	 al.	 2011).	 So	 far,	 high	 efficiency	whole	heart	gene	delivery	in	small	animals	has	only	been	effectively	achieved	with	AAV	serotype	9	(Pacak	et	al.	2006	and	Bostick	et	al.	2007).		The	overall	purpose	of	 this	chapter	was	to	 investigate	whether	adeno-associated	virus	(AAV)	 serotype-9	 (AAV9)	 can	 (i)	 successfully	 deliver	 IGF-1Ea	 into	 the	 heart	 after	myocardial	 infarction	and	 (ii)	ameliorate	 the	adverse	effects	of	heart	 remodeling	after	ischemic	injury	in	a	clinically	relevant	setting.		
	
5.2	 pAAV9.IGF-1Ea	 expression	 on	 neonatal	 cardiomyocytes	 and	 AAV9.IGF-1Ea	
infection	of	HL-1	cells	
Mus	musculus	IGF-1Ea	consensus	cDNA	sequence	was	cloned	into	a	pAC-cTNT	backbone.	Successful	 cloning	 was	 assessed	 by	 (i)	 restriction	 enzyme	 analysis	 and	 (ii)	 plasmid	sequencing	 (Methodology,	 Section	 2.11).	 Following	 this	 assessment	 and	 prior	 in	 vivo	
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work,	 IGF-1Ea	 expression	 levels	 were	 evaluated	 in	 vitro	 by	 transfecting	 rat	 neonatal	cardiomyocytes	with	the	pAAV9.IGF-1Ea	vector.	Three	days	after	transfection,	the	IGF-1Ea	 mRNA	 levels	 were	 10000-fold	 increased	 when	 compared	 with	 the	 control	untransfected	cardiomyocytes	(Figure	5.1A).	This	increase	also	correlated	with	higher	levels	 of	 IGF-1	 protein	measured	 by	western	 blot	 (Figure	 5.1B).	 In	 a	 different	 set	 of	experiments,	the	luciferase	activity	of	the	AAV9.IGF-1Ea	virus	was	assessed	by	a	chemo	luminescence	 assay	 indicating	 that	 the	 bi-cistronic	 mRNA	 was	 fully	 functional	 as	Luciferase	activity	was	observed	three	days	after	infection	(Figure	5.1C).		
	
Figure	5.1.	Rat	neonatal	 cardiomyocytes	 transfected	with	pAAV9.IGF-1Ea	vector.	 IGF-1Ea	levels	 were	 analysed	 by	 (A)	 qPCR	 and	 (B)	 western	 blot	 3	 days	 after	 transfection.	 1.5x104		neonatal	cardiomyocytes	were	transfected	for	this	experiment,	with	500ng	of	the	vector.	n=3.	(C)	Relative	 luciferase	activity	of	5x105	HL-1	cells	 infected	with	 the	AAV9.IGF-1Ea	virus	 three	days	after	 infection.	 n=4.	 Mean	 values	 ±	 SEM	 are	 shown.	 *p<0.05.	 Two-tailed	 Student’s	 t-test	 was	performed	to	compare	Control	CM	vs.	pAAV9.IGF.1Ea.		
5.3	Characteristics	of	intravenous	AAV9.IGF1-Ea	gene	transfer	To	 evaluate	 the	 therapeutic	 potential	 of	 AAV9-mediated	 IGF-1Ea	 gene	 transfer,	 we	constructed	an	AAV9	vector	encoding	the	IGF1-Ea	mouse	cDNA,	the	expression	of	which	was	 driven	 by	 the	 cardiac	 troponin	 promoter	 (cTNT).	 The	 vector	 also	 contained	 an	internal	 ribosomal	 entry	 site	 (IRES)	 for	 the	 firefly	 luciferase	 reporter	 gene	 (Figure	
5.2A),	allowing	gene	delivery	to	be	readily	assayed.	The	in	vivo	transduction	levels	were	first	 assessed	 by	 administering	 3.5x1011	 GC	 of	 AAV9.IGF1Ea	 in	 a	 single	 intra-femoral	vein	injection	to	C57/BL6	mice.			Quantitative	 analysis	 of	 luciferase	 and	 IGF-1Ea	 expression	 verified	 increased	 levels	 of	mRNA	by	3	days	post-injection,	however,	IGF-1Ea	levels	were	not	significantly	induced	
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until	7	days	post-injection	(Figure	5.2B	and	5.2C).	Immunohistochemistry	for	luciferase	confirmed	extensive	expression	throughout	the	heart	with	a	mosaic-like	pattern	(Figure	
5.2D,	5.2E,	5.2F	and	5.2G)	typical	of	AAV	gene	transfer	(Prasad	et	al.	2011).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.2.	AAV9.IGF-1Ea	timecourse	of	expression	in	the	murine	heart	after	intravenous	
injection.	 (A)	Schematic	representation	of	recombinant	AAV	vector.	The	construct	contains	the	IGF-1Ea	mouse	gene	(462	bp)	and	an	internal	ribosomal	entry	site	(IRES)	followed	by	the	firefly	
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luciferase	 reporter	 gene.	 The	 expression	 of	 this	 bi-cistronic	 DNA	 is	 under	 the	 control	 of	 the	cardiac	 troponin	 promoter	 (cTNT),	 and	 the	 SV40	 polyA	 signal,	 flanked	 by	 the	 AAV	 inverted	terminal	repeats	(ITR),	shown	as	hairpin	loops.	The	AAV	vectors	(AAV9.GFP	and	AAV9.IGF-1Ea)	were	packaged	into	AAV9	capsids.	Quantitative	qPCR	analysis	of	(B)	luciferase	and	(C)	IGF-1Ea	in	the	 heart	 at	 several	 timpoints	 after	 AAV9.IGF-1Ea	 viral	 injection.	 n=3.	Mean	 values	 ±	 SEM	 are	shown.	*P<0.05,	**P<0.001.	One-way	ANOVA	with	Dunnett’s	Multiple	Comparison	test	with	 I/R	group	(no	virus	group).	 (D-G)	 Immunohistochemistry	of	 luciferase	expression	 in	heart	sections	28	days	after	ischemia/reperfusion	(I/R).	(D-E)	I/R	group	(no	virus	group),	(F-G)	AAV9.IGF-1Ea	3.5x1011	 GC	 group,	 5	 hours	 after	 I/R.	 (D	 and	 F)	 whole	 heart.	 Scale	 bar,	 1	 mm.	 (F	 -	 G)	 40x	magnification.	Scale	bar,	250	μm.	RV,	right	ventricle.	LV,	left	ventricle.		
	By	 contrast,	 there	was	 no	 difference	 in	 IGF-1Ea	mRNA	 expression	 levels	 between	 I/R	control	group	and	AAV9.IGF-1Ea	groups	in	liver	and	lung	(Figure	5.3A	and	5.3B).	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.3.	IGF-1Ea	mRNA	levels	28	days	after	ischemia/reperfusion.	(A)	liver	and	(B)	lung.	n=	 5-9	 per	 group.	 Mean	 values	 ±	 SEM	 are	 shown.	 *p<0.05.	 Two-tailed	 Student’s	 t-test	 was	performed	to	compare	I/R	vs.	AAV9.IGF1Ea	3.5x1011	28	days	after	MI.		The	 in	vivo	 expression	 of	 luciferase	was	 evaluated	 at	 different	 timepoints.	 	 Significant	expression	of	 luciferase	 in	vivo	was	 seen	 in	 the	heart	 at	 7	days	post-injection.	 Ectopic	expression	in	the	liver	was	detected	at	much	lower	levels	than	in	the	heart,	as	early	as	2	days	 post-injection	 (Figure	 5.4),	 temporarily	 overriding	 the	 specificity	 of	 the	 cTNT	promoter.	Ex	vivo	imaging	detected	luciferase	expression	in	the	heart	as	early	as	3	days	post-injection	(Figure	5.4A,	5.4B	and	5.4C).	Further	analysis	revealed	that	the	emission	of	photons	at	3	days	was	blocked	by	the	tissue	thickness	and	composition	of	 the	chest	(not	shown).	In	conclusion,	cardiac	expression	of	IGF-1Ea	starting	between	3	and	7	days	
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after	 i.v	 injection	exhibited	 robust	 and	 sustained	gene	expression,	 and	bioluminescent	imaging	of	luciferase	was	an	indicator	of	co-expressed	IGF-1Ea.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
	
	
	
	
	
	
	
Figure	 5.4	 Bioluminecesce	 imaging	 illustrating	 the	 distribution	 of	 luciferase	 at	 several	
timepoints	 after	 intravenous	 injection	 of	 AAV9.IGF1Ea.	Ex	vivo	 bioluminescence	 images	 of	(A)	 whole	 body	 and	 (B)	 at	 indicated	 organs	 from	 mice	 that	 received	 AAV9.IGF1Ea	 3.5x1011	genome	 copies	 (GC)	 at	 several	 timepoints.	 (C)	 Bioluminescence	 analysis	 of	 AAV9.IGF1Ea.1011	specificity	 after	 intravenous	 delivery.	 Mean	 values	 of	 luciferase	 shown	 as	 average	 radiance	(photons/s/cm2/sr)	from	the	regions	of	interest	and	plotted	against	time	in	individual	organs.	
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5.4	 Echocardiography	 assessment	 of	 AAV9.IGF-1Ea	 gene	 delivery	 after	
ischemia/reperfusion.		To	test	the	efficacy	of	virally	delivered	IGF-1Ea	in	ameliorating	the	response	to	cardiac	injury,	mice	underwent	myocardial	ischemia	for	45	min	followed	by	reperfusion	(Figure	
5.5A).	Four	groups	of	animals	were	compared;	I/R	group	(no	virus	group)	and	a	group	receiving	 3.5x1011	 genome	 copies	 (GC)	 of	 AAV9.GFP	 (I/R	 +	 AAV9.GFP)	 were	 used	 as	negative	 controls;	 for	 AAV9.IGF1Ea	 two	 different	 viral	 titers	were	 tested,	 3.5x1010	 GC	and	3.5x1011	GC	(I/R	+	IGF1Ea.1010	and	I/R	+	IGF1Ea.1011),	respectively	based	on	Jessup	et	al.	2001.	AAV9	administration	was	performed	5	hours	after	surgery	by	intra-femoral	vein	 injection	 and	 mice	 were	 sacrificed	 28	 days	 after	 injection	 (Figure	 5.5A).	 A	significant	 dose-dependent	 increase	 in	 IGF-1Ea	 mRNA	 level	 was	 observed	 in	 those	groups	 that	 received	 the	 AAV9.IGF1Ea	 treatment	 (Figure	 5.5B).	 ELISA	 quantification	revealed	no	differences	in	IGF-1	serum	levels	between	groups	(Figure	5.5C),	confirming	our	previous	study.	IGF-1Ea	strongly	adheres	into	the	extracellular	matrix,	retaining	the	propeptide	 locally,	 preventing	 their	 release	 into	 the	 circulation,	 and	 minimizing	 the	potential	hazard	of	ectopic	effects	(Hede	et	al	2012).															
	
Figure	 5.5.	 AAV9.IGF-1Ea	 gene	 transfer	 experimental	 design.	 (A)	 AAV9.IGF1Ea	 was	administered	 intravenously,	 5	 hours	 after	 ischemia/reperfusion	 (I/R)	 and	 echocardiographic	measurements	were	taken	at	3	days	and	28	days.	(B)	IGF-1Ea	mRNA	levels	in	the	heart	28	days	after	 I/R	 and	 after	 treatment	were	 quantified	 by	 qRT-PCR.	 n=3-7.	 (C)	 Serum	 concentration	 of	IGF-1,	28	days	post-I/R.	Mean	values	±	SEM	are	 shown,	n=6-14.	 *P<0.05,	 **P<0.001.	 	One-way	ANOVA,	Dunnett’s	Multiple	Comparison	test	with	I/R	group	(no	virus	group).	
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5.4.1	 AAV9.IGF1Ea	 gene	 transfer	 improves	 global	 left	 ventricular	 function	 after	
ischemia/reperfusion.		Echocardiographic	analysis	at	28	days	after	 I/R	revealed	 improved	cardiac	 function	 in	mice	 treated	 with	 AAV9.IGF1Ea	 (I/R+IGF1Ea.1010	 and	 I/R+IGF1Ea.1011)	 compared	 to	untreated	 mice	 and	 mice	 injected	 with	 AAV9.GFP	 (Figure	 5.6A	 and	 Table	 5.1).	 LV	systolic	 function	 in	 IGF-1Ea	 overexpressing	 mice	 at	 28	 days	 was	 also	 improved	compared	to	function	at	3	days	in	the	same	mice.	In	addition,	AAV9.IGF1Ea	treated	mice	showed	reduced	LV	dilation	28	days	post-I/R	(Figure	5.6B,	Figure	5.6C	and	Table	5.1)	compared	to	I/R	and	AAV9.GFP.	All	four	groups	showed	similar	functional	worsening	in	cardiac	parameters	 and	 chamber	dilation	3	days	post-I/R	 regardless	of	 the	 treatment,	suggesting	that	initial	infarct	size	was	analogous	among	all	groups	(Table	5.1).	Notably,	functional	 improvement	 was	 more	 evident	 in	 those	 groups	 where	 the	 highest	AAV9.IGF1Ea	viral	titer	was	administered.																	
Figure	5.6.	 IGF-1Ea	gene	 transfer	 improves	cardiac	 function	and	 left	ventricular	dilation	
28	days	after	ischemia	reperfusion.	(A-C)	Echocardiographic	was	performed	at	3	and	28	days	post-I/R.	(A)	Left	ventricular	ejection	fraction,	LVEF,	and	(B,	C)	Left	ventricular	end	systolic	and	diastolic	 volumes,	 LVESV	 and	LVEDV,	 respectively.	Mean	 values,	 ±	 SEM	are	 shown.	 n=	4-6	 per	group.	 *P<0.05	 I/R	 vs.	 AAV9.GFP,	 AAV9.IGF1Ea	 groups.	 One-way	 ANOVA	with	 Dunnett's	 post-test.	 †P<0.05.	 Two-way	ANOVA	 to	 compare	 the	4	 groups	with	Bonferroni	 post-tests.	 ‡	 P<0.05.	Two-way	 ANOVA	 to	 compare	 3	 days	 vs.	 28	 days	 with	 Bonferroni	 post-tests.	 The	 dashed	 line	shows	the	ejection	fraction	of	basal	group.	
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5.4.2	Left	ventricular	regional	wall	motion	is	enhanced	by	28	days	after	AAV9.IGF1Ea	gene	
transfer.	Quantitative	 evaluation	 of	 LV	 regional	 wall	 motion	 after	 infarction	 and	 ischemia	was	performed	using	echocardiographic	analysis.		Consistent	with	the	LV	systolic	functional	data,	 a	 reduction	 in	 the	 heart	 failure	 marker	 Acta1	 was	 significantly	 reduced	 in	AAV9.IGF1Ea	 treated	 group	 (Figure	 5.7A).	 Improvements	 in	 the	 wall	 score	 motion	index	(WSMI)	were	also	observed	 in	 those	groups	after	 IGF-1Ea	gene	transfer	(Figure	
5.7B).	 Moreover,	 mice	 over-expressing	 IGF-1Ea	 showed	 fewer	 akinetic	 segments	compared	 to	 I/R	 and	 I/R+GFP	 control	 groups	 (Figure	 5.7C).	 In	 agreement	 with	 our	evidence	that	initial	infarct	size	was	not	changed,	no	significant	difference	was	observed	between	 the	 different	 groups	 for	 either	WSMI	 or	 individual	 segment	 assessment	 at	 3	days	post-I/R	(Table	5.1).	Both	the	WSMI	and	the	contraction	assessment	indicate	that	AAV9.IGF1Ea	treatment	improves	the	overall	contractile	function	of	the	heart.	
	
Figure	5.7.	 IGF-1Ea	gene	 transfer	 reduces	cardiac	damage,	 improves	cardiac	motion	and	
reduces	 dilation	 after	 ischemia/reperfusion.	 (A)	 mRNA	 levels	 of	 α-skeletal	 actin.	 (B)	Wall	score	motion	index.	(C)	Segment	analysis	based	on	wall	motion	and	systolic	thickening.	Segment	scores	 are	 colored	 coded	 from	 green	 to	 red	 representing:	 normal	 or	 hyperkinesis	 =	 green,	hypokinesis	=	yellow,	akinesis	=	red.	Black	bars,	3	days	after	I/R.	White	bars,	28	days	port	I/R.	n=7-13.	Mean	 values,	 ±	 SEM	 are	 shown.	 *P<0.05	 I/R	 vs.	 AAV9.GFP,	 AAV9.IGF1Ea	 groups.	One-way	 ANOVA	 with	 Dunnett's	 Multiple	 Comparison	 post-test.	 †P<0.05.	 Two-way	 ANOVA	 to	compare	the	4	groups	with	Bonferroni	post-tests.	‡	P<0.05.	Two-way	ANOVA	to	compare	3	days	vs.	28	days	with	Bonferroni	post-tests.	The	dashed	line	shows	the	EF	of	basal	group.		
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3	Days	post	I/R	
	
I/R	
I/R	+	AAV9.IGF1Ea	
3.5x1010	GC	
I/R	+	AAV9.IGF1Ea	
3.5x1010	GC	
I/R	+	AAV9.GFP	
3.5x1011	GC	
LVIDD	 3,647±0.1249	 3.978±0.1978	 3.782±0.1363	 3.757±0.1431	
LVIDS	 2,909±0.129	 3.251±0.1334	 3.192±0.1345	 3.236±0.1563	
LVEDV	 62,07±4,661	 55,3±4,093	 58,94±7,967	 57,11±4,329	
LVESV	 47,34±4,199	 42,53±3,303	 45,73±7,232	 44,25±4,031	
LVEDA	 12.76±0.6272	 13.56±0.8405	 13.54±1.338	 12.43±0.9266	
LVESA	 9,543±0,5581	 9,99±0,6829	 10,37±1,017	 9,183±0,9007	
Number	of	
segments	affected	
6.038±0.3645	 5.4±0.6403	 5.714±0.5759	 4.857±0.8071	
Cardiac	score	 22,77±3,03	 21,71±4,11	 20,71±3,15	 21,30±4,19	
Wall	score	motion	
index	
1,90±0,25	 1,81±0,34	 1.73±0.26	 1,78±0,35	
	 	 	 	 			 28	Days	post	I/R	
	
I/R	
I/R	+	AAV9.IGF1Ea	
3.5x1010GC	
I/R	+	AAV9.IGF1Ea	
3.5x1010	GC	
I/R	+	AAV9.GFP	
3.5x1011	GC	
LVIDD	 4.627±0.1226	‡	 4.705±0.2768	‡	 4.291±0.1993	*	 4.016±0.1145	*†	
LVIDS	 4.022±0.1352	‡	 3.62±0.2105	‡	 3.183±0.1778	 3.216±0.2105	*†	
LVEDV	 104.8±8.251	‡	 104.1±15.72	‡	 85.51±2.737	 72.6±3.541	†	
LVESV	 80.01±5.973	‡	 75.58±12.47	‡	 46.36±3.986	*†	 39.89±3.386	*†	
LVEDA	 17.04±0.5598	‡	 17.53±1.801	‡	 16.36±1.123	 14.07±0.8024	
LVESA	 12.24±0.6517		‡	 12.85±1.412	‡	 10.21±0.9048	 8.491±0.6365	*†	
Number	of	
segments	affected	
5.867±0.3326	 6±1.204	 4.571±1.077	†	 3.7±0.4955		*†‡	
Cardiac	score	 23,69±3,25	 22,50±7,50	 18,57±5,35	*	 16,20±1,99	*†‡	
Wall	score	motion	
index	
1,97±0,27	 1,88±0,63	 1,55±0,45	*†	 1,35±0,17	*†‡	
HW/BW	 7,98±2,14	 8,11±1,93	 7,99±1,21	 7,71±2,87	
n	 13	 7	 10	 10		 	 	 	 	
Table	5.1.	Echocardiographic	measurements	at	3	and	28	days	after	ischemia/reperfusion	
(I/R).	 LVIDD,	 left	 ventricular	 internal	 diameter	 in	 diastole;	 LVIDS,	 left	 ventricular	 internal	diameter	 in	 systole;	 LVEDV,	 left	 ventricular	 end-diastolic	 volume;	 LVESV,	 left	 ventricular	 end-systolic	 volume;	 LVEDA,	 left	 ventricular	 end-diastolic	 area;	 LVESA,	 left	 ventricular	 end-systolic	area.	 Number	 of	 segments	 affected,	 number	 segments	 with	 abnormal	 contractility	 out	 of	 12	segments	in	the	LV	short	axis	view,	as	shown	in	Figure	5.7C.	Cardiac	score,	sum	of	the	severity	score	 of	 each	 segment	 with	 lower	 values	 indicating	 better	 motion.	 Wall	 motion	 score	 index,	cardiac	score	divided	by	the	total	number	of	segments.	HW/BW,	heart	weight/body	weight.	n=7-13.	 Mean	 values	 ±	 SEM	 are	 shown.	 *P<0.05	 I/R	 vs.	 AAV9.GFP,	 AAV9.IGF1Ea	 groups.	 One-way	ANOVA	with	Dunnett's	Multiple	Comparison	post-test.	†P<0.05.	Two-way	ANOVA	to	compare	the	4	groups	with	Bonferroni	post-tests.	‡	P<0.05.	Two-way	ANOVA	to	compare	3	days	vs.	28	days	with	Bonferroni	post-tests.		
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5.5 IGF-1Ea	gene	transfer	reduces	infarct	size	and	cardiac	fibrosis	To	 determine	 infarct	 size,	 infarct	 expansion	 and	 scar	 thickness	 after	 AAV9.IGF1Ea	treatment	 histological	 analysis	 was	 performed.	 Improved	 cardiac	 function	 in	 the	AAV9.IGF1Ea	groups	was	accompanied	by	thicker	scars	when	compared	with	I/R	group	(no	 virus	 group)	 and	 I/R	 +	 GFP	 control	 groups	 (Figure	 5.8A).	 Scar	 length	 was	 also	diminished	 in	 the	 IGF-1Ea	 treated	 groups	 (Figure	 5.8B),	 suggesting	 reduced	 infarct	expansion.	Total	fibrosis	was	also	reduced	(Figure	5.8C).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.8.	IGF1Ea	gene	transfer	reduces	infarct	expansion	and	myocardial	remodeling	in	
AAV9.IGF1Ea	 treated	mice.	(A)	Scar	thickness,	(B)	 length	and	(C)	total	 fibrosis	were	analyzed	28	 days	 post-I/R	 using	 histological	 methods.	 (D)	 Col	 Iα1/Col	 Iα3	 ratio,	 (E)	 Lox	 and	 (F)	 Thy1	mRNA	 relative	 levels	 were	 analyzed	 by	 qRT-PCR.	 n=	 5-12	 per	 group.	 Mean	 values	 ±	 SEM	 are	shown.	*	P	<	0.05	I/R	vs.	all	three	conditions.	One-way	ANOVA	followed	with	Dunnett’s	post-test.	From	 the	Masson’s	 trichrome-stained	 images,	 infarct	 scar	wall	 thickness,	 scar	 length	 and	 total	
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fibrosis	was	measured	with	NIH	ImageJ	software.	Anterior	wall	thickness	was	measured	at	three	different	points	 in	 infarction	area	of	anterior	wall	perpendicularly	and	average	was	taken.	Scar	length	 was	 determined	 in	 Masson’s	 trichrome-	 stained	 sections	 using	 the	 midline	 method	(Takagawa	 et	 al.	 2007).	 The	 ratio	 of	 scar	 length	 to	 left	 ventricular	 circumferences	 of	 the	endocardium	and	epicardium	was	determined	and	expressed	as	a	percentage	of	infarct	size	(%	of	LV)	which	was	calculated	as	 (infarct	 length/total	LV	 length)×100.	Transverse	 fibrosis	and	 total	left	 ventricular	 areas	 were	 measured	 and	 expressed	 as	 percent	 fibrosis.	 Collagen	 ratio	 was	calculated		as	the	ratio	of	Collagen	Iα1	and	Collagen	Iα3	relative	expression	levels.		Functional	and	histological	findings	were	confirmed	at	molecular	level	by	monitoring	LV	fibrosis	markers	and	the	main	cell	types	producing	them:	collagen	1	(Col	Iα1),	collagen	3	(Col	 Iα3),	 lysyl	 oxidase	 (Lox)	 and	 Thy1/CD90.	 Measured	 28	 days	 after	 cardiac	 gene	transfer,	 the	 Col	 Iα1/Col	 Iα3	 mRNA	 ratio	 was	 increased	 in	 the	 AAV9.IGF1Ea	 groups	(Figure	5.8D),	 indicating	a	difference	in	extracellular	matrix	ECM	composition.	Higher	levels	 of	 Lox	were	 also	 detected	 (Figure	 5.8E).	 Lox	molecules	 crosslink	 collagen	 and	elastin	 molecules	 into	 mature	 fibers,	 potentially	 strengthening	 the	 scar.	 As	 a	measurement	 of	 fibroblast	 proliferation,	we	quantified	Thy1/CD90	 levels,	which	were	increased	in	the	AAV9.IGF1Ea	group	(Figure	5.8F).	
	
5.6	BrdU+	nuclei	quantification	after	IGF-1Ea	gene	transfer	Interestingly,	 the	 scars	 of	 AAV9.IGF1Ea	 treated	 mice	 were	 characterised	 by	 higher	cardiomyocyte	content	(Figures	5.9	A-D).		
	
Figure	 5.9.	 Representative	masson	 trichrome	 staining	 sections	 of	 the	 scar	 region	 in	 the	
four	 groups	 28	 days	 after	 ischemia/reperfusion.	 Healthy	 myocardium	 (red)	 and	 fibrosis	(blue)	are	represented.	Scale	bar,	250	μm.		
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To	 assess	 the	 generation	 of	 new	myocardial	 tissue	 in	 the	 infarcted	 hearts,	mice	were	given	 BrdU	 for	 28	 days	 to	 visualise	 cumulative	 DNA	 synthesis.	 Consistent	 with	observations	 in	 cardiac-specific	 IGF-1Ea	 transgenic	 mice	 (Santini	 et	 al.	 2007),	 the	I/R+AAV9.IGF1Ea.1011	 group	 moderately	 increased	 percentage	 of	 BrdU	 positive	cardiomycytes	 at	 28	 days	 post-I/R	 (Figure	 5.10A,	 5.10B	 and	 5.10C).	 The	 greatest	difference	 was	 obtained	 with	 the	 I/R+AAV9.IGF1Ea.1011	 so	 the	 higher	 viral	 titer	 was	used	in	preceding	experiments.	As	no	significant	differences	were	observed	between	I/R	group	(no	virus	group)	and	the	I/R	GFP	control	groups,	only	I/R	group	is	presented.	
	
Figure	5.10.	AAV9.IGF1Ea	gene	transfer	increases	the	number	of	BrdU+	cardiomyocytes	28	
after	ischemia/reperfusion.	(A,	B)	Representative	confocal	images	of	paraffin	heart	sections	28	
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days	 post-I/R	of	 (A)	 I/R	 group	 (no	 virus)	 and	 (B)	AAV9.IGF1Ea	3.5x1011	 group.	 Sections	were	stained	with	cardiac	troponin	I	(red,	cardiomyocytes),	anti-BRDU	(green)	and	DAPI	(blue,	nuclei).	Scale	bar,	100	μm.	(C)	Quantification	of	BrdU+	cardiomyocytes	after	 in	vivo	 labeling.	n=3-6.	For	quantification	 whole	 heart	 sections	 where	 analysed	 for	 BRDU+	 Cardiomycytes.	 At	 least	 three	heart	 sections	 per	 heart	 where	 analysed.	 White	 arrows	 indicate	 BrdU	 positive	 nuclei.	 Mean	values	±	SEM	are	shown.	*p<0.05.	Two-tailed	Student’s	t-test	was	performed	to	compare	I/R	vs.	AAV9.IGF1Ea	3.5x1011	28	days	after	MI.	
	Phospho-H3	 staining,	 a	 mitosis	 marker,	 did	 not	 reveal	 any	 significant	 difference	between	the	groups	at	28	days	(Figure	5.11),	suggesting	a	lack	of	on-going	proliferation	at	that	stage.		
	
Figure	5.11.	Phospho-H3	immunohistochemistry	of	 I/R	and	AAV9.IGF1Ea	treated	groups,	
28	days	after	 ischemia/reperfusion.	(A	and	B)	I/R	group	(no	virus	group)	and	(C	and	D)	IGF-1Ea	3.5x1011	GC	treated,	28	days	after	ischemia/reperfusion.	Scale	bar	(A	and	C),	250	um.	Scale	bar	(C	and	/D),	100	um.		We	also	assessed	whether	IGF-1Ea	gene	transfer	promoted	enhanced	vascularization	for	proper	 blood	 supply	 to	 the	 scars.	 Indeed,	 as	 in	 IGF-1	 transgenic	 mice	 (Santini	 et	 al.	2011),	 αSMA	 immunohistochemistry	 showed	 an	 increase	 in	 arterioles	 in	 the	AAV9.IGF1Ea	 treated	 group	 with	 the	 highest	 AAV9	 titer	 (Figures	 5.12A,	 5.12B	 and	
5.12C).		
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Figure	 5.12.	 αSMA	 immunohistochemistry	 and	 vessel	 quantification	 in	 I/R	 and	
AAV9.IGF1Ea	 treated	 mice,	 28	 days	 after	 ischemia/reperfusion.	 αSMA	immunohistochemistry	of	(A)	I/R	group	(no	virus	group)	and	(B)	AAV9.IGF1Ea	3.5x1011	treated	hearts	after	ischemia-reperfusion.	White	arrows	indicate	αSMA	positive	vessels.	n=4-6.	Scale	bar,	100	μm.	(C)	αSMA	vessel	quantification.	For	quantification	whole	heart	sections	where	analysed	for	αSMA+	cells.	At	least	three	heart	sections	per	heart	where	analysed.	Mean	values	±	SEM	are	shown.	 *p<0.05.	 Two-tailed	 Student’s	 t-test	 was	 performed	 to	 compare	 I/R	 vs.	 AAV9.IGF1Ea	3.5x1011	28	days	after	MI.			
5.7	AAV9.IGF1Ea	treatment	promotes	cardiac	Akt-mediated	signalling	The	main	effects	of	IGF-1	are	achieved	through	the	Akt	signalling	pathway.	In	the	heart,	IGF-1	 mediates	 Akt	 phosphorylation	 on	 the	 serine-473	 residue,	 which	 indicates	 Akt	activation	(Santini	et	al.	2011).	AAV9.IGF1Ea	treatment	increased	IGF-1	protein	content	in	 the	heart	by	1.5	 fold	when	compared	with	 the	 I/R	group.	At	28	days	post-I/R,	mice	treated	with	AAV9.IGF1Ea	exhibited	a	1.7	fold	increase	in	P-Ser473Akt.	Phosphorylation	of	mTOR,	downstream	of	Akt,	was	also	increased	by	1.8	fold	after	I/R	in	the	AAV9.IGF1Ea	treated	groups	(Figure	5.13A	and	5.13B).				
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Figure	5.13.	IGF-1Ea	gene	transfer	activates	the	Akt	signaling	pathway.	(A)	Representative	western	 blot	 images	 of	 protein	 extracts	 from	 the	 remote	 myocardium	 of	 I/R	 and	 I/R-AAV9.IGF1Ea	treated	groups	28	days	post-I/R.	(B)	Western	blot	quantification	of	IGF-1Ea,	p-Akt,	and	mTOR,	28	days	after	cardiac	 transfer	by	scanning	densitometry.	n=	6-10	per	group.	 	Mean	values	±	SEM	are	shown.	*p<0.05.	Two-tailed	Student’s	t-test	was	performed	to	compare	I/R	vs.	AAV9.IGF1Ea	3.5x1011	28	days	after	MI.		
	
5.8	Discussion	In	this	chapter,	it	is	demonstrated	for	the	first	time	that	a	single	intravenous	injection	of	AAV9.IGF1Ea	 after	 ischemic	 injury	 induced	 improvements	 in	 LV	 cardiac	 function	following	 myocardial	 infarction.	 This	 improvement	 is	 through	 partial	 recovery	 of	 LV	contraction	 and	 quality	 motion	 reducing	 total	 fibrosis	 and	 infarct	 expansion	 limiting	adverse	remodeling.	Interestingly,	analysis	of	the	main	ECM	components,	collagen	1	and	
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collagen	3,	showed	a	skewing	in	favour	of	collagen	synthesis	which	may	confer	different	mechanical	 and	 physical	 properties	 to	 the	 infarct.	 TGF-β	 is	 a	 well	 know	 activator	 of	collagen	I	synthesis	by	activated	fibroblast	(Bujak	et	al.	2007).	Consequently,	a	reduction	in	total	TGF-β	levels	in	the	infarcted	area,	could	be	explain	the	reduction	in	total	fibrosis.		As	 discussed	 in	 the	 Introduction,	 Section	 1.4.2,	 over	 the	 years,	 the	 use	 of	 AAVs	 in	preclinical	 (Konkal	 et	 al.	 2014,	 Fang	 et	 al.	 2013	 and	 Kaspar	 et	 al.	 2005)	and	 clinical	studies	(Muller	at	el.	2006	and	Giacca	et	al.	2011)	has	positioned	AAVs	as	the	vector	of	choice	 for	 cardiac	 gene	 transfer.	 	 This	 is	 mainly	 due	 to	 the	 diverse	 tissue	 tropism	determined	by	the	capsid	serotype,	 the	 lack	of	pathogenicity,	 low	 immunogenicity	and	robust	 gene	 expression,	 achieved	with	 this	 system	 (Jessup	 et	 al.	 2011).	 This	 chapter’s	findings	 show	 that	 single	 administration	of	 the	AAV9	virus	provided	 robust	 and	 early	onset	of	 IGF-1Ea	expression	 in	 the	heart,	with	 the	cTNT	promoter	providing	sufficient	expression	 to	 achieve	 therapeutic	 IGF-1Ea	 transcription	 levels	 after	 a	 single	 systemic	injection.	 AAV9-mediated	 luciferase	 gene	 expression	was	 also	 detected	 in	 the	 liver	 at	much	lower	levels,	which	overrode	the	cardiac	specificity	of	the	cTNT	promoter	(Prasad	et	al	2011,	Fang	et	al.	2013	and	Kaspar	et	al.	2005).		However,	this	was	not	paralleled	by	an	increase	in	IGF-1Ea	mRNA	levels	in	the	liver	after	AAV9.IGF1Ea	treatment,	indicating	that	IGF-1Ea	overexpression	was	cardiac-specific.	Notably,	in	this	study,	we	show	for	the	first	time	that	the	IGF-1Ea	propeptide	can	be	successfully	delivered	and	overexpressed	in	 the	heart	by	 this	 gene	 therapy	approach.	The	Ea	moiety	 in	 the	 IGF-1Ea	propeptide,	which	 is	 efficiently	 cleaved,	 anchors	 IGF-1	 to	 the	 extracellular	matrix	 in	 other	 tissues	preventing	its	clearance	and	reducing	off-target	effects	(Hede	et	al.	2012).	This	feature	dampens	 the	risks	associated	with	elevated	systemic	 IGF-1	 levels	such	as	hypotension	(Cheng	et	al.	2014)	and	hypoglycaemia	(Kovacs	et	al.	1999).			As	described	in	the	Introduction,	Section	1.5,	the	diverse	functions	of	IGF-1	are	mediated	through	the	same	receptor	(IGF-1R)	which	upon	activation	 leads	to	 the	recruitment	of	other	 substrates	 that	 in	 turn	 activate	different	 signalling	pathways	 (Butler	 et	 al.	 1998	and	 Coolican	 et	 al.	 1997).	 Upon	 IGF-1R	 activation,	 active	 PI3-kinase	 phosphorylates	inositol	phospholipids	(Introduction,	Section	1.5.2.2)(Fujio	et	al.	2000	and	Rommel	et	al.	2001).	This	phosphorylation	 is	required	to	 induce	several	downstream	targets	such	as	Akt,	which	 promotes	 protein	 synthesis	 and	 cell	 survival,	 among	 other	 functions.	 	 IGF-1Ea	also	 induces	the	expression	of	the	calcineurin	splicing	variant	CnAβ	(Lara-Pezzi	et	al.	 2007).	 Interestingly,	 the	 effects	 of	 AAV9.IGF1Ea	 are	 reminiscent	 of	 those	 of	 CnAβ1	overexpression,	which	results	in	Akt	activation,	improved	vascularization	of	the	infarct	
Imperial	College	London	 	 Chapter	5	–	AAV9.IGF-1Ea	gene	transfer	
Enrique	Gallego-Colon	 131	
region	 and	 reduced	 infarct	 expansion	 leading	 to	 reduced	 remodeling	 and	 improved	cardiac	 function	 post-infarction	 (Prasad	 et	 al.	 2011	 and	 Felkin	 et	 al.	 2011).	 As	 with	previous	models	of	IGF-1	administration,	the	AAV9	virus	was	able	to	induce	an	increase	in	the	formation	of	new	capillaries	(Santini	et	al.	2011).			Although	 BrdU+	 labelling	 showed	 increased	 percentage	 of	 positive	 cardiomyocites	 in	AAV9.IGF1Ea	 treated	group,	no	differences	were	observed	with	Phospo-H3	staining	at	28	 days,	 suggesting	 that	 the	 beneficial	 effect	 of	 IGF-1	 is	more	 likely	 due	 to	 improved	vascularization	of	 the	 infarct	 region,	which	 leads	 to	 reduced	 infarct	expansion,	 in	 turn	reducing	 dilation	 and	 improving	 LV	 cardiac	 function.	 Regarding	 the	 BRDU+	 CM.	 We	prompted	 the	 question:	 Does	 IGF-1Ea	 induce	 proliferation	 of	 resident	 CM	 or	 homing	cardiac	 stem	 cells?	We	have	 indications	 suggesting	 that	 CM	proliferation	 is	 originated	from	 c-kit	 progenitors	 cells	 recruited	 from	 the	 bone	 marrow	 (Santini	 et	 al.	 2011).	Regarding	the	improvement	in	vascular	density	in	the	heart	could	increase	the	levels	of	MCP2	 and	 VEGF-A	 (Santini	 et	 al.	 2011).	We	 have	 noted	 that	 the	 scars	 of	 the	 IGF-1Ea	treated	groups	are	characterise	by	an	increase	number	of	BRDU+/Phospo-H3	cells.	This	fact	 along	 with	 the	 up-regulation	 of	 Thy1	 suggests	 that	 IGF-1Ea	 supplemental	expression	activates	fibroblast	proliferation	(Chapter	6).		We	 have	 previously	 shown	 that	 cardiac	 overexpression	 of	 IGF-1	 in	 transgenic	 mice	resulted	in	repression	of	the	pro-inflammatory	cytokines	IL-1β	and	IL-6,	while	the	anti-inflammatory	IL-4	and	IL-10	showed	higher	expression	levels	when	compared	to	wild-type	 (WT)	 animals	 after	 cardiotoxin	 injury.	 	 We	 found	 that	 IGF-1Ea	 decreased	 the	number	of	apoptotic	cells	at	the	injured	site,	which	is	at	least	in	part	attributable	to	the	induction	 of	 UCP-1,	 metallothionine	 2	 and	 the	 cardioprotective	 cytokine	 adiponectin	(Santini	et	al.	2007)	reducing	infarct	size	(Introduction,	Section	1.5.4).	We	hypothesised	that	IGF-1Ea	gene	transfer	may	prevent	damaged	cardiomycytes	to	undergo	necrosis.		Although	 the	 salutary	 effects	 of	 direct	 intramyocardial	 injection	 of	 IGF-1	 expression	vectors	 has	 been	 previously	 documented	 (Davis	 et	 al.	 2006,	 Khan	 et	 al.	 2014	 and	Lawrence	 et	 al.	 2012).	 This	 is	 the	 first	 report	 of	 sustained	 effective	 improvement	 by	virally	encoded	IGF-1Ea	propeptide	in	a	more	therapeutically	relevant	delivery	mode.	
	
5.8.1	Limitation	of	the	project	The	main	disadvantage	of	 the	AAV	approach	 is	 the	 limited	 size	of	 the	AAV	genome	 (<	5Kb).	 Additionally,	 although	 two	 levels	 of	 cardiac	 specificity	 were	 applied,	 ectopic	
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expression	was	 observed	 in	 the	 liver.	 Thus,	 the	 efficiency	 of	 IGF-1Ea	 gene	 transfer	 to	target	the	heart	was	not	as	specific	as	expected.	On	the	other	hand,	as	described	in	the	Introduction,	 Section	 1.4.2.2.1,	 the	 presence	 of	 neutralizing	 antibodies	 may	 play	 a	limiting	 role	 if	 this	 approach	 ever	 reaches	 human	 trials.	 From	 a	 wetlab	 standpoint,	sequencing	the	ITR	took	longer	than	expected,	delaying	the	project	for	several	months.	However,	 sequencing	 of	 these	 regions	must	 be	 performed	 to	make	 sure	 that	 the	 ITR	integrity	 is	 preserved.	 Basically,	 the	 supercoiled	 3D	 T-shape	 structure	 of	 the	 ITRs	prevented	the	amplification	of	these	regions	during	the	sequencing	process	(Chapter	2,	
Figure	2.8).	To	overcome	this	problem,	a	specific	protocol	to	facilitate	sequencing	of	GC-rich	regions	was	designed	as	described	 in	Methodology	2.11.7.	Another	 limitation	was	also	 found	 during	 AAV	 delivery,	 we	 noted	 that	 more	 than	 1	 cycle	 of	 defrosting	considerably	diminished	AAV	transduction	efficiency.	Therefore,	each	aliquot	was	used	once.	 From	 an	 experimental	 standpoint,	 samples	 should	 have	 been	 harvested	 at	 early	timepoints,	 thus,	 an	 apoptosis	 assays	 should	 have	 been	 performed.	 At	 experimental	level,	 IGF-1Ea	 immunohistochemistry	 did	 not	 provide	 reliable	 results	 do	 to	 the	sensitivity	 and	 specificity	 of	 the	 IGF-1Ea	 antibody.	 Consequently,	 only	 Luciferase	immunohistochemistry	was	presented.		
5.8.2	Outcomes	The	 escalating	 incidence	 of	 acute	 cardiovascular	 diseases	 leading	 to	 heart	 failure	underscores	 the	 increasingly	 urgent	 need	 for	 improved	 therapeutic	 strategies	 to	 limit	cardiac	 tissue	damage	and	 improve	 functional	 outcomes	 in	 translational	 settings.	 This	study	demonstrates	that	intravenous	delivery	of	AAV9.IGF1Ea	is	effective	in	improving	post	I/R	cardiac	function,	preventing	infarct	expansion	and	dilation.	This	is	attributed	to	the	combined	effects	of	a	cardiotropic	gene	delivery	vehicle,	AAV9,	and	the	pleiotropic	action	of	IGF-1Ea	in	the	heart.		From	a	clinical	standpoint,	 intravenous	 injection	 is	 the	 least	 invasive	mode	of	delivery	for	cardiac	gene	therapy,	although	higher	efficiency	could	be	achieved	by	delivering	the	AAV9.IGF1Ea	 vector	 via	 intracoronary	 infusion	 during	 cardiac	 catheterization	 in	patients.	 These	 results	 provide	 a	 rationale	 to	 conduct	 additional	 studies	 in	 larger	animals	for	translation	to	clinical	application.	
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Chapter	6	–	Concluding	remarks	and	future	directions	
	
6.1	Concluding	remarks	The	 goal	 of	 this	 thesis	 was	 to	 investigate	 the	 potential	 of	 new	 strategies	 to	 deliver	 a	beneficial	payload	to	the	diseased	heart	in	animal	models.	Through	my	PhD,	I	attempted	to	 combine	 the	 knowledge	 on	 IGF-1Ea	 reparative	 effects	 with	 the	 design	 of	 specific	clinically	 relevant	 therapeutic	 strategies	 to	 deliver	 IGF-1Ea	 at	 the	 right	 time	 after	myocardial	 infarction.	Consequently,	 the	main	aim	of	 this	 thesis	was	 (i)	 to	understand	the	 mechanism	 underlying	 the	 IGF-1Ea	 reparative	 effects	 after	 myocardial	 infarction,	and	 (ii)	 to	 design	 a	 suitable	 cell-	 or	 gene-based	 approach	 to	 deliver	 IGF-1Ea	 to	 the	infarcted	heart	promoting	cardiac	repair	and	preventing	adverse	ventricular	remodeling	in	a	clinically	relevant	settings.		In	Chapter	3,	I	have	observed	improved	cardiac	function	in	mice	overexpressing	cardiac-specific	 IGF-1Ea	 as	 early	 as	 7	 days	 after	 myocardial	 infarction.	 Analysis	 at	 gene	transcription	level	revealed	that	supplemental	IGF-1Ea	also	regulated	the	expression	of	key	 metalloproteinases	 (MMP-2	 and	 MMP-9),	 their	 inhibitors	 (TIMP-1	 and	 -2)	 and	collagens	(Col1α1	and	Col1α3)	in	the	first	week	after	injury.	Infiltration	of	inflammatory	cells,	which	direct	 the	 remodeling	process,	was	 also	 altered;	 in	particular	 there	was	 a	notable	reduction	in	inflammatory	Ly6C+	monocytes	at	day	3	followed	by	an	increase	in	anti-inflammatory	CD206+	macrophages	 at	 day	7.	 These	 results	 indicate	 that	 the	 IGF-1Ea	 transgene	 shifts	 the	 balance	 of	 innate	 immune	 cell	 populations	 early	 after	infarction,	 favouring	 a	 reduction	 in	 inflammatory	 myeloid	 cells.	 This	 correlates	 with	reduced	extracellular	matrix	degradation	and	changes	in	collagen	composition	that	may	confer	 enhanced	 scar	 elasticity	 and	 improved	 cardiac	 function.	 From	 this	 chapter,	 I	uncovered	 that	 IGF-1Ea	 supplemental	 expression	 is	 causing	 major	 changes	 in	 the	resolution	 of	 the	 inflammatory	 process	 in	 the	 hearts	 after	 myocardial	 infarct.	 This	pinpoints	 the	 fact	 that,	 in	order	 to	 enhance	 repair	 IGF-1Ea	must	be	present	within	an	early	window	of	7	days	after	myocardial	infarction.			In	 Chapter	 4	 and	 5,	 I	 have	 designed	 two	 IGF-1Ea	 therapeutic	 strategies	 taking	 into	account	 that	 IGF-1Ea	must	be	delivered	as	early	as	possible	 to	enhance	repair,	 ideally,	within	 3-7	 days	 after	 myocardial	 infarction.	 	 By	 delivering	 IGF-1Ea	 in	 a	 clinically	relevant	 setting,	 I	 looked	 to	 achieve	 a	 similar	 enhancement	 in	 repair	 as	 found	 in	 the	αMHC-IGF-1Ea	hearts	(Introduction,	Section	1.5.4).		
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In	 the	Rosenthal	group,	numerous	projects	have	attempted	to	deliver	 IGF-1Ea	 into	 the	infarcted	 myocardium	 in	 an	 efficient	 way	 using	 combinatorial	 cell/growth	 factor	therapies	to	improve	function	following	myocardial	infarction.		In	Chapter	4,	I	explored	the	use	of	BMdMs	as	a	therapeutic	vehicle.	These	cells	are	found	in	the	infarcted	area	as	early	as	2	days	after	myocardial	infarction,	thus	being	a	potential	vehicle	 for	 IGF-1Ea	 delivery.	 In	 vitro	 studies	 indicated	 that	 IGF-1Ea	 can	 be	overexpressed	 in	 BMdMs,	 however	 the	 process	 is	 very	 inefficient.	 The	 in	 vivo	 studies	showed	 that	macrophages	 indeed	 engrafted	 into	 the	 injured	muscle,	 nonetheless,	 the	process	 is	 very	 inefficient	 and	 the	 numbers	 of	 cells	 retained	were	 just	 a	 few,	 besides,	high	retention	was	observed	in	 liver	and	 lung.	Taking	these	two	aspects	together,	 IGF-1Ea	 delivery	 using	 BMdMs	 proved	 not	 to	 be	 as	 therapeutically	 relevant	 as	 hoped.	 At	present,	 we	 lack	 a	 suitable	 cell-based	 therapy	 to	 deliver	 IGF-1Ea	 and	 confer	 lasting	functional	preservation,	mainly	due	to	lack	of	sufficient	engraftment	of	the	transplanted	cells.		Therefore,	 I	 decided	 to	 change	 towards	 a	 gene-based	 therapeutic	 approach	 using	 an	adeno-associated	virus	 (AAV)	as	delivery	vehicle.	Although	 it	 is	 a	 completely	different	approach,	 studies	 (Introduction,	 Section	 1.4.2)	 have	 shown	much	 better	 transduction	efficiency	 than	 cell-based	 therapies.	 From	a	 clinical	 stand	point,	 AAVs	 are	much	more	tractable	 than	 BMdMs	 as	 isolation	 and	 culture	 procedures	 are	 not	 required.	 In	particular,	I	decided	to	use	AAV9	as	vehicle,	as	it	has	been	shown	to	be	the	most	efficient	serotype	to	achieve	high	transduction	efficiency	into	the	myocardium	(Chapter	5).			In	Chapter	5,	I	developed	an	AAV	based,	clinically	relevant	mode	of	IGF-1Ea	delivery	to	the	 heart	 to	 examine	 the	 effects	 of	 local	 IGF-1Ea	 production	 on	 adverse	 ventricular	remodeling	 after	 ischemia/reperfusion.	 A	 cardiotropic	 AAV9	 vector	 carrying	 a	cardiomyocyte-specific	 IGF-1Ea-luciferase	 bi-cistronic	 gene	 expression	 cassette	(AAV9.IGF-1Ea)	 was	 administered	 intravenously	 to	 mice	 5	 hours	 after	 ischemia	followed	by	reperfusion	(I/R),	as	a	model	of	myocardial	infarction.	Virally	encoded	IGF-1Ea	 in	 the	 heart	 improved	 global	 left	 ventricular	 function	 and	 LV	 remodeling,	 as	measured	by	wall	motion	and	thickness,	28	days	after	delivery,	with	higher	viral	titers	yielding	better	recovery.	 	Thus,	the	use	of	AAV9	to	deliver	IGF-1Ea	represents	a	highly	efficient	approach	for	the	treatment	of	myocardial	infarction.				
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6.2	Future	directions	The	 cell-	 and	gene-based	 therapeutic	 approaches	pursued	 in	 this	 thesis	 indicated	 that	the	 most	 efficient	 clinically-relevant	 route	 to	 deliver	 IGF-1Ea	 is	 via	 adeno-associated	virus	 (Chapter	 3).	 Cell-based	 therapies,	 particularly,	 macrophage	 therapies,	 point	 out	the	main	 limitations	 of	 these	 approaches,	 based	 on	 the	 engraftment	 capacity	 of	 these	cells	 (Chapter	 4).	 This	 suggests	 that	 future	 directions	 in	 the	 IGF-1Ea	 therapeutic	 field	should	be	viral-orientated.	In	contrast	to	cell-therapy	approaches,	viral	approaches	are	advancing	much	faster.	In	the	AAV	field,	new	serotypes	are	being	designed,	which	have	higher	 and	 better	 tropism	 towards	 the	 organ	 of	 interest.	 Although	 viral	 approaches	using	AAV	are	not	perfect,	mainly	due	to	the	presence	of	Nab,	they	appear	to	be	the	most	promising	 approach.	 Regarding	 AAV9.IGF-1Ea,	 it	 is	 time	 to	 bring	 the	 study	 a	 step	forward	 and	 to	 be	 tested	 on	 higher	 animal	 models	 such	 porcine	 or	 eventually	 to	 be	tested	 in	 human	 trials.	 Due	 to	 the	 fact	 that	 the	 results	 on	 AAV9.IGF-1Ea	 look	 very	promising	for	the	treatment	of	myocardial	infarction,	we	have	submitted	an	abstract	to	a	pharmaceutical	company,	to	apply	for	funding	to	carry	forward	this	approach	to	human	trial.	 However,	 pharmaceutical	 companies	 are	 hesitant	 to	 invest	 in	 light	 of	 existing	intellectual	property	covering	many	aspects	of	IGF-1	based	therapies,	 thus	 limiting	the	novelty	 and	 patentability	 of	 AAV9.IGF-1Ea.	 	 Although	 clinical	 trials	 are	 still	 very	 far	away,	more	basic	 research	 is	warranted	 to	 refine	 IGF-1Ea	based	 therapeutic	protocols	and	to	explore	the	mechanism	of	action	whereby	growth	factor-mediated	control	of	the	immune	response	to	damage	is	a	beneficial	component	of	regenerative	medicine.			
6.3	Future	work	
For	chapter	3	To	further	investigate	the	beneficial	component	of	IGF-1Ea	in	repair	I	will	perform	the	following	experiments:			
1)	Study	of	the	resident	macrophage	population	(cTM)	in	the	αMHC-IGF-1Ea	hearts.	If	 we	 compare	 the	 number	 of	 Ly6Clow	 monocytes	 and	 the	 number	 of	 CD206+	macrophages	in	the	injured	heart	at	day	7,	the	numbers	do	not	add	up.	There	are	more	CD206+	 macrophages	 than	 infiltrating	 monocytes	 overall.	 We	 hypothesised	 that	 IGF-1Ea	may	be	stimulating	resident	macrophage	proliferation	and	polarisation	towards	an	M2	phenotype.			In	order	to	 investigate	the	above	hypothesis,	we	will	study	the	 inflammatory	response	
ex	vivo	using	a	technique	developed	by	Prof.	Cesare	Terraciano	for	electrophysiological	
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purposes.	 Prof.	 Cesare	Terracciano’s	 group	has	 developed	 a	 technique	 to	 obtain	 heart	slices,	which	can	be	cultured	ex	vivo	for	a	week.	I	will	address	the	effect(s)	that	IGF-1Ea	exerts	 on	 the	 resident	 macrophage	 population	 in	 these	 heart	 slides	 after	 cryoinjury.	Consequently,	 an	 ‘immune’	 response	 limited	 to	 the	 resident	 macrophage	 populations	can	be	more	easily	studied	in	each	heart	slice.	The	experiments	will	be	as	follow:		
Experiment	 1:	 BrdU	 assays	 will	 be	 performed	 to	 compare	 the	 proliferative	capacities	of	resident	macrophages	in	WT	and	αMHC-IGF-1Ea	heart	slices	using	the	same	timepoints	as	in	Chapter	3,	24	hours,	3	days,	5	days	and	7	days.		
Experiment	2:	Flow	cytometry	analysis	will	be	performed	to	study	the	phenotype	of	 the	resident	macrophages	after	cryoinjury	 in	WT	and	αMHC-IGF-1Ea	hearts.	The	phenotype	of	the	resident	macrophages	will	be	assessed	overtime	using	the	following	markers:	CD45,	CD11b,	CD14,	Ly6C,	CD206.	The	resident	macrophage	populations	 can	 be	 characterised	 by	 the	 expression	 of	 the	 CX3CR1	marker	 as	described	by	Pinto	et	al.	2012.	Additionally,	these	macrophages	populations	will	be	 sorted	 and	 the	 expression	 of	 inflammatory-mediated	 markers	 will	 be	analysed	by	qPCR.		
Experiment	3:	 qPCR	 gene	 expression	 analysis	 of	whole	WT	 and	αMHC-IGF-1Ea	heart	slices	after	cryoinjury	will	be	performed.	As	described	in	Chapter	3,	Figure	3.6,	 the	αMHC-IGF-1Ea	hearts	are	characterise	by	an	early	up-regulation	of	 the	anti-inflammatory	 cytokine	 IL-10	 during	 the	 first	 24	 hours	 after	 myocardial	infarction.	Therefore,	it	will	be	very	interesting	to	know	if	whole	heart	slices	and	sorted	resident	macrophages	(Experiment	2)	up-regulate	the	levels	of	IL-10	after	cryoinjury.		If	the	resident	macrophages	display	a	reparative	phenotype	after	cryoinjury,	this	will	be	in	accordance	with	the	data	in	Chapter	3,	Figure	3.10.	The	results	will	indicate	that	IGF-1Ea	promotes	its	reparative	activity	is	mediated	through	the	stimulation	of	the	resident	macrophage	 population,	 this	 fact	 could	 also	 explain	 the	 bias	 towards	 the	 reparative	environment	found	in	the	αMHC-IGF-1Ea	hearts.				
Imperial	College	London		 	 Chapter	6	-	Concluding	remarks	
Enrique	Gallego-Colon	 137	
2)	Expression	of	IL-1	β,	IL-10,	MCP-1,	CCL5	and	Collagen	by	macrophages,	neutrophils	and	
dendritic	cells.	As	 discussed	 in	 the	 Introduction,	 Section	 1.5.4	 and	 in	 Chapter	 3,	 IGF-1Ea	 modulates	several	aspects	of	 the	 inflammatory	process,	 including	cytokine	expression	and	matrix	turnover	genes.	It	will	be	interesting	to	know	if	the	main	inflammatory	cells	studied	in	Chapter	3	are	actually	responsible	for	the	cytokines	and	the	matrix	turnover	expression	pattern	found	in	the	αMHC-IGF-1Ea	hearts.			Although	 it	 is	not	mentioned	 in	 this	 thesis,	 cell	 sorting	was	also	performed	along	with	the	 flow	 cytometry	 analysis	 in	 Chapter	 4.	 The	 following	 cells	 were	 sorted	 at	 all	timepoints:	 Inflammatory	 macrophages	 (Ly6Chigh/CD206low),	 reparative	 macrophages	(Ly6Clow/CD206high),	neutrophils	(CD45+,	CD11b+,	F4/80-,	CD11c-,	Ly6G+)	and	dendritic	cells	(CD45+,	CD11b+,	F4/80-,	CD11c+,	Ly6G-).		It	will	be	 interesting	 to	elucidate	 if	 IGF-1Ea	alters	 the	gene	expression	profile	of	 these	cells,	 at	 early	 timepoints.	 In	 particular,	 a	 series	 of	 qPCR	will	 be	 performed	 to	 further	investigate	the	mechanism	underlying	the	distinct	cytokine	profile	found	in	the	αMHC-IGF-1Ea	hearts.		 - CCL2,	 the	 main	 ligand	 for	 monocyte	 recruitment,	 is	 released	 by	 activated	neutrophils	(Pelletier	et	al.	2014).	Thus,	a	reduction	in	the	CCL2	mRNA	levels	in	neutrophils	 in	 the	αMHC-IGF-1Ea	hearts,	 24	 hours	 after	myocardial	 infarction,	could	explain	the	reduced	levels	of	CCL2	found	at	that	particular	timepoint	in	the	αMHC-IGF-1Ea	hearts.		 - The	 enhanced	 repair	 achieved	 in	 the	 αMHC-IGF-1Ea	 mice,	 has	 always	 been	associated	with	high	 levels	of	 the	anti-inflammatory	cytokine	 IL-10.	Reparative	macrophages	have	been	 identified	 as	 one	of	 the	main	producers	of	 IL-10	 after	myocardial	 infarction,	 facilitating	 the	 shift	 from	 the	 inflammatory	 to	 the	reparative	phase	(Mosser	et	al.	2003	and	Nahrendorf	2010).	Thus,	 I	would	 like	to	know	if	sorted	αMHC-IGF-1Ea	macrophages	at	day	1	up-regulate	IL-10	mRNA	levels,	 compared	 to	 WT	 macrophages.	 If	 so,	 this	 can	 explain	 the	 IL-10	 up-regulation	observed	in	the	αMHC-IGF-1Ea.		- Reparative	macrophages	 are	 responsible	 for	 collagen	 degradation	 through	 the	mannose	receptor	(Madsen	et	al.	2013).	I	would	like	to	assess	if	αMHC-IGF-1Ea	
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reparative	 macrophages	 up-regulate	 the	 levels	 of	 the	 mannose	 receptor	 upon	injury.	If	so,	this	fact	could	explain	in	part	the	reduction	in	the	collagen	content	found	in	the	αMHC-IGF-1Ea	hearts.		
3)	Understanding	the	distinct	composition	of	 the	scar	 tissue	 in	 the	αMHC-IGF-1Ea	hearts	
after	myocardial	infarction.	The	changes	in	collagen	expression	observed	in	Chapter	3,	could	be	due	to	proliferation	and	 activation	 of	 fibroblast	 into	 myofibroblast	 (Van	 Nieuwenhoven	 et	 al.	 2013	 and	Simmons	et	al.	2002).	This	is	also	supported	by	the	fact	that	αMHC-IGF-1Ea	(Chapter	3,	
Figure	 3.3	 and	 Figure	 6.1)	 and	 the	 AAV9.IGF1Ea	 scars	 (Chapter	 5,	 Figure	 5.9	 and	
Figure	6.1)	are	characterise	by	an	accumulation	of	fibroblast-like	cells	at	the	scar	site,	besides	 the	 up-regulation	 of	 the	 CD90/Thy1	marker	 in	 the	 scars	 of	 the	 AAV9.IGF1Ea	treated	 group	 (Chapter	 5,	 Figure	 5.8).	 Therefore,	 I	 would	 like	 to	 perform	immunohistochemistry	staining	against	CD90/Thy1,	to	confirm	that	the	accumulation	of	the	cells	in	the	scar	tissue	are	fibroblasts.															
Figure	 6.1.	 Masson	 Trichrome	 representative	 staining	 of	 WT	 and	 IGF-1Ea	 scars	 after	
myocardial	 infarction.	 (A)	 WT	 and	 (B)	 αMHC-IGF-1Ea	 scar	 tissue	 28	 days	 after	 permanent	coronary	 artery	 occlusion.	 (C)	 I/R	 and	 (D)	 AAV9.IGF1Ea	 treated	 scar	 tissue	 28	 days	 after	ischemia	reperfusion.	Scale	bar,	250μm.				
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For	Chapter	5	There	are	two	main	experiments	that	I	would	like	to	perform	which	will	provide	us	with	a	better	understanding	on	how	to	tune	IGF-1Ea	in	future	therapeutic	approaches.		
Experiment	1:	One	of	the	most	interesting	findings	of	this	thesis	is	the	increase	in	BrdU+	cardiomyocytes	 that	 I	 found	 after	 AAV9.IGF1Ea	 treatment.	 As	 discussed	 in	 Chapter	 5,	the	increase	in	BrdU+	cardiomycytes	from	1	to	2%	does	not	explain	such	improvement	in	 cardiac	 function.	However,	 it	will	 be	 very	 interesting	 to	 pinpoint	when	 exactly	 this	event	 occurs,	 as	 it	 would	 be	 very	 helpful	 to	 target	 future	 IGF-1Ea	 therapies	 to	 that	particular	 timepoint.	 Thus,	 I	 would	 like	 to	 perform	 a	 Phospho-H3,	 Aurora	 B	immunofluorescence	 timecourse	 and	 BrdU	 studies	 at	 1,	 3,	 5	 and	 7	 days	 after	ischemia/reperfusion	to	determine	when	exactly	cardiomyocyte	division	is	occurring.		
Experiment	2:	The	scars	of	the	IGF-1Ea	treated	mice	are	characterises	by	an	increase	in	cardiomyocyte	content,	which	is	BrdU	negative	(Chapter	5,	Figure	5.10).	On	the	other	hand,	IGF-1Ea	is	involved	in	preventing	apoptosis	at	the	injured	site	(Santini	et	al.	2007).	Therefore,	 I	would	 like	 to	 look	 for	apoptosis	by	TUNEL	assay	 to	determine	 if	 IGF-1Ea,	indeed	 promotes	 survival	 pathways	 after	 AAV9.IGF1Ea	 administration.	 TUNEL	 assay	will	be	performed	at	the	same	timecourse	as	described	in	Experiment	1.		
Experiment	3:	In	order	to	clarify	the	composition	and	structure	of	the	scars	analyses	of	the	scars	by	a	polarized	microscope	will	be	performed.	
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Appendix	1.	pAAV9.IGF-1Ea	quality	controls	AAV9	viral	production	required	a	full	characterisation	of	the	plasmid	to	confirm	that	all	the	 elements	 inside	 the	 vector	 were	 present:	 3’ITR/LTR,	 5’ITR/LTR,	 promoter,	transgene	and	polyadenylation	signal.	The	maximum	size	of	an	AAV	vector	from	ITR	to	ITR	must	be	4.9Kb	or	below,	pAAV9.IGF-1Ea	has	2336	bp.			
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